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Abstract  
The overall aim of this project was to provide an evidence-based means for comparison of 
feline biochemical analytes to increase the ability to distinguish between sickness and health 
of cats and enhance veterinarians’ clinical decision-making.   
Chapter 1, the literature review, has two sections; the first outlines how traditional, 
population-based reference intervals are generated, followed by a description of subject-
based reference limits that are being implemented in human clinical pathology. The second 
section describes the current approaches for method comparison of analyte values obtained 
from clinical pathology analysers.   
Since in-house biochemistry analysers are unable to be calibrated by end-users (such as 
veterinary hospital staff), any inherent bias in the determination of analyte values cannot be 
corrected (as it can for commercial laboratory analysers).  Bias of in-house biochemistry 
equipment is well recognised, and Chapter 2 provides the first concurrent assessment of 
multiple analysers, using a grading system that was devised to assess constant bias and 
degree of proportional bias.  It conclusively demonstrates that results from in-house analysers 
should not be directly compared to results from others, nor to those determined by 
commercial laboratory analysers. 
A potential solution may lie in the ability of correctly generated reference intervals to account 
for these analysers’ inherent bias. Chapter 3 demonstrates that reference intervals provided by 
in-house biochemistry analyser manufacturers as well as a commercial laboratory do not 
appear to account for the biases for all analytes and consequently may be inaccurate for local 
hospital population feline populations.  
It is now recognised in human clinical pathology, that for many biochemical analytes, 
traditional population-based reference intervals have limitations,  as a significant change in 
an individual’s analyte concentration within  the reference limits may still be an important 
medical indicator for that individual.  Conversely, values outside these limits are not always 
clinically important for an individual.  For appropriate analytes, subject-based reference 
values, often called ‘reference change values’ are used; these are determined from biological 
variation data which reflect the inherent physiological variation of these analytes within and 
between individuals. Chapter 4 defines the biological variation of clinical biochemical 
analytes in cats, determining which analytes are suited for traditional reference interval 
interpretation or would be better interpreted with reference change values.  The high 
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individuality found for most analytes indicate that subject-based reference values (which are 
determined and documented) should be used to assess feline plasma biochemistry samples. 
The generation of biological variation data enabled assessment of precision (repeatability) of 
in-house analysers in relation to this data, the recognised technique for human clinical 
pathology.  These results are documented in Chapter 5 which found that the precision of 
results from these in-house and commercial laboratory analysers were generally acceptable, 
so large differences between repeated results from the same patient are more likely to be due 
to biological changes rather than analyser variation. 
Chapter 6 assesses the total error (based on a combination of bias and precision) of values 
from three in-house biochemistry analysers in relation to a commercial laboratory analyser 
for feline plasma using multiple quality specifications. This study required an adaptation of 
method comparison techniques used for human clinical pathology so that these techniques 
could be used with equipment that is unable to be calibrated.  This chapter concludes that in-
house analysers provide acceptable results and few clinical decisions would be different 
based on the results determined by three in-house analysers compared to those determined by 
the commercial laboratory. 
The last chapter is a discussion on the impact this research will have on veterinary practice, 
the projects’ limitations and future directions for this avenue of research.  
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Abbreviations  
ACVIM- American College of Veterinary Internal Medicine 
ASVCP –American Society for Veterinary Clinical Pathology 
BV- biological variation: random, physiological fluctuations of an analyte around a 
homeostatic setting point
1
 
CLSI - Clinical and Laboratory Standards Institute  
CV- coefficient of variation: the standard deviation of a number of results divided by their 
mean, usually expressed as a percentage  
CVA- analyser coefficient of variation: variation of results attributable entirely to the analyser 
CVG - group (inter-individual/between individual) coefficient of variation: the variation in 
homeostatic setting points between individuals
1
 
CVI - individual (intra-individual/within individual) coefficient of variation: random, 
physiological fluctuations of an analyte within an individual around a homeostatic setting 
point
1
 
EQA- external quality assessment  
HPLC- high performance liquid chromatography  
IFCC - International Federation of Clinical Chemistry  
IRIS- International Renal Interest Society 
QCM- quality control material 
RCV- reference change value: the difference between two consecutive test results in an 
individual that is statistically significant.
2
 Synonyms include  ‘Significant Change Value’3 
and ‘Critical Difference’4 
RI- reference interval 
SD- standard deviation: a statistic that describes the dispersion or spread of a set of 
measurements about the mean value
5
  
TE- total error: the net or combined effect of random and systematic errors
5
 
TEa- total allowable (acceptable) error assessment of both the precision and bias of one 
method compared to an established method
6-7
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Glossary of standard definitions  
Analytical quality specifications: guidelines for the amount of analytical error (or variation) 
that is acceptable for the intended use of the test. The amount of variation in results should 
not compromise test interpretation, and therefore patient care. These specifications may be 
determined from biological variation data, expert consensus, regulatory requirements, or 
technological capabilities of equipment being assessed.
8
 
Analytical variation: variation in results solely attributable to analyser variation (and not due 
to ‘biological variation’). Analytical variation is commonly composed of bias (accuracy) and 
imprecision (repeatability).
9
 
Bias: also known as ‘systemic error’ or ‘inaccuracy’; the difference between what a 
procedure estimates a value to be and the true value of that quantity. The difference may be 
consistent across all concentrations (‘constant bias’) or by degree depending on the 
concentration measured (‘proportional bias’).6  
Biological variation: inherent physiological variation of analytes; can  isolate  ‘between-
subject’ or  ‘inter-individual’  or ‘group’ biological variation (CVG) and ‘within-subject’ or 
‘intra-individual’ biological variation (CVI).
6
 
Correlation: a statistical measure that indicates the extent to which two or more variables 
fluctuate together. In method comparison studies this is commonly reflected by assessment of 
how tightly clustered the observations are around a straight line indicating the line of identity.  
This line is used as a reference in a two-dimensional scatter plot comparing two sets of data 
expected to be identical under ideal conditions. When the corresponding data points from the 
two data sets are equal to each other, the corresponding scatters fall exactly on the identity 
line. Correlation is not a measure of agreement, as it is possible for two methods to be highly 
associated but still have considerable systematic error between them. This value should be 
used in method comparison studies to help determine if a sufficient range of values has been 
obtained and to ensure that simple linear regression is appropriate for analysis. It should not 
be used as a means of determining method suitability.
6
 
Distribution: refers to the spread and shape of a frequency curve of a particular variable, can 
be displayed as a histogram that shows the frequency of observations on the y-axis versus the 
magnitude on the x-axis.  Normal (Gaussian) distribution is centrally symmetrical and has a 
mean equal to the median equal to the mode.
5
   
Inaccuracy: refers to the ‘‘trueness’’ of a test result (how close the test result is to the ‘‘true’’ 
value of the analyte).   In clinical chemistry, an analyte’s ‘‘true’’ value is represented by a 
6 
 
thoroughly researched ‘‘definitive method’’ or ‘‘reference method’’ (e.g., HPLC). Clinical 
method comparison studies may compare a newer field method to a definitive or reference 
method or, more commonly, compare two field methods.
10
 
Index of Individuality:  a ratio of between-subject biological variation (CVG ) and within-
subject biological variation (CVI) that also accounts for analytical variation (CVA).
1
  
Method comparison: also known as ‘comparison of methods experiment’. A method 
validation experiment in which a series of patient samples are analysed both by the test 
method (the one under study) and a comparison method (an established method). The purpose 
is to assess whether a systematic difference (i.e. bias or inaccuracy) exists between the two 
methods. The differences in results by the two methods are interpreted as analytical errors 
between the methods.
5
  
Non-parametric: statistical techniques that do not rely on data belonging to any particular 
distribution. 
11
  
Parametric:  statistical approaches that rely on data having a specified distribution.
11
 
 Standard: parametric statistical method that assumes data distribution is normal. 
11
 
Robust: parametric statistical method that assumes data distribution is symmetric 
without being necessarily normal (Gaussian). 
11
 
Precision: the opposite of ‘imprecision’; a determination of the repeatability of results by 
testing the same sample multiple times and is often expressed as the coefficient of variation 
(CV) of a test or method.  Lack of precision is often referred to as ‘random error’ in relation 
to clinical pathology assessments.
10
 
Quality control material: a material (plasma, serum, whole blood, or other type of patient-
derived specimen, lyophilized preparation, solution, or device) that is used in the quality 
control process.
10
 
Reference change values: subject based reference limits that have been defined as “that 
difference between two consecutive test results in an individual that is statistically 
significant” 2 and expresses the difference that must be observed before a change of patient 
values should be considered clinically important.
5
 They have also been described as 
‘Significant Change Value’3 and ‘Critical Difference’.4 
Reference intervals: a range of results, typically determined from the central 95% of results 
obtained from a normal distribution of healthy individuals.
11
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Common reference intervals:  a determination of reference intervals from multiple 
laboratories, potentially using different methods, with laboratory and method biases 
corrected by using control material assessments, determined solely by calculation.
12
  
Harmonised reference intervals:  a determination of reference intervals from 
multiple laboratories, potentially determined with different instruments (methods) 
determined by consensus as well as calculation.
13
     
Total error: the net or combined effect of random error (precision) and systematic error 
(bias).
5
 
Transference: a technique to assess if an established reference interval is appropriate for a 
new method; compares results from 20 healthy reference individuals collected from the 
clinical population with the proposed reference interval. Reference intervals are considered 
valid if one or two results are outside the interval.  Transference is rejected if three or more 
results fall outside the reference interval.
14
  
 
 
 
Style Note 
This thesis uses English spelling, however, Chapters 5 and 6 were originally published as 
original studies using American spelling.  The title pages for these chapters include the 
published titles of these chapters. Hence, the word ‘analyser’ is spelled ‘analyzer’ on these 
title pages but has been changed to ‘analyser’ for the text of these chapters for consistency 
with the rest of the thesis. 
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Chapter 1: 
Literature review 
 
General overview of research 
Plasma biochemical analytes have a role in making a diagnosis, monitoring of illness or 
confirming health.
15-17
  The determined values have no meaning unless there is some basis for 
comparison so they can be interpreted as either ‘normal’ or ‘not normal’.16  Typically, this 
interpretation is made by comparing the measured analyte value with a population-based 
reference interval that describes the central 95% of a healthy population.
16, 18
 Reference 
intervals for biochemical analytes published in textbooks or provided by commercial 
laboratories or analyser manufacturers usually either fail to define or poorly define the 
reference population.  Supplied reference intervals seldom provide other critical information 
(such as whether results were generated with plasma or serum) that may affect the 
interpretation of results.
18-19
 Further, for nearly all analytes measured by any method, the 
within-subject biological variation is much smaller than the between-subject variation. The 
major consequence of this marked individuality is that conventional population-based 
reference intervals, irrespective of whether generated by an individual laboratory,  common 
or harmonised, are of limited utility in evaluating the results of an individual in screening or 
diagnosis, since many individuals may have values which are highly unusual for them but 
still lie within reference intervals; conversely, clinically normal subjects may have analytes 
outside the reference intervals.
17
 It is accepted in human clinical pathology
17
 and 
recommended for veterinary clinical pathology
4, 16, 20-22
 that for those analytes with high 
individuality, subject-based reference intervals (reference change values) provide advantages 
for the detection and monitoring of disease,
16-17
 however, the biological variation of feline 
clinical biochemistry analytes had not been defined prior to this project.  
Even if the most appropriate basis for comparison of results is chosen, there is no certainty 
that values determined from one analyser are comparable to those determined from another, 
because bias compared to commercial laboratory analysers has been recognised for in-house 
biochemistry analysers for feline samples.
23-28
 
This review is divided into two sections:  
1. Reference intervals/reference change values. This section discusses the theory that 
underpins how analyte values are assessed in relation to other values from a population of 
healthy animals or compared to values from the same individual. 
2. Analytical performance of analysers, which assesses method comparison, i.e. how analyte 
values obtained from one analyser are compared to another. 
The review concludes with a statement of the overall objective of this research and the 
specific aims.   
12 
 
Reference intervals 
The introduction of reference intervals as currently understood, is typically attributed to 
Gräsbeck et al (1968)
29-30
 in the late 1960’s who expanded on the initial work of  Wooton et 
al (1951).
15
  Wooton et al obtained blood samples from 100 healthy human volunteers which 
were assessed for 18 biochemical analytes.  If the distribution was not normal, the results 
were normalised by log transformation and the normal distribution was assessed for the upper 
and lower 10% and 1% limits. Wooton suggested that results outside the 10% limits should 
be viewed with suspicion, while results falling outside the 1% limit may be considered 
abnormal.
15
 Gräsbeck et al (1968) first documented using limits of two standard deviations 
from the mean of a normal (or normalised) value distribution which results in the central 95% 
range of what is considered typical in ‘healthy’ individuals and used to the current day. His 
group additionally initiated definitions of ‘normal’ in relation to health.29-30 The introduction 
of such reference intervals to veterinary medicine is generally attributed to Lumsden and 
Muller in 1978,
31
 although there are earlier references that provide means and standard 
deviations only without any attempt to normalise the results’ distributions.32-33  
The main considerations when determining reference intervals have remained essentially 
unchanged since Gräsbeck et al
29-30
 and can be grouped as follows:
14, 18, 34-35
 
(1) Pre-analytical (selection of individuals and sample factors such as collection, transport 
and storage of specimens). 
(2) Analytical (analytical method used). 
(3) Post-analytical (statistical techniques used). 
(1) Pre-analytical considerations 
a) Selection of the population should be relevant to individuals being assessed. 
There are two studies assessing differences in reference intervals between  cat breeds, both 
have demonstrated differences between breeds.
36-37
 There are also a few studies assessing 
differing reference intervals for age
38-41
 and sex
19
 in cats, which are recognised covariates in 
human clinical pathology.
34
  Therefore, reference intervals should be determined from a 
population of cats that approximates the age, sex (including whether neutered or entire) and a 
mix of breeds (or partitioned by breed) in the proportions seen in the population/practice in 
question.
14
  Additionally, it is also recognised in human clinical pathology that geographical 
variations in reference intervals occur.
42
  This does not appear to have been widely 
investigated for veterinary clinical pathology but is likely to occur since geographical 
variations are recognised for proportions of blood types.
43-46
 Therefore  it is prudent that any 
reference intervals used should be generated in the same geographical region.  
b) Selection of ‘healthy’ individuals  
i. How is ‘healthy’ defined? 
Since the purpose of clinical pathology testing is to distinguish health from ill-health, it 
makes intuitive sense that the individuals chosen to determine reference intervals should be 
healthy.  However, the definition of ‘health’ is problematic in human clinical pathology.  The 
World Health Organisation defines health as “a state of complete physical, mental and social 
wellbeing and not merely absence of disease or infirmity”48 which is a challenging guideline 
even for human subjects and open to interpretation.  For veterinary clinical pathology, health 
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for a reference population of individuals is defined as ‘clinically normal’ and typically 
determined solely by history and physical examination.
14
  However, a more extensive 
investigation into the patients’ health status is possible, potentially including haematology, 
biochemistry, urinalysis, imaging, faecal examination for parasites, and clinical follow-up.  
The extent of investigation will vary depending on the source of reference individuals and 
specifications of the reference interval study. It is recommended that exclusion criteria are 
defined at the outset to identify animals that should not be recruited.
14, 18
 
ii. Is perfect health a realistic aim?  
The ASVCP reference interval guidelines state that: “Demographics of the reference 
population should represent the animal population for which the RI will be used.” (page 
442)
14
 and for human clinical pathology, it has been stated that: “The majority of people 
seeking care have non-life-threatening, yet troublesome complaints.  In other words, persons 
who are in a reasonable state of health and who are not suffering from significant illness.  
Therefore the relevant cohort should fit this description, not individuals who lack any clinical 
or laboratory issues” (page 702).49  
Any attempt to omit all but entirely healthy individuals is likely to be too restrictive to 
achieve enough subjects and may even result in reference intervals that do not reflect the 
clinical population.  Examples of a condition that may be permitted for inclusion in a 
reference population of cats being assessed for plasma biochemistry reference intervals might 
include mild to moderate dental disease.  This condition typically does not affect plasma 
biochemical values.   
c) Sampling factors 
i. Patient factors:  
Variations in results can occur depending on: whether individuals are fasted (or not), stressed, 
sedated for sampling, the time of day for sampling, circadian rhythms and hormonal 
fluctuations.
50-51
 These factors need to be standardised for each reference population in 
advance of determining reference intervals.  Some suggestions of exclusion factors for stress 
are increased body temperature or heart rate.
14, 18
 In feline practice, the effect of patient 
handling is a further consideration, as cats are recognised to be susceptible to stress 
hyperglycaemia that can occur with hospital visits, physical restraint and/or venipuncture.
51
 
ii. Sample collection:  
Sample collection should also be consistent between the reference population and the general 
population. Studies have found differences in blood glucose concentrations in samples 
collected from ear veins compared to those collected from jugular veins;
52-53
 differences have 
been observed for creatinine and potassium results from samples collected from jugular veins 
compared to cephalic or saphenous veins in dogs.
54
  Poor technique may result in increase of 
enzyme activities such as creatine kinase activity due to muscle damage as a direct result of 
sample collection.
55
  Differences in results have been demonstrated for humans sampled  in 
different postures or associated with the preparation of the site (e.g. alcohol being sprayed or 
wiped or other aseptic techniques);
56
 whether such changes may also occur in animals has not  
been investigated.  
The collection system (e.g. needle and syringe or vacutainer) should be consistent.  For 
humans, it is recommended to use needle gauges large enough to avoid intense shearing of 
14 
 
RBC and haemolysis, and, for the same reason, to exert only moderate negative pressure 
when aspirating blood with syringes;
57
 such changes do not appear to have been  investigated 
in veterinary settings but may  occur.  Collection of small volumes using capillary tubes does 
not appear to cause clinically relevant differences in biochemistry variables in cats and 
dogs.
58-60 
iii. Anticoagulant and tube choice: 
Plasma or serum samples to determine reference intervals should be collected with the same 
anti-coagulant (for plasma) used for testing the general population.
14, 18
  Differences in 
reference intervals for glucose
61
 and potassium
62 
in  plasma compared to  serum  have been 
recognised.  
Glass and plastic tubes have been shown to result in comparable results for human 
biochemical analytes
63
 but this has not been validated for animal specimens.
50
 Inconsistencies 
of results between tubes with or without gel layers to optimise separation of blood 
components has not been widely investigated but is known to occur with total tri-
iodothyronine assessments in humans.
64
 
iv. Specimen handling  
It is recommended that samples exhibiting haemolysis or lipaemia or any other change that 
may affect the determination of analytes should be excluded.
11, 14, 18, 34
  Delays in  processing 
or analyte determination can be problematic: for example, feline potassium concentrations 
decline  with  time when there is a delay in decanting the serum or plasma from full blood.
62
  
Time to testing should be considered in relation to transportation of samples.  Additionally, 
the timing of centrifugation (or not) as well as duration and speed should be determined for 
the reference population in accordance with handling of samples for the general population. 
Storage of samples should also be in accordance with the time and conditions (e.g. ambient 
temperature) of what can be expected in the clinical situation.
14, 18
 
2) Analytical considerations/Analytical method used:  
Reference specimens should be analysed in the same manner as patient specimens. Different 
analysers may use different methods to determine analyte concentrations so reference 
intervals established on one brand (and most likely model as well) of analyser do not equate 
to other analysers.
6 
Additionally, quality control of analytical methods is critical for the 
reliability of the values obtained.  Changes in reagent lots and technical staff should be 
integrated into RI studies whenever possible to approximate standard operating procedures 
and normal working conditions. 
11, 14, 18, 34 
3) Post-analytical considerations 
Determining reference intervals has become easier since the introduction of freeware such as 
Reference Value Advisor
65
 that performs many of the statistical tasks and mathematical 
calculations required.  However, understanding the theory and terminology of these facilitates 
generation of the most appropriate reference interval from the provided (calculated) options.  
a) Non-parametric techniques 
The standard statistical approach for determining reference intervals from a reference 
population of 120 or more individuals is to use non-parametric estimates of the 95% 
reference interval (and present each limit with 90% confidence intervals). Observations are 
15 
 
ranked according to size, and the 2.5 and 97.5 percentiles are obtained as the 0.025 (n + 1) 
and 0.975 (n + 1) ordered observations. If the estimated rank values are not integers, then 
linear interpolation is carried out. When less than 120 subjects are available, non-parametric 
assessments become less accurate with 39 being the minimum number of samples for which 
95% non-parametric RI can be determined.
11,66
 When reducing individuals from 120 (or 
more) to 39, the precision to estimate the confidence values declines and at very low 
numbers, it becomes impossible to calculate confidence intervals, since with so few 
individuals the most extreme values serve as the lower and upper limits.
11, 14, 18, 66
 
b) Parametric techniques  
(Standard and Robust) 
When less than 120 individuals are available to determine reference intervals, it becomes 
appropriate to use parametric techniques, however these require the values to be 
symmetrically distributed.  The standard method assumes that the data distribution is 
Gaussian and uses ± 2 SD as the limits of the reference interval. The robust method assumes 
that the data distribution is symmetric without being necessarily Gaussian. It is built using 
robust statistics (median and median absolute deviation) that are less sensitive to outliers. 
Thus the reference interval is obtained by a process that iteratively gives a smaller weight to 
data far from the central location. 
11, 14, 18, 66
 
i. Normal (Gaussian) distribution 
A normal distribution is centrally symmetrical and has a mean equal to the median and equal 
to the mode.  Determining normality of the distribution of data can be done by graphical 
inspection, or numerically. There are over 40  tests to verify normality.
67
  The most basic 
numerical tests assess skewness (i.e. deviation from symmetry)
68
 and kurtosis (central 
peakedness).
69
 Tests that combine assessments of kurtosis and skewness are called omnibus 
tests (or ‘goodness of fit’ tests), examples include the Anderson-Darling test, the Shapiro-
Wilk test, the Kolmorov-Smirnov test and the Lilliefors test.  There is debate as to which test 
is preferable under various circumstances.
67, 70-71
 
If the distribution is not normal, the data can be transformed to attempt to fit a normal 
distribution.  The most common transformation technique used to determine reference 
intervals is the Box-Cox transformation.
70
 Box-Cox transformations use the formula:  
x(λ) = (xλ - 1) / λ 
[if λ = 0, then x(λ) = ln(x) is used] and determine a value for λ to result in a normal 
distribution].
70
 
ii.  Outliers 
Outliers are values that do not truly belong to the reference distribution; they can include 
extreme values resulting from inadvertent inclusion of samples from unhealthy or non-
representative individuals or those affected by pre-analytical (e.g., poor sample quality), 
analytical, or post-analytical (e.g., transcription) errors.  The major difficulty with outliers is 
recognising whether values are truly aberrant observations or extreme values from clinically 
normal individuals (i.e. that should be part of the normal distribution).  Outliers can be 
visually detected via a histogram or using numerical tests such as Dixon-Reed’s (when only 
one outlier is suspected) or Tukey’s (when multiple outliers are present).14,18 The Tukey 
outlier identification method determines outliers based on the median and interquartile range. 
16 
 
In brief: Q1, Q2 and Q3 represent the first, second and third quartiles of the distribution and 
IQ = Q3 - Q1 is the inter-quartile range. Outliers are lower than Q1-3*IQ or higher than 
Q3+3*IQ and suspect values are within Q1-3 * IQ and Q1-1.5 * IQ or between Q3+1.5*IQ 
and Q3+3*IQ;
72
 this technique is appropriate for the relatively small numbers of subjects 
typically used in veterinary reference interval studies. It has been stated that no method 
optimally detects all outliers.
73
 Such outliers should be removed if they are considered not to 
belong to the reference population (such as poor sample quality or unhealthy individuals) but 
retained if these extreme results are considered to be from clinically normal individuals. 
When in doubt, the emphasis should be on retaining such results.
18
  
iii. Reference interval subclasses 
Reference intervals can also be partitioned into subclasses that account for sex, age or breed 
and should be considered if the additional reference intervals created are clinically useful.
14, 18
 
In many circumstances, the differences between subclasses have not been assessed for 
veterinary reference intervals.  Age
38-40, 74-75
 and breed
36-37
 based on clinical pathology 
differences have been described for cats.  However, partitioning should be considered only if 
there are at least 40 individuals within each subclass or if there are clear clinical reasons for 
doing so.
14
 Statistical criteria should consider not only subgroup means but also subgroup 
standard deviations.
14
 
c) Validation 
Validation describes a determination of the applicability of existing reference intervals to a 
new technique (instrument and/or method).  The most direct validation method is known as 
‘transference’.  This technique compares results from 20 healthy reference individuals 
collected from the clinical population with the proposed reference interval.
11,14
  Reference 
intervals are considered valid only if one or two results are outside the interval.  Transference 
is rejected if three or more results fall outside the reference interval.  Zero values falling 
outside the reference interval suggests that the reference interval is too wide and that its 
sensitivity in detection of abnormal individuals should be re-assessed.
11, 14
  If bias exists 
between the new and existing method, reference limits can be adjusted using regression 
statistics or difference of means. Transference between methods in this way should be limited 
to a single occurrence. Instrument precision and laboratory quality should be similar between 
new and existing methods. Any differences in analytical quality reduce the appropriateness of 
using transference.
11, 14
 
Transference also assumes that patient populations are comparable. This means that complete 
demographic information on the original reference sample group should be available so that it 
can be determined if it corresponds to the demographics of the new population.
14, 18
 
Transference validation should not be considered as a substitute for correct calculation of 
reference intervals and its use should be limited to circumstances where the complexity, cost, 
effort and obtaining sufficient number of adequate specimens precludes de-novo production 
of reference intervals.
76
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Reference change values 
Reference change values (RCV) are subject-based reference limits defined as: “that 
difference between two consecutive test results in an individual that is statistically 
significant”.2  
Essentially, RCV distinguishes if a change in results (from prior testing) in an individual for a 
specific analyte is physiological or clinically significant.  RCV depends on biological 
variation for each analyte to determine its applicability and to calculate its value.
2, 16-17
 
Biological variation has two components: within-individual and between-individual variation, 
which are generally expressed in terms of coefficients of variation: CVI and CVG for intra-
individual and inter-individual (or ‘group’ variation), respectively. CVI relates to random, 
physiological fluctuations of an analyte around a homeostatic setting point. The homeostatic 
set points between individuals also vary, and this variation is known as between-, inter- 
individual or group variation.
1
 
The applicability of using a RCV for a particular analyte is determined by that analyte’s 
‘Index of Individuality’.  Index of Individuality is essentially a ratio of CVI and CVG but must 
also take into account how much analytical variation (CVA) occurs, i.e. the variation 
attributable to the analyser.
1
 Therefore the formula to determine the Index of Individuality is: 
 
√( CVA 
2
+  CVI
2
 ) /CVG 
 
This formula results in lower values for increased individuality of each analyte and therefore, 
the reciprocal form of this formula has been advocated,
22, 77
 i.e.: 
 
CVG /√( CVA 
2
+  CVI
2
 ) 
 
This formula is considered more intuitive as it results in higher values for increased 
individuality of each analyte. 
With the traditional use of CVG as the denominator, indices of individuality less than, or 
equal to 0.6 indicate that subject-based reference values are more appropriate (and 
population-based reference intervals are of limited utility); and indices greater than, or equal 
to 1.4 indicate population-based reference intervals are more appropriate.
1
 With the inverse 
formula (CVG as the numerator) indices of individuality greater than, or equal to 1.67 indicate 
that subject-based reference values are more appropriate and indices less than, or equal to 0.7 
indicate population-based reference intervals are more appropriate.  For those analytes with 
intermediate indices of individuality between 0.6 and 1.4 (or 0.7 and 1.67 by the inverse 
formula), interpretations are made similarly, but with reference to the population-based 
reference interval as well. 
RCVs are generally calculated in percentage terms according to:  
 
RCV = Z*√2 * √( CVA 
2
+  CVI
2
 ). 
 
Generally, a Z value is chosen to a 95% probability of significance; thus, any variation 
beyond the RCV has a 95% probability of being clinically significant (and not merely 
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physiological).  One-sided (Z = 1.65) or two-sided (Z = 1.96) results are calculated depending 
on whether the analyte is likely to require interpretation when concentrations are either high, 
or low (one-sided) or for both high or low concentrations (two-sided).  
Although established for over thirty years
1, 9, 78-79
 and widely regarded as more appropriate to 
use than traditional population based RIs (for appropriate analytes),
1-2, 17, 80-81
 the use of 
RCVs are slowly making inroads  into human clinical pathology.  The advantages and 
disadvantages were assessed in a recent ‘opinion paper’.3 Advantages included that their use 
gives clinicians the ability to differentiate physiological change from analytical variation, 
RCV is independent of a study population (that is required for reference intervals), and that 
results are valuable for clinical validation.  Disadvantages included the requirement for serial 
testing, changes to laboratory reporting systems are required and further training of 
laboratory and clinical staff is required to interpret the results.  
Until recently, the concept of RCVs within veterinary practice, received little attention after 
initial reports in the early 1990s established biological variation (BV) values and RCVs for 
many analytes in dogs,
4, 82-83
 and cows.
84
  However, in the last 10 years, BV values and RCVs 
have been reported for racing pigeons and budgerigars,
20-21
 exotic species such as Dumeril’s 
monitors
85
 and captive Bald Eagles;
86
 further, the ASVCP reference interval guidelines,
14
 a 
recent review article
16
 and additional information for dogs
22, 87
 has brought these concepts to  
current attention for veterinary clinical pathology.  Prior to this project, there were no 
published peer-reviewed reports of BV or RCV data for cats.
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Analytical performance (assessing in-house and commercial laboratory analysers) 
There are a variety of in-house and commercial laboratory analysers available, often using 
different methods to determine a value of a clinical analyte. This can result in varying values 
when the sample is analysed with different machines.
6
 For example, creatinine can be 
measured by the Jaffé reaction
88-89
 or enzymatic methods.
90-91
 In relation to the reference 
method of HPLC, the Jaffé reaction has been shown to be less reliable to determine creatinine 
concentrations in cats.
92
 
Comparison of methodologies from one analyser to another is primarily concerned with the 
assessment of bias as part of the total analytical error or the quality specification for a test.  
Total analytical error comprises (1) ‘random error’, also known as ‘precision’ or 
‘imprecision’, which assesses the repeatability of results by testing the same sample multiple 
times and; (2) ‘systemic error’, also known as ‘bias’ or inaccuracy which assesses how much 
variation from a recognised method occurs and if any variation is consistent across all 
concentrations (‘constant bias’) or varies by degree depending on the concentration measured 
(‘proportional bias’).  
Method Comparison 
(1) Precision 
Precision depends only on the amount of random error and does not relate to the trueness of 
the result obtained. Although the aim is to be able specify the ‘precision’ of a method, 
measuring how much variation occurs within a set of results generated by testing the same 
sample repeatedly is actually a determination of ‘imprecision’.  Imprecision is calculated as 
the standard deviation (SD) divided by the mean of these results to determine the coefficient 
of variation (CV).
6 
The assessment of imprecision also depends on comparison to a defined 
standard, i.e. what CV is acceptable for a particular analyte? Tonks was one of the first 
clinical chemists to propose maximum allowable limits of random analytical error in 1963.
93
 
Tonks set maximum allowable limits based on reference interval (RI) limits such that: 
 
Allowable limits of error (%) = + (0.25 x ‘normal range’) / mean of normal range x 100 
 
with maximum limits set at + 10%.
93 
The limitations of this approach are that it depends on 
correctly determined RIs, the difficulties of which are outlined earlier  as well as  the 
determination of such RIs may themselves be influenced by imprecision. 
In 1968 Barnett defined 'medically significant CV' for 16 biochemical analytes on the basis of 
opinions of 125 internists and 100 general practitioners.
94
 Although the opinions of experts 
are valuable, they are subjective and, certainly when initially proposed, were based on results 
with undetermined imprecision. 
Cotlove in 1970, proposed the assessment of imprecision in relation to biological variation 
with the recommendation that the analytical CV (CVA) be no greater than half the previously 
determined intra-individual variation (CVI) for each analyte:
9
 i.e. 
 
CVA  <  0.5 x CVI 
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By this standard, CVA contributes no more than 12% to total variability (CVT) in a sample since, 
if CVA  = 0.5 x CVI, and given that  CVT
2
 = CVA
2
  + CVI
2
, then: 
 
CVT
2
  = CVA
2
  + (CVA/2)
2
 
=1.25 x CVA
2 
CVT =√(1.25 x CVA
2
) 
=1.12 x CVA 
 
This has become known as ‘desirable’ imprecision.95 The tiered approach described by Fraser 
in 1997
95
 recognizes that analytes with large biological variation (such as bilirubin) easily 
attain quality standards and accordingly, a more stringent standard should be applied, so 
‘optimal’ imprecision is defined as: 
 
CVA  <  0.25 x CVI 
Conversely the available methodology and technology limit the ability to reach desirable 
quality standards for those analytes with minimal biological variation such as electrolytes 
and, consequently, a ‘minimal’ quality standard is also described: 
 
CVA  <  0.75 x CVI 
Currently accepted standards for analytical quality specifications are based on the ‘Stockholm 
Consensus’8 which defines a hierarchy (see Table 1).   
The highest level of this hierarchy is ‘evaluation of the effect of clinical performance on 
clinical outcomes in specific clinical situations’ i.e. Table 1, no 1. However, it is generally 
regarded that the required conditions are difficult to define and require complicated and 
individualised models which may not be relevant in other clinical settings.
96
 Therefore, most 
international professional bodies such as the International Federation of Clinical Chemistry 
(IFCC) and Clinical and Laboratory Standards Institute (CLSI) generally use the next 
hierarchical level based on biological variation to determine quality specifications.
96
 
Performance standards remain an emerging concept within veterinary clinical pathology.
6, 97-
99
 Several studies have assessed precision of veterinary in-house biochemistry analysers.
23-24, 
100-104
  However, these precision determinations were neither assessed in relation to biological 
variation nor statistically compared to a commercial laboratory analyser. For example, Little 
et al., 1992 assessed the precision of 20 biochemical analytes on the IDEXX Vet-Test 8008 
analyser in relation to ‘Tonks Limits’ based on RIs provided by the manufacturer;100 and 
Sutton et al 1999 assessed the precision of 12 biochemistry analytes on the Abaxis VetScan
24
 
in relation to published standards.
105
 To date, no studies have assessed the precision of 
biochemistry analysers in relation to biological variation. 
21 
 
 
Table 1  ‘Stockholm Consensus’ Hierachy used to define the hierarchy of models that should be applied to 
set analytical quality specifications.
 8
 
 
1. Evaluation of the effect of analytical performance on clinical outcomes in specific clinical settings. 
2. Evaluation of the effect of analytical performance on clinical decisions in general: 
a. Data based on components of biological variation. 
b. Data based on analysis of clinicians' opinions. 
3. Published professional recommendations: 
a. From national and international expert bodies. 
b. From expert local groups or individuals. 
4. Performance goals set by: 
a. Regulatory bodies. 
b. Organizers of External Quality Assessment schemes. 
5. Goals based on the current state of the art: 
a. As demonstrated by data from or Proficiency Testing scheme. 
b. As found in current publications on methodology. 
 
Pooled plasma vs commercial Quality Control Materials 
A further difficulty for precision studies is the choice of material used for repeated testing.  
Most commercial laboratories test their analysers daily with commercially available quality 
control materials (QCMs) which are prepared from human or animal serum with analyte 
concentrations manipulated by the addition of various animal extracts, usually from a variety 
of species as well as non-protein materials including preservatives and stabilisers to maintain 
product integrity over time.
106-109
 Ideally, QCMs should be ‘commutable’ with patient plasma 
or serum; that is, the results from QCMs should be consistent with those from plasma or 
serum samples from healthy and diseased individuals.
110
 Species-specific plasma or serum 
samples, pooled from multiple individuals, are considered the ideal standard for QCMs 
instead of  commercially available QCMs. 
106
  However, with pooled plasma samples, analyte 
concentrations can decline over time,  requiring new batches of material to be prepared at 
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regular intervals and the concentrations of analytes within each batch to be re-established to 
confirm that each batch is comparable.
111
 Also analyte concentrations in pooled plasma 
samples can differ from population normal ranges, pooled plasma may be not be commutable 
for all analytes being assessed, there can be difficulty recruiting donors with pathologic 
analyte concentrations, and only limited quantities of pooled plasma may be available. For 
these reasons, authentic clinical specimen pools are not considered practical for large multi-
constituent surveillance quality assurance studies.
112
 Commercial QCMs do not appear to 
have been assessed for commutability with cat or dog serum or plasma.  Commercial QCMs 
are acceptable for precision studies under ASVCP guidelines.
10
 
Precision varies with concentration 
Validation of the analytical method should be performed at biologically relevant 
concentrations for the analyte.  However, precision varies with concentration for numerous 
biochemical analytes including albumin, bilirubin, chloride, cholesterol, creatinine, 
phosphorus, total protein and urea and typically precision improves with greater 
concentrations.
113-115
 For example, bilirubin can have CVA greater than 20% for 
concentrations less than 17μmol/L, compared to 5 to 6% at concentrations around 100μmol/L 
regardless of method used.
113
 Studies assessing precision of veterinary in-house analysers 
have typically found most analytes had CVAs <5%.  Where CVAs were higher, most studies 
noted that the quality control solution had very low concentrations of the analyte.
100-102
 
(2) Bias 
Bias (or inaccuracy) refers to ‘systemic error’, which (as noted above) assesses variation 
compared to a recognised method and whether the variation is consistent across all 
concentrations (‘constant bias’) or varies depending on concentration (‘proportional bias’). 6-7 
Bias is determined by repeated measurements (theoretically, infinite numbers of 
measurements) at different concentrations of the test method which are ideally compared to 
the known true values.  ‘True’ values of analytes can be considered to be a theoretical 
concept so the results from a new method are usually compared to a well standardised, highly 
stable laboratory method known as a ‘definitive method’.6-7  Commercial laboratories 
frequently use definitive methods but these can be flawed. One example is that the popular 
Jaffé  method to determine creatinine concentrations (widely used by commercial 
laboratories) varied for results in dogs, rats, mice
116
 and cats
92
 when compared to 
concentrations determined by HPLC, which is regarded as having greater analytical 
specificity than conventional creatinine measurement.
117
  Enzymatic analysis of creatinine 
provides results consistent with HPLC. 
92, 116
 
A minimum of 40 patient samples should be tested by both the recognised (or comparative) 
and new method.
118
  Ideally, the sample concentrations should cover the working range of the 
methods and represent the typical spectrum of diseases expected for the target species.  
There is no universally recognised statistical technique to assess bias between two methods.  
Possible approaches to assess bias include regression analyses,
119-122
 Lin’s concordance 
correlation coefficient
123-124
 and Bland-Altman (difference) plots.
125-126
 
Data analysis usually begins with plotting the data from the new method (y-axis) against the 
comparative method (x-axis); the resulting data points are visually assessed in relation to the 
line of identity (x = y) to indicate the relationship between the results, the data distribution 
23 
 
and data range.
6
 Correlation analysis should be performed if x and y appear to be linearly 
related and data are not clumped at one end of the  range.  
Pearson’s correlation coefficient (r)127 is calculated to assess which regression technique is 
appropriate,
6
 and is used to determine Lin’s concordance correlation coefficient.123 Pearson’s 
correlation coefficient assesses the tightness of clustering of observations around a straight 
line.  Pearson’s correlation coefficient (r) is  1.00 when the results across a range of analyte 
values  fall along a straight line when plotted against results from the commercial laboratory 
analyser irrespective of the deviation of this line from the 45˚ line through the intercept (the 
line of perfect concordance or agreement). Closeness of correlation can be sensitive to the 
range over which the results are being measured; in which case, correlation may be improved 
by increasing the range over which measurements are obtained.  In one study, the correlation 
coefficient between two methods using a narrow range of values was 0.763 but increased to 
0.849 with only one additional data point that increased the range; and then to 0.953 with 
adding only a single extra data point to further increase the range.
128
  
Lin’s concordance correlation coefficient measures agreement and is calculated as the 
product of Pearson’s correlation coefficient and the bias parameter, a measure that describes 
how far the reduced major axis line of best fit deviates from the line of perfect concordance.  
A perfect 45˚ line (slope =1.00) with constant bias (i.e. the average difference of results not 
close to 0) will have a relatively poor Lin's coefficient (though this can be overcome for 
clinical use in most cases by adjusting the reference interval).  Proportional bias is when the 
slope varies by a non-trivial amount from 1.00.
123
 
There is no universal descriptive scale for the degree of agreement as determined by Lin’s 
concordance correlation coefficient. The scale shown in Table 2 has been proposed.
124
 
 
 
Simple linear regression (also called ‘ordinary least squares’ regression) is considered to 
provide useful information about constant error and proportional error from intercept and 
Table 2 Proposed scale for degree of agreement 
determined by Lin’s concordance correlation 
coefficient 
Strength-of-
agreement 
Lin’s Correlation 
Coefficient  
Almost perfect >0.99 
 
Substantial >0.95–0.99 
 
Moderate 0.90–0.95 
 
Poor <0.90 
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slope when the correlation coefficient (r) is > 0.975 (for data encompassing a small range) or 
> 0.99 (for data encompassing a wide range).
6, 120
 Proportional error exists if the slope differs 
from 1; constant error is present if the intercept differs significantly from 0 (and the slope 
does not differ greatly from 1). Ordinary least squares regression assumes that the 
comparative (accepted) method is free of error and that the error of the new method is 
normally distributed and constant over the range studied.
122
 These assumptions are almost 
never fulfilled, because both methods are usually subject to random measurement
errors, and the standard deviations of the error distributions are more likely to be proportional 
to the analyte concentration rather than constant.
129
   However, when there is high association 
between methods (r approaches 1.00), the degree of these errors has minimal effect so 
ordinary least squares regression is appropriate to use. 
There is some debate concerning the most appropriate regression techniques to be used for 
clinical chemistry comparison, particularly where r differs from 1.00.
119-120
 The two most 
commonly used alternatives are Deming regression and Passing-Bablok regression.
6
  For 
Deming regression, errors for the two variables are assumed to be independent and normally 
distributed, and the ratio of their variances is known. This ratio is typically estimated from 
precision data generated previously; however, this regression procedure takes no account of 
possible errors in estimating this ratio.
129
 Passing-Bablok regression makes no assumptions 
about the distribution of errors; this technique assesses the slopes between all possible sets of 
two points, which are then calculated and ranked. The median slope is reported.  The 
intercept is estimated so that at least half of the data points are located above or on the 
regression line and at least half the data points below or on the regression line.
121, 130-131
 An 
advantage of Passing-Bablok regression is its robustness to outliers since the slope caused by 
occasional outlying values is unlikely to have a bearing on the median slope. This 
‘robustness’ has also been described as a disadvantage as outlying values are essentially 
ignored.
132
 
There is no statistically ‘best’ regression method and where variation between results is 
found, underlying reasons for the variation should be sought.  It has been argued that 
regression should not be applied at all in relation to method comparison, and that Bland-
Altman bias plots should be used alone.
125-126
  
Bland-Altman difference plots are constructed by plotting the difference between the 
methods (new method minus comparative method) on the y-axis against the mean of the 
methods ([new method plus comparative method]/2) on the x-axis.
125
 The mean and SD of 
the differences in results between the new method and the comparative method are used to 
calculate 95% limits of agreement (mean difference ± 1.96 × SD). The mean difference in 
results between the new method and the comparative method can then be expressed as a 
percentage of the mean result for each analyte on each analyser, thus enabling comparison 
between analytes. The range of the 95% limits of agreement can similarly be expressed as a 
percentage of the mean result for each analyte on each analyser. 
Proportional bias can be assessed with Bland-Altman analyses by determining the correlation 
coefficient for the association between the differences and the mean of the two measurements 
(essentially the slope of the plot), and an F-test of equality of means and variances
133
 can be 
used to determine the significance of this slope. Proportional bias can be considered to be 
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present when the correlation coefficient is markedly different from zero and the P value for 
the F-test is low. 
Constant bias is determined by the mean difference when proportional bias is not present (i.e. 
the correlation coefficient approaches zero). 
(3) Total Acceptable Error (also called Total Allowable Error) 
Total analytical error comprises both the precision and bias of one method compared to an 
established method.
6-7
 The amount of analytical error that is acceptable should be determined 
so as to not compromise test interpretation, and therefore patient care.
9, 94, 128
 Such quality 
requirements can be determined from biological variation data, expert consensus or 
regulatory requirements.
7
 For human clinical pathology, currently accepted standards for 
analytical quality specifications are based on the ‘Stockholm Consensus’8 which defines a 
hierarchy (presented as  Table 1).   
In short, acceptance limits for bias and precision are calculated from within and between 
individual biological variation values and then summated with the multipliers for both bias 
and precision varying with each quality standard level. These calculations can be summarized 
as: 
 
Allowable imprecision = X*CVi 
 
Where CVi = intra-individual biological variation and X varies from 0.75 to 0.5 to 0.25 for 
minimal, desirable and optimal quality standards. 
 
Allowable bias = Y*√(CVi2  + CVg2) 
 
Where CVg = between individual biological variation and Y varies from 0.375 to 0.25 to 
0.125 for minimal, desirable and optimal quality standards. 
 
Total allowable error  = 1.65*(Allowable imprecision) + Allowable bias, or 
 
TEa     = 1.65*(X*CVi) + Y*√(CVi2  + CVg2) 
 
Data based on analysis of clinicians’ opinions comes next in the hierarchy, consistent with 
the recently published ASVCP allowable total error guidelines limits.
135
   
Performance targets based on ‘current state of the art’ can be determined from precision 
studies from the equipment being assessed; two examples are ‘calculated total error’ and 
‘expanded measurement uncertainty’.6, 136-138   
‘Calculated total error’ (TEc) is based on the imprecision and bias for each analyte on each 
analyser being assessed as: 
 
Bias + 2 x CVin-house.
136, 138 
 
The ‘multiplier’ factor chosen can vary, typically from 2 to 6; 2 x CV is considered a strict 
standard and 2 x CV falling within the TEc range is commonly used to represent an 
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approximately 95% probability level.
136
 Since CV is a percentage expression of standard 
deviation (SD), 2 x CV is the same 2 x SD from the mean which provides a 95% confidence 
limit for the mean. Bias can be chosen from that found at concentrations of particular clinical 
interest or, in cases of proportional bias, the average bias determined may, or may not be, 
appropriate to use.  
Expanded measurement uncertainty is based on the joint imprecision of the commercial 
analyser and each in-house analyser and an expanded measurement uncertainty coverage 
range can be calculated for each analyte for each analyser as: 
 
Bias + 2 x √(CV2commercial + CV
2
in-house) 
6, 137, 139 
 
The ‘multiplier’ factor of 2 is commonly used to give a confidence level of 95%. 137, 139 This 
means there is 95% confidence that the true value for each analyte would lie within this 
range.  As with calculated total error, bias can be chosen from that found at concentrations of 
particular clinical interest or, in cases of proportional bias, the average bias found may be 
appropriate to use. 
Despite widespread literature devoted to acceptable/allowable within human clinical 
pathology, 
96, 134, 140-147
 performance standards remain an emerging concept within veterinary 
clinical pathology. 
6-7, 97-99
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Summary and aims of this research project 
 
Currently, population-based reference intervals are recognised as the standard with which to 
interpret feline biochemistry results.  Reference intervals are determined by individual 
laboratories or in-house equipment manufacturers, but minimal citations are provided for the 
specific details of how these reference intervals were derived.  Despite clinical guidelines and 
recommendations,  such as those provided by the International  Renal Interest Society 
(IRIS) renal disease grading system,
148
 for diagnosis of diabetes mellitus,
149
 the American 
College of Veterinary Internal Medicine (ACVIM) proteinuria consensus statement
150
  and 
published reference intervals in textbooks,
151, 152
 there appears to be no universal attempt for a  
harmonised method of analysis and/or reference intervals so that results produced by different 
laboratories may be used interchangeably. Furthermore, there is a growing body of literature 
that has recognised age
74-75
 and breed
36-37
 based clinical pathology differences for cats.  An 
additional problem with clinical practice guidelines is that multiple studies have recognised 
bias for several analytes compared to results determined by commercial laboratory analysers 
when analysing feline samples.
23-28
 However, many of these studies have been based on small 
numbers of individual animals (26 cats or less)
23-24
 or assessed less commonly used 
analysers.
25-27
 None of these studies assessed multiple analysers concurrently, nor specifically 
assessed or categorised bias. 
Although the use of subject-based reference intervals (reference change values) is emerging 
for dogs,
4, 16, 22, 82-83
 the current lack of biological variation data for cats precludes this 
approach.  The lack of biological variation data also precludes the use of the accepted 
standard for method comparison studies (for human clinical pathology).
96
  These method 
comparison studies have been devised for commercial laboratory equipment and assume that 
the equipment can be calibrated to reduce any bias found in each analyte. However point-of-
care, in-house veterinary biochemistry analysers are unable to be calibrated by the end-user 
and it would be ideal to adapt this methodology so that these widely-used analysers could be 
critically assessed by currently accepted standards. 
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Overall aim of this project: 
 
To provide an evidence-based means for comparison of feline biochemical analytes to 
increase the ability to distinguish between sickness and health of cats and enhance 
veterinarians’ clinical decision-making. . 
 
Therefore the specific aims of this project were to: 
 
 define biological variation for the commonly used clinical biochemistry analytes for cats.  
 determine which analytes are suited for traditional reference interval interpretation or would 
be better interpreted with reference change values, and if so, to calculate the relevant 
reference change values.   
 assess repeatability of results (in relation to biological variation) of in-house analysers and a 
commercial laboratory analyser; as well as compare systematic differences in results between 
these in-house analysers and a commercial laboratory analyser utilising a novel grading 
system to assess constant or proportional bias.   
 establish the clinical acceptability of results from these in-house analysers by adapting 
established guidelines used in human clinical pathology for  application to analysers with  
identified biases.  
 determine reference intervals for each analyser, and assess these in comparison to the 
provided reference intervals. 
 make recommendations for clinical biochemistry interpretation for veterinarians treating 
feline patients.  
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Bias in feline plasma biochemistry results 
between three in-house analysers and a 
commercial laboratory analyser: results 
should not be directly compared 
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Abstract 
In-house analysers are commonplace in small animal practices but cannot be calibrated by the 
operator; therefore, any bias in the generated plasma analyte values cannot be corrected. 
Guidelines such as grading of renal disease and published reference intervals (RIs) in veterinary 
textbooks assume plasma biochemistry values generated by different analysers are equivalent. This 
study evaluated the degree of bias, as well as if bias was constant or proportional, for feline plasma 
biochemical analytes assessed by three in-house biochemistry analysers compared with a 
commercial laboratory analyser. Blood samples were collected on 101 occasions from 94 cats and, 
after centrifugation, plasma was divided into four aliquots. One aliquot was sent to the commercial 
laboratory and the remaining three were tested using the in-house biochemistry analysers. Results 
from each analyser were compared with the commercial laboratory results by difference plots and 
analyses, and by comparing percentages of results within provided RIs. Substantial bias was evident 
relative to the results of the commercial analyser for at least half of the analytes tested for each 
machine. In most cases, bias was proportional, meaning that the difference between the methods 
varied with the concentration of the analyte. The results demonstrate that values obtained from 
these analysers should not be directly compared and that RIs are not transferable between these 
analysers. Potential effects of bias on clinical decision making may be overcome by use of 
appropriately generated RIs, or reference change values which, for most biochemistry analytes, are 
more appropriate than subject-based RIs. 
 
Introduction 
In-house veterinary biochemistry analysers are commonplace in small animal practice. While 
such analysers provide useful information for point-of-care decision making, they cannot be 
calibrated by the end user (veterinary practice personnel). Analytical methodologies often 
differ between in-house and commercial laboratory analysers, and manufacturers of in-house 
analysers often provide reference intervals (RIs) that vary from published RIs
1,2 
for many 
analytes. The fact that there is variation of RIs between analyser types suggests there are 
systematic differences (or ‘bias’) between results generated by different analyser models. 
Bias can be classified as constant where the average difference in results from an established 
method remains the same, regardless of the 
concentration being measured, or proportional, 
where the average difference in results 
increases(or decreases) with increasing analyte 
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concentration. Other studies have indicated that in-house analysers show bias for several 
analytes compared with results determined by commercial laboratory analysers when 
analysing feline samples.
3–8
 However, these studies have mostly been small (<26 cats)
3,4
 or 
assessed less commonly used analysers.
5–7
 None of these studies assessed multiple analysers 
concurrently, nor specifically assessed or categorized bias. Bias between analysers is 
important because, in feline veterinary practice, many recommendations assume biochemistry 
results generated from different analysers are equivalent. Examples of this include the 
International Renal Interest Society (IRIS) renal disease grading system,
9
 diagnosis of 
diabetes mellitus,
10
 the American College of Veterinary Internal Medicine proteinuria 
consensus statement
11
 and published RIs in textbooks.
1,2
 Additionally, practitioners who use a 
particular model of in-house analyser may be required to interpret results from another 
analyser (eg, when receiving results from another practice or a commercial laboratory). In 
this situation, anecdotally, most practitioners seem to interpret results on the basis of if they 
are within, above or below the provided RI. 
Unlike method comparison studies, which aim to determine the amount of error that exists in 
the instrument being evaluated compared with that of a well-characterised 
instrument/method,
12
 the aim of this study was to assess whether bias existed for routine 
feline biochemical analytes in plasma by three commonly used in-house veterinary analysers 
when compared with a commercial laboratory analyser, and further, if bias existed, to assess 
whether it was constant and/or proportional. 
Materials and methods 
Subjects and sampling 
All plasma samples (n = 101) that were collected from 94 cats seen in a primary accession, 
feline-only veterinary practice (Paddington Cat Hospital, Sydney, Australia) over a 2 month 
period were included. Cats ranged in age from 16 weeks to 20 years; 49 cats were male (six 
entire) and 45 were female (five entire); 48 were domestic shorthairs, 14 were Burmese, six 
were Siamese, five were Russian Shorthairs and the remainder were other breeds (Devon 
Rex, Cornish Rex, Maine Coon, Persian or Himalayan). At the time of testing, cats were 
clinically healthy (63 samples) or clinically unwell (38 samples). Blood was collected from 
each cat by single jugular venepuncture into a lithium heparin tube. Each tube was 
centrifuged at 4000 rpm (1790 g) for 5 mins within 30 mins of collection, and then the 
plasma was immediately divided into four aliquots. One aliquot was sent by courier to a 
commercial laboratory (Gribbles Veterinary Laboratory, Rhodes, Sydney, Australia) and 
processed by a Cobas-Integra 400 biochemical analyte analyser; the remaining three were 
immediately tested on three in- house biochemistry analysers: Abaxis Vetscan VS-2 Point of 
Care Analyser, Heska Dri-Chem Veterinary Chemistry Analyser, and an IDEXX VetTest 
VT8008 and an IDEXX VetLyte (IDEXX has a separate instrument to measure electrolytes) 
for the following 13 biochemistry analytes: albumin, alkaline phosphatase (ALP), alanine 
amino transferase (ALT), total bilirubin, calcium, chloride (not available for Abaxis), 
creatinine, glucose, phosphate, potassium, sodium, total protein and urea. This resulted in a 
total of 38 analyte determinations across all three in-house analysers (three determinations for 
12 analytes and two determinations for one analyte [chloride]). When a result was ‘out of 
range’, the sample was diluted with 0.9% saline and the particular analyte was reanalysed. 
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Laboratory methods 
The methods by which each instrument determined the concentration for each analyte are 
summarised in Table 1. 
The Cobas-Integra 400 analyser at the commercial laboratory was calibrated according to 
manufacturer’s recommendations. The Heska and Abaxis analysers were installed to the 
manufacturers’ specifications by their respective local agents. Although 10 years old and 
already present at the testing site, the IDEXX analysers had been serviced (by the 
manufacturer) 3 months prior to the assessment period. 
The precision of all four analysers was assessed using commercial quality control materials 
(at two concentrations) approximately every second day over a 1 month period and was found 
to be similar for all four analysers.
13
 
Statistical analyses 
Descriptive analyses were conducted for each analyte. The results for each analyte on each 
analyser were compared with the commercial laboratory results using the Bland–Altman 
approach.
14
 Difference (limits of agreement; Bland–Altman) plots (scatterplots of differences 
between results from each in-house analyser and the commercial laboratory for the sample 
plotted against the means of the two results) were assessed. The average difference was 
calculated as the mean of the differences in results between each in-house analyser and the 
commercial laboratory. 
The mean and SD of the differences in results between each in-house analyser and the 
commercial laboratory for each analyte were then used to calculate 95% limits of agreement 
(mean difference ± 1.96 x SD). The mean difference in results between each in-house 
analyser and the commercial laboratory for each analyte was also expressed as a percentage 
of the mean result for each analyte on each analyser, thus enabling comparison between 
analytes. The range of the 95% limits of agreement was similarly expressed as a percentage 
of the mean result for each analyte on each analyser. 
Proportional bias was assessed using both the correlation coefficient for the association 
between the differences and the means of the two measurements and the F-test of equality of 
means and variances.
 15 
Proportional bias was considered to be present when the correlation 
coefficient was greater than 0.15 (Table 2) and the P value for the F-test was <0.05. Where 
proportional bias was considered to be present, the value of the correlation 
coefficient was used to grade the degree of proportionality as shown in Table 2.  
Proportional bias was considered as mutually exclusive to constant bias since, in a practical 
context, knowing the extent of constant bias is only useful when the slope is close to 1. 
A system was devised to categorise the presence or absence, type and degree of bias for each 
analyte from each analyser (Table 2). Analyses were performed with Stata (version 11; 
Statacorp) and R (http://www.r-project.org/). 
Although some cats contributed more than one plasma sample (seven cats contributed two 
samples), because the mean number of samples per cat was close to 1, results from each 
sample were assumed to be statistically independent of results from all other samples. 
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Additionally, to assess whether the provided RIs account for any bias, percentages of results 
for each analyte that were below, within and above the RIs supplied by manufacturers of each 
in-house analyser (for results from their analyser), or by the laboratory (for results from its 
analyser), were calculated. 
Results 
Although a total of 101 samples were collected, the number of samples processed by each 
analyser for each analyte varied between 80 and 101; some samples were not processed for 
logistical reasons such as insufficient supply of test ‘slides’ on individual days, insufficient 
sample quantity, exceeding the provided number of tests or, on one occasion, instrument 
failure. Results obtained by dilution of samples (one creatinine, one phosphate and one urea 
result from both the Heska and IDEXX equipment) were excluded since dilution introduced 
human error and may have influenced results.  Additionally, glucose concentrations 
determined by the commercial laboratory in the first twelve samples collected were 
substantially lower than those from all three in-house analysers. These results 
Table 1 Assay method for analyte concentrations by the Abaxis VetScan, IDEXX VetTest/VetLyte and Heska Dri-
Chem analysers, and by a Cobas-Integra biochemistry analyser at a commercial laboratory Cobas-Integra 
(commercial) 
Analyser: 
Cobas-Integra 
(commercial) 
Abaxis IDEXX Heska 
Analyte     
Albumin Bromcresol green 
binding 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alkaline 
Phosphatase 
p-NPP 
hydrolyzation 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alanine 
Aminotransferase 
Catalyzation 
(form pyruvate and 
N-glutamate)  
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Total Bilirubin 
Diazo method 
Enzymatic 
(bilirubin oxidase)  
Diazo-based dry film Diazo-based dry film 
Calcium 
Spectrophotometric 
(CPC)  
Spectrophotometric 
(arsenazo III) 
Spectrophotometric 
(arsenazo III)  
Spectrophotometric 
(Chlorophosphonazo 
III)  
Chloride Ion selective 
electrode (ISE)  
Not analyzed by this 
instrument 
as for Cobas-Integra Potentiometric 
Creatinine 
Jaffe reaction 
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine deiminase)  
Glucose Hexokinase as for Cobas-Integra Glucose oxidase Glucose oxidase 
Phosphate 
Phosphomolybdate 
Enzymatic  
(phosphoglucomutase) 
as for Cobas-Integra 
Spectrophotometric 
(PNP)  
Potassium 
Ion selective 
electrode (ISE)  
Enzymatic 
(pyruvate kinase)  
as for Cobas-Integra Potentiometric 
Sodium 
Ion selective 
electrode (ISE)  
Enzymatic 
(beta-galactosidase)  
as for Cobas-Integra Potentiometric 
Total Protein Biuret as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Urea Coupled-enzyme 
reaction 
as for Cobas-Integra Ammonia indicator 
Bromcresol 
green/ammonia 
‘as for Cobas-Integra’ indicates the same method as the commercial laboratory 
p-NPP = p-nitrophenylphosphate; CPC = o-cresolphthalein complexone; PNP = purine-nucleoside phosphorylase  
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were excluded because it was suspected that red blood cells were accidentally aspirated into 
the plasma for these samples. This may have affected the commercial laboratory results due 
to the delay between blood sample collection and analysis, while any effect on the in-house 
analyser results would have been minimal since samples were tested immediately after 
collection.  No subsequent samples had such dramatic variation in glucose results. 
Distributions of results for each analyte are summarized in Table 3, difference plots for each 
analyte are shown in Figure 1 and numerical analyses are shown in Tables 4 and 5.  Bias is 
indicated by deviation of the mean difference from zero (Table 4) and/or if there is evidence 
of proportional bias. When assessed as a percentage of the mean result for each analyte on 
each analyser (Table 5), for 26/38 analytes, mean differences were within 10%, with 17 of 
these within 5%. This is demonstrated graphically by the deviation of the observed average 
agreement (dashed line) from zero; for example, in Figure 1, the difference plot of sodium 
values from the IDEXX analyser compared to the commercial laboratory analyser shows the 
in-house analyser results were, on average, approximately 12.5 mmol/L higher (8% of the 
mean result for sodium on the IDEXX analyser) than those from the commercial laboratory 
analyser. 
The 95% limits of agreement were determined and also expressed as percentages of the mean 
result for each analyte on each analyser (Table 5) to enable comparison between analytes.  
Only 10/38 analytes had 95% limits of agreement that were less than 20% of the mean (five 
from IDEXX analyser, three from the Abaxis analyser and two from the Heska analyser) 
meaning that, for these analytes, 95% of the results differed from the mean difference by less 
than 10% of the mean.   
Correlation coefficients for the association between difference and mean can vary from zero 
(indicating no proportional bias) to either + 1 (indicating substantial proportional bias). 
Values approaching zero are associated with a near horizontal reduced major axis regression 
line (solid lines in Figure 1) and were found for the Abaxis analyser for albumin (-0.08), urea 
(0.08), glucose (-0.12), sodium (0.15), total protein (-0.15) and urea (0.08); the Heska 
analyser for potassium (0.02), bilirubin (0.05), and glucose (0.10); and for the IDEXX 
analyser for glucose (0.12) and potassium (0.12).   
In contrast, for example, a large (negative) correlation coefficient (-0.90) was observed for 
urea measured on the IDEXX instrument (solid line in Figure 1).  Urea results on this 
analyser were, on average, approximately 10% of the mean from this analyser lower than  
 
Table 2 Categorisation system for presence, type and degree of bias. Mean difference percentage was calculated as 
absolute mean difference divided by mean result for the analyte on the same analyser. Note that the mean difference has 
no bearing on whether proportional bias is present or not 
Presence of 
bias 
Type Degree Mean 
difference 
percentage 
Absolute value of 
correlation coefficient for 
association between 
difference and mean 
P-value for equality 
of means and 
variances 
No bias - - <5% <0.15 - 
Bias Constant - ≥5% <0.15 - 
Bias Proportional Mild - 0.15-0.30 <0.05 
Bias Proportional Moderate - 0.30-0.45 <0.05 
Bias Proportional Pronounced - >0.45 <0.05 
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those obtained from the commercial laboratory analyser at the lower end of the reference 
Table 3 Summary of distributions of results from all analysers, showing number of samples tested (n), minimum (Min), median (Med) 
and maximum (Max) results, as well as lower quartile (25th percentile), upper quartile (75th percentile), mean and SD 
 
Analyte Analyser n Min Lower 
Quartile 
Median Upper 
Quartile 
Max Mean SD 
Albumin 
(g/L) 
Abaxis 80 28 38 39 42 46 39.3 3.4 
IDEXX 99 18 30 32 34 39 32.1 3.4 
Heska 96 21 31.5 33 35 40 32.9 3.2 
Cobas-Integra 99 19 32 35 37 44 34.3 3.9 
ALP (U/L) Abaxis 82 11 20 25 35 122 32.9 22.1 
IDEXX 101 20 32 39 52 206 53.3 37.2 
Heska 101 21 33 37 47 162 47.8 27.7 
Cobas-Integra 101 7 18 23 34 160 34.8 30.3 
ALT (U/L) Abaxis 82 32 48 62 79 258 74.9 46.6 
IDEXX 101 10 23 39 58 369 55.5 60.6 
Heska 101 27 50 64 84 416 84.8 69.4 
Cobas-Integra 101 20 41 55 76 434 74.9 66.4 
Calcium 
(mmol/L) 
Abaxis 80 2.02 2.50 2.62 2.76 3.27 2.64 0.21 
IDEXX 99 2.12 2.54 2.64 2.73 3.18 2.65 0.16 
Heska 99 2.14 2.63 2.75 2.91 3.49 2.76 0.21 
Cobas-Integra 99 2.04 2.51 2.64 2.74 3.42 2.66 0.24 
Chloride 
(mmol/L) 
Abaxis 0 - - - - - - - 
IDEXX 95 114 123 124 126 130 123.8 2.8 
Heska 84 96 113 116 119 126 115.0 5.9 
Cobas-Integra 96 106 116 117 119 124 117.1 3.6 
Creatinine 
(umol/L) 
Abaxis 82 40 111 133 174 277 142.5 50.1 
IDEXX 100 63 140 172 210 421 179.5 60.5 
Heska 100 38 103 129 160.5 357 137.1 53.6 
Cobas-Integra 100 40 100 121 147.5 340 128.7 47.0 
Glucose 
(mmol/L) 
Abaxis 70 4.2 5.8 6.5 7.7 16.0 7.1 2.06 
IDEXX 89 4.18 5.9 6.6 7.9 16.2 7.1 1.99 
Heska 89 4.3 5.8 6.4 7.5 16.4 7.0 2.04 
Cobas-Integra 89 2.9 5.4 6.0 7.1 15.5 6.5 1.98 
Phosphate 
(mmol/L) 
Abaxis 80 0.75 1.27 1.53 1.80 3.53 1.64 0.52 
IDEXX 94 0.65 1.14 1.33 1.57 5.73 1.49 0.66 
Heska 98 0.67 1.14 1.35 1.65 6.96 1.54 0.77 
Cobas-Integra 99 0.59 1.10 1.30 1.58 6.14 1.47 0.68 
Potassium 
(mmol/L) 
Abaxis 79 2.9 3.8 4.1 4.6 6.0 4.17 0.53 
IDEXX 97 2.7 3.6 3.9 4.2 5.7 3.94 0.51 
Heska 85 2.3 3.3 3.6 3.9 4.7 3.63 0.48 
Cobas-Integra 98 2.7 3.4 3.7 4.0 5.3 3.77 0.48 
Sodium  
(mmol/L) 
Abaxis 79 141 149 151 153 159 151.0 3.09 
IDEXX 97 144 160 161 163 167 161.0 3.30 
Heska 85 130 147 151 153 157 149.1 6.36 
Cobas-Integra 98 135 147 149 150 155 148.6 2.78 
Total 
bilirubin 
(umol/L) 
Abaxis 82 2 4 4 4 14 4.24 1.70 
IDEXX 100 2 2 2 2.5 8 2.48 1.10 
Heska 99 1 1 1 1 15 1.66 2.28 
Cobas-Integra 100 2 4.5 6 7 17 5.80 2.19 
Total Protein 
(g/L) 
Abaxis 80 53 67.5 74 78 94 73.3 7.70 
IDEXX 99 51 65 70 75 86 69.9 7.19 
Heska 98 52 64 70 74 89 69.6 7.34 
Cobas-Integra 99 50 67 73 78 98 72.7 8.45 
Urea 
(mmol/L) 
Abaxis 82 3.9 8.3 9.2 12.2 38.9 10.85 5.02 
IDEXX 100 3.5 7.4 8.3 10.7 29.3 9.43 4.03 
Heska 100 4.2 8.7 10.0 12.7 38.7 11.50 5.26 
Cobas-Integra 100 3.9 8.3 9.6 12.5 37 11.03 5.09 
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those obtained from the commercial laboratory analyser at the lower end of the reference 
interval, but approximately 20% lower at three times the upper limit of normal. 
Based on the categorisation system, the Abaxis analyser was determined to have no bias for 
three analytes (sodium, total protein and urea), constant bias for three analytes (albumin, 
glucose, potassium) and proportional bias for the remaining six analytes.  The IDEXX 
analyser had no bias for potassium and phosphate, constant bias for one analyte (glucose) and 
proportional bias for the remaining 10 analytes.  The Heska analyser had no bias for 
potassium only, constant bias for bilirubin only and proportional bias for the remaining 11 
analytes.  For two analytes, phosphate on the Heska analyser and total protein on the IDEXX 
analyser, proportional bias was not confirmed by a low p-value for equality of means and 
variances; visual inspection of the difference plots appeared to support that proportional bias 
was present.  Proportional bias varied from mild (Abaxis: 2/6, IDEXX: 2/10, Heska: 6/11) to 
pronounced (Abaxis: 3/6, IDEXX: 6/10, Heska: 3/11).  The categorisation of each analyte 
from each analyser is shown in Table 5.   
The width of the limits of agreement is independent of the categorisations but a wide limits of 
agreement band affects the clinical interpretation of results.  This can mean that an individual 
result on one analyte that has been graded as having no bias or constant bias but has a very 
wide band can have individual values that differ markedly between the in-house analyser and 
the commercial laboratory.  For example, the total bilirubin values determined on the Heska 
analyser had a limit of agreement that was 600% of the mean result from that analyser, 
indicating that 95% of results could have a true value up to three times the mean lower or 
higher than that determined.  
Proportional bias is less relevant for clinical practice (even if classified as pronounced) when 
the limits of agreement are narrow such as for calcium on the IDEXX analyser since the 
greater slope is within a range of only 10% above or below the average result. 
Percentages of results from all analysers that were below, within and above the reference 
intervals supplied by the manufacturer or laboratory are shown in Table 6.  Percentages of 
results below and above the reference interval varied markedly between analysers for all 
analytes.  Total bilirubin had the most consistency between analysers (percentages of samples 
within reference intervals varied from 96% [Heska] to 100% [IDEXX]). The IDEXX 
analyser also had relatively fewer values above the reference interval for both total protein 
(all values were within reference interval compared to 9-16% for the other analysers) and 
urea (only 11 % of values exceeding the reference interval compared to 32-34% for the other 
analysers) and there were no values below the reference interval for chloride (compared to 8-
14% for the other analysers).  For ALP, 4% of values from the Abaxis analyser were above 
the reference interval compared to 9-12% for the other analysers.  Large percentages of 
values exceeded the upper limit of the reference interval for the commercial laboratory 
analyser for albumin (41%) and calcium (76%), and below the lower limit of the reference 
interval for phosphate (50%) and potassium (52%); these were markedly different from 
results for these analytes from the other analysers.  The Heska analyser yielded 
approximately twice as many results above the Heska reference interval for glucose (31%) 
compared to the other analysers.   
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Figure 1 Difference plots comparing analyte results by each in-house analyzer to the results found by the commercial 
laboratory analyzer (‘CobasIntegra’) from the same sample. The long dashed line indicates the (observed) mean 
difference; the short dashed lines indicate the 95% confidence limits for this mean. The solid lines are the reduced major 
axis regression lines between differences and means; with proportional bias, the slope of this line deviates from zero 
(horizontal). Note that the units apply to both x and y-axes. 
 
Discussion 
The findings of this study indicate that bias is common in in-house analysers, and this is 
commonly proportional bias. In many cases, this bias is sufficient to invalidate comparisons 
of biochemical results obtained from different analysers. Further, the inconsistency between 
results with/above/below the provided reference intervals means results cannot be compared 
on the basis of where they lie in reference to the provided reference intervals. In general, it 
may be possible to reduce biases through improvement of the assay methods and 
recalibration of the analyser, however, the in-house analysers assessed cannot be calibrated 
by the end-user and assay methods may not be able to changed for the ‘dry slide’ (Heska and  
IDEXX equipment) or ‘rotor’ (Abaxis equipment) technologies utilized by these analysers.  
Furthermore, performance may vary between analysers of the same make (even after 
calibration), so ideally, biochemical results should be interpreted using reference intervals 
determined specifically for the particular analyser being used. 
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 Table 4 Results of Bland-Altman approach analyses.  The mean difference describes the average difference between results 
found on each in-house analyser to those found on the commercial laboratory analyser. The subsequent column shows the 
difference between the upper limit of the reference interval on the commercial laboratory analyser to each in-house analyser 
(as provided by the manufacturer of each analyser); mean difference should agree with this result if the provided reference 
interval correctly accounts for the bias found. The correlation coefficients for the association between difference and mean 
results (second last column) give a quantitative assessment of the degree of proportional bias determined by Bland-Altman 
analyses. If the value is 0, there is no proportional bias and the regression line on the difference plot (solid lines in Figure 1) is 
horizontal.  A positive value means that the average difference in results (in-house analyser minus commercial laboratory) 
increases with increasing analyte concentration; the regression line will slope upwards to the right.  A negative value means that 
the average difference in results (in-house analyser minus commercial laboratory) becomes more negative with increasing 
analyte concentration; the regression line will slope downwards to the right. A low p-value for equality of means and variances 
supports rejecting the null hypothesis that the variance does not vary with the mean, and hence concluding that proportional 
bias is present. (n= number of observations) 
Analyte Analyser n Mean difference (95% 
limits of agreement) 
Difference between 
upper reference limits 
of in-house analyser 
and the commercial 
laboratory 
Correlation 
coefficient for 
association 
between difference 
and mean 
P-value for 
equality of 
means and 
variances 
Albumin 
(g/L) 
 
Abaxis 80   4.56 (-1.35, 10.47) 9 -0.08 <0.001 
IDEXX 99 -2.15 (-6.89, 2.59) 5 -0.19 <0.001 
Heska 96 -1.33 (-6.54, 3.87) 0 -0.27 <0.001 
ALT (U/L) Abaxis 82   0.09 (-11.72, 11.89) 10 -0.74 <0.001 
IDEXX 101 18.50 (0.28, 36.71) 31  0.75 <0.001 
Heska 101  13.04 (-0.87, 26.95) 10 -0.37 <0.001 
ALP (U/L) Abaxis 82    5.65 (-3.98, 15.28) 10 -0.54 <0.001 
IDEXX 101 -19.35 (-38.40, -0.30) 20 -0.59 <0.001 
Heska 101    9.890 (-13.48, 33.27) 50  0.26 <0.001 
Total 
Bilirubin 
(umol/L) 
Abaxis 81 -1.15 (-5.40, 3.10) 0  0.17 <0.001 
IDEXX 99 -3.33 (-7.55, 0.89) 5 -0.62 <0.001 
Heska 99 -4.17 (-9.16, 0.81) -1  0.05 <0.001 
Calcium 
(mmol/L) 
Abaxis 80 -0.05 (-0.28, 0.18) 0.45 -0.38 <0.001 
IDEXX 99 -0.02 (-0.25, 0.21) 0.33 -0.70 <0.001 
Heska 99  0.10 (-0.13, 0.33) 0.5 -0.27 <0.001 
Chloride 
(mmol/L) 
IDEXX 95  6.66 (2.00, 10.33) 6 -0.44 <0.001 
Heska 84 -2.50 (-15.29. 10.31) 2  0.51 <0.001 
Creatinine 
(umol/L) 
Abaxis 82 14.85 (-13.47, 43.17) 16  0.47 <0.001 
IDEXX 100 50.80 (19.44, 82.16) 52  0.84 <0.001 
Heska 100   8.41 (-18.42, 35.24) -1  0.48 <0.001 
Glucose 
(mmol/L) 
Abaxis 69   0.43 (-0.17,  1.02) 1.2 -0.05 <0.001 
IDEXX 88   0.52 (-0.17 , 1.22) 1.33  0.12 <0.001 
Heska 88   0.41 (-0.37, 1.19) -0.3  0.25 <0.001 
Phosphate 
(mmol/L) 
Abaxis 80   0.20 (-0.02,  0.43) 0.48  0.27 <0.001 
IDEXX 93   0.02 (-0.22,  0.26) 0.16 -0.24 <0.001 
Heska 95   0 .07 (-0.21, 0.35) 0.7  0.65 0.85 
Potassium 
(mmol/L) 
Abaxis 79   0.38 (-0.17, 0.94) 1.2  0.09 <0.001 
IDEXX 97   0.16 (-0.34 , 0.67) 1.2  0.12 <0.001 
Heska 85 -0.15 (-0.71, 0.42) 0.7  0.02 <0.001 
Sodium 
(mmol/L) 
Abaxis 79   2.48 (-3.25, 8.21) 12  0.15 <0.001 
IDEXX 97 12.45 (8.04, 16.87) 13  0.24 <0.001 
Heska 85   0.28 (-12.26, 12.82) 0  0.68 <0.001 
Total Protein 
(g/L) 
Abaxis 80 -0.24 (-7.65, 7.18) 2 -0.15 <0.001 
IDEXX 99 -2.90 (-9.150, 3.37) 9 -0.40 0.36 
Heska 98 -3.04 (-10.42, 4.34) 0 -0.29 <0.001 
Urea 
(mmol/L) 
Abaxis 82 -0.30 (-1.41, 0.82) 0  0.08 <0.001 
IDEXX 100 -1.60 (-3. 90, 0.70) 2.2 -0.90 <0.001 
Heska 100   0.48 (-0.88, 1.83) 0.72  0.25 <0.001 
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Table 5 Summary of biases. Mean differences and 95% limits of agreement, are both expressed as percentages of the mean 
value for that analyte from that analyser so that direct comparisons between analytes can be made. Limits of agreement (LOA) 
that were less than 20% are bolded; for these analytes, 95% of results differed from the mean difference by less than 10% of the 
mean value found on that analyser and thus proportionality is less relevant clinically. (n=number of observations) 
Analyte Analyser n Mean 
difference 
(%) 
 
Width of 
95% LOA 
(%) 
 
Correlation 
coefficient 
for 
association 
between 
difference 
and mean 
P-value for 
equality of 
means and 
variances 
Bias Degree of 
Proportionality 
Albumin 
(g/L) 
 
Abaxis 80 11.6 30.0 -0.08 <0.001 Constant - 
IDEXX 99 -6.7 29.5 -0.19 <0.001 Proportional Mild 
Heska 96 -4.0 31.6 -0.27 <0.001 Proportional Mild 
ALP (U/L) 
Abaxis 82 0.3 71.8* -0.74 <0.001 Proportional Pronounced 
IDEXX 101 34.7 68.4* 0.75 <0.001 Proportional Pronounced 
Heska 101 27.3 58.2* -0.37 <0.001 Proportional Moderate 
ALT (U/L) 
Abaxis 82 7.5 25.7 -0.54 <0.001 Proportional Pronounced 
IDEXX 101 -34.8 68.6* -0.59 <0.001 Proportional Pronounced 
Heska 101 11.7 55.1*  0.26 <0.001 Proportional Mild 
Total 
Bilirubin 
(umol/L) 
Abaxis 81 -27.1 200.5*  0.17 <0.001 Proportional Mild 
IDEXX 99 -134.3 340.2* -0.62 <0.001 Proportional Pronounced 
Heska 99 -251.2 600.7*  0.05 <0.001 Constant - 
Calcium 
(mmol/L) 
Abaxis 80 -1.9 17.1 -0.38 <0.001 Proportional Moderate† 
IDEXX 99 -0.8 17.3 -0.70 <0.001 Proportional Pronounced† 
Heska 99 3.6 16.4 -0.27 <0.001 Proportional Mild† 
Chloride 
(mmol/L) 
IDEXX 95 5.4 6.7 -0.44 <0.001 Proportional Moderate† 
Heska 84 -2.2 22.3  0.51 <0.001 Proportional Pronounced 
Creatinine 
(umol/L) 
Abaxis 82 10.4 39.7  0.47 <0.001 Proportional Pronounced 
IDEXX 100 28.3 34.9  0.84 <0.001 Proportional Pronounced 
Heska 100 6.1 39.1  0.48 <0.001 Proportional Pronounced 
Glucose 
(mmol/L) 
Abaxis 69 6.1 16.8 -0.05 <0.001 Constant - 
IDEXX 88 7.3 19.5  0.12 <0.001 Constant - 
Heska 88 5.9 22.3  0.25 <0.001 Proportional Mild 
Phosphate 
(mmol/L) 
Abaxis 80 12.2 27.3  0.27 <0.001 Proportional Mild 
IDEXX 93 1.3 32.0 -0.01 <0.001 No bias - 
Heska 95 4.5 36.0  0.43 0.85 Proportional
‡ 
 
Moderate 
Potassium 
(mmol/L) 
Abaxis 79 9.1 26.6  0.09 <0.001 Constant - 
IDEXX 97 4.1 25.6  0.12 <0.001 No bias - 
Heska 85 -4.1 30.9  0.02 <0.001 No bias - 
Sodium 
(mmol/L) 
Abaxis 79 1.6 7.6  0.15 <0.001 No bias - 
IDEXX 97 7.7 5.5  0.24 <0.001 Proportional Mild† 
Heska 85 0.2 16.8  0.68 <0.001 Proportional Pronounced† 
Total 
Protein 
(g/L) 
Abaxis 80 -0.3 20.2 -0.15 <0.001 No bias - 
IDEXX 99 -4.2 17.9 -0.40 0.36 Proportional
‡ 
 
Moderate† 
Heska 98 -4.4 21.2 -0.29 <0.001 Proportional Mild 
Urea 
(mmol/L) 
Abaxis 82 -2.8 20.6  0.08 <0.001 No bias - 
IDEXX 100 -17.0 48.6 -0.90 <0.001 Proportional Pronounced 
Heska 100 4.2 23.5  0.25 <0.001 Proportional Mild 
*Independent of categorisation, clinical interpretation of results should be interpreted cautiously because of very wide limits of agreement 
†Proportional bias is less relevant for clinical practice for these because of the narrow limits of agreement 
‡Proportional bias not confirmed by low P value 
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Table 6  Feline reference intervals’s (RI’s)for biochemistry analytes (provided by manufacturers of analysers and a commercial 
laboratory) with percentages of results that were below, within and above the RI’s supplied by that manufacturer or 
laboratory.   A lower percentage above and/or below the RI than other analysers suggests that the RI may be too wide, which 
would result in reduced diagnostic sensitivity for detection of abnormal cats.  A larger percentage above and/or below the RI 
than other analysers suggests that the RI may be too narrow, which would result in reduced diagnostic specificity of the assay.  
The large proportion of results from the commercial laboratory that were above the commercial laboratory's RI’s for calcium 
and albumin and below the RI’s for phosphate and potassium (without consistent clinical signs in these cats) suggests 
inaccuracy of the RI’s for these analytes for the commercial laboratory. Inconsistencies between analysers (ie a higher or lower 
percentage than from other analysers) are shown in bold. 
 
 
Analyte Analyser Provided RI Below Within Above 
Albumin (g/L) 
Abaxis 22-44 0.0% 97.5% 2.5% 
IDEXX 22-40 2.0% 98.0% 0.0% 
Heska 23-35 2.1% 80.2% 17.7% 
Cobas-Integra 22-35 1.0% 57.6% 41.4% 
ALP (U/L) 
Abaxis 10-90 0.0% 96.3% 3.7% 
IDEXX 14-111 0.0% 91.1% 8.9% 
Heska 0-90 0.0% 90.1% 9.9% 
Cobas-Integra 5-80 0.0% 88.1% 11.9% 
ALT (U/L) 
Abaxis 20-100 0.0% 84.1% 15.9% 
IDEXX 12-130 6.9% 84.2% 8.9% 
Heska 0-85 0.0% 76.2% 23.8% 
Cobas-Integra 5-80 0.0% 79.2% 20.8% 
Calcium 
(mmol/L) 
Abaxis 2.00-2.95 0.0% 93.7% 6.3% 
IDEXX 1.95-2.83 0.0% 90.3% 9.7% 
Heska 2.20-3.00 2.0% 87.9% 10.1% 
Cobas-Integra 1.75-2.50 0.0% 24.2% 75.8% 
Chloride 
(mmol/L) 
Abaxis * * * * 
IDEXX 112-129 0.0% 98.9% 1.1% 
Heska 107-125 8.3% 90.5% 1.0% 
Cobas-Integra 115-123 13.5% 84.4% 2.1% 
Creatinine 
(umol/L) 
Abaxis 27-186 0.0% 84.1% 15.9% 
IDEXX 71-212 2.0% 75.0% 23.0% 
Heska 71-159 7.0% 68.0% 25.0% 
Cobas-Integra 70-160 6.0% 75.0% 19.0% 
Glucose (mmol/L) 
Abaxis 3.9-8.7 0.0% 84.1% 15.9% 
IDEXX 4.11-8.83 0.0% 86.4% 13.6% 
Heska 3.9-7.2 0.0% 69.3% 30.7% 
Cobas-Integra 3.9-7.5 1.1% 80.9% 18.0% 
Phosphate 
(mmol/L) 
Abaxis 1.10-2.74 5.0% 91.2% 3.8% 
IDEXX 1.00-2.42 13.3% 81.1% 5.6% 
Heska 0.84-1.94 2.1% 83.0% 14.9% 
Cobas-Integra 1.29-2.26 49.5% 41.4% 9.1% 
Potassium 
(mmol/L) 
Abaxis 3.7-5.8 12.7% 86.0% 1.3% 
IDEXX 3.5-5.8 13.4% 86.6% 0.0% 
Heska 3.4-5.3 26.1% 73.9% 0.0% 
Cobas-Integra 3.8-4.6 52.0% 43.9% 4.1% 
Sodium 
( mmol/L) 
Abaxis 142-164 1.3% 98.7% 0.0% 
IDEXX 150-165 2.1% 92.8% 5.2% 
Heska 147-156 22.4% 76.4% 1.2% 
Cobas-Integra 147-156 17.4% 82.7% 0.0% 
Total Bilirubin 
(μmol/L) 
Abaxis 2-10 0.0% 97.5% 2.5% 
IDEXX 0-15 0.0% 100.0% 0.0% 
Heska 0-9 0.0% 96.0% 4.0% 
Cobas-Integra 2-10 0.0% 97.0% 3.0% 
Total Protein 
(g/L) 
Abaxis 54-82 1.3% 87.5% 11.3% 
IDEXX 57-89 3.0% 97.0% 0.0% 
Heska 60-80 8.2% 82.7% 9.2% 
Cobas-Integra 56-80 3.0% 80.8% 16.2% 
Urea (mmol/L) 
Abaxis 3.6-10.7 0.0% 65.9% 34.1% 
IDEXX 5.7-12.9 6.0% 83.0% 11.0% 
Heska 5.35-11.42 2.0% 66.0% 32.0% 
Cobas-Integra 5.4-10.7 4.0% 62.0% 34.0% 
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At least half the analytes tested on each machine showed substantial bias (either >5% mean 
difference or at least moderate proportionality or both).  This was not surprising since in-
house biochemistry equipment cannot be calibrated by the user and each manufacturer 
provides a different reference interval for each analyte, suggesting that a constant bias from 
the true values may be present.  However, varying reference intervals can only fully account 
for constant bias and approximately half of all analytes tested (for each analyser) also showed 
proportional bias.  Varying the reference interval does not fully address marked proportional 
bias when comparing results between analysers; and even more complex strategies may not 
be effective if the degree of difference changes in a non-linear way with increasing analyte 
concentration. 
Difference (Bland-Altman) analysis can appear to indicate notable proportional bias when the 
calculated 95% limits of the observed average agreement are within a narrow range.  Stated 
differently, if the values from an in-house analyser do not vary widely relative to those from 
the commercial laboratory analyser, the regression slope of those differences can appear to 
result in substantial proportional bias but this is relatively unimportant clinically because this 
slope is over a narrow range.  An example demonstrating this is calcium as measured on the 
IDEXX analyser; although the correlation between difference and mean was -0.70 (poor 
since it is approaching an absolute value of 1.0), 95% of results were only ~0.2mmol/L above 
or below the average results. 
Although average differences compared to the commercial laboratory analyser differed from 
zero for most analytes across all in-house analysers, this could be addressed by adjustment of 
reference intervals (provided the extent of proportional bias was minor).  The average 
difference between results from each in-house analyser compared to the commercial 
laboratory analyser is shown in Table 4 (and by percentage in Table 5). The adjacent column 
in Table 4 shows the differences between the upper limits of the manufacturer’s 
recommended reference intervals and the commercial laboratory’s recommended upper limit 
for each analyte on each machine, respectively.  The values in these two columns would 
agree if bias had been corrected for by altering the reference interval.  These values are 
similar in some cases (for example, chloride and sodium on the IDEXX analyser, and 
creatinine on Abaxis and IDEXX analysers).  In other cases, the values differ substantially: 
ALT on the Heska analyser was 9.9 mmol/L higher (on average) than the commercial 
laboratory analyser but the difference between upper limits of the two reference intervals was 
50 mmol/L; ALT on the IDEXX instrument had  an observed average difference which was 
19.3 mmol/L less than the commercial laboratory analyser but the difference in reference 
interval upper limits was 20 mmol/L greater; sodium on the Abaxis machine was 2.5mmol/L 
higher than the commercial laboratory analyser, yet the reference interval difference is 
12mmol/L.  Such comparisons assume the reference intervals for all analytes from each 
analyser (including the commercial laboratory analyser) have been correctly determined.  In 
the course of this study, for most analytes, approximately 80% of observations were within 
the reported normal range but some observations were challenging to interpret: for example , 
78/99 (75.8%) calcium results from the commercial laboratory were above the upper limit of 
the reference interval, (2.50 mmol/L) despite no clinical evidence of hypercalcemia 
suggesting this reference interval was incorrect; additionally, many  values from the 
commercial laboratory analyser were above the reference interval for albumin (41.4%) and 
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below the reference interval for phosphate (49.5%) and potassium (52.0%) without consistent 
clinical signs in these cats, suggesting an inaccuracy of the reference intervals for these 
analytes, also. These changes are shown in Table 6 which also demonstrates a lack of 
consistency of percentage of results within/above/below the provided reference intervals.  If 
the reference intervals overcame the bias of the analysers, approximately the same percentage 
of results would have been found in each category.  Where two or three analysers were 
consistent (and the fourth different), it suggested that those different had an incorrect 
reference interval.  Too few results above or below the reference interval suggests that the 
range is too broad and pathology is likely to be missed.  Too many elevated or decreased 
results may mean patients are incorrectly diagnosed with pathology that is not present. 
These inconsistencies may result in either unnecessary clinical management or missing a 
diagnosis.  For example, if albumin alone was used as a measure of dehydration based on the 
commercial laboratory analyser and using the Gribbles upper limit of reference interval, 
approximately 40 additional cats may have received unnecessary treatment such as fluid 
therapy compared to if the IDEXX and Abaxis analysers were used.  Conversely, using urea 
as an indicator of dehydration, the approximately 20% less cats over the reference limit on 
the IDEXX analyser may mean that if this analyser alone was used, approximately 20 cats 
may not have receive appropriate management of azotaemia.  ALP is regarded as a sensitive 
indicator of hepatopathy in cats since it has a short half of approximately 6 hours in this 
species.
16
   The mean and median results for ALP are similar for Abaxis and Cobas-Integra 
analysers yet the reference interval is 10U/L lower for the Abaxis analyser resulting in 5-8% 
less cats having an elevated level.  This 5-8% of cats may not receive appropriate further 
diagnostics.  Inaccurate diagnosis of hypercalcaemia (as appears likely for approximately 65 
cats when assessed by the Gribbles reference interval) could lead to unnecessary 
investigations to determine ionised calcium and parathyroid hormone levels as well as the 
potential for unnecessary treatment. 
No proportional bias was recognised for any analyser for potassium (demonstrated by the 
straight lines showing the average in Figure 1 for this analyte) and the mean average 
differences were only 4% (though in opposite directions) for each of the Abaxis and IDEXX 
analysers.  Therefore, for this analyte, reference interval adjustments alone should be able to 
provide direct comparisons between analysers yet >50% of results from the commercial 
analyser and >25% of results from the Heska analyser were recognised as hypokalaemic 
which may result in unnecessary supplementation of these cats. 
IRIS stages chronic kidney disease based on creatinine levels and ‘Stage 2’ for cats is defined 
as creatinine concentrations of 140-250 μmol/L.9 The mean differences in creatinine 
concentrations for the in-house analysers were 8 μmol/L (Heska), 15 μmol/L (Abaxis) and 51 
μmol/L (IDEXX) compared to the commercial laboratory.  The result of these differences 
means that cats assessed by these in-house analysers (particularly IDEXX) will be staged 
with more advanced kidney disease than if they were assessed by the commercial laboratory 
analyser. This may have implications on management for anaesthesia, ongoing monitoring 
and long term prognostication.   
Reference interval adjustments may not overcome substantial proportional bias but any 
assessment of proportional bias assumes that the commercial laboratory analyser results are 
correct. Commercial laboratory analyser analysis was chosen as the ‘gold standard’ for this 
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study since this is generally considered the ‘highest standard’ routinely available to 
practitioners.  However, commercial laboratory analyser results may not always be the most 
accurate. For example, the method for creatinine analysis used by the commercial laboratory 
in this study was the Jaffe reaction. Compared to high performance liquid chromatography 
(HPLC), the Jaffe reaction has a strong positive proportional bias.
17
 By inference, the 
negative proportional bias to the commercial laboratory analyser found by the enzymatic 
method of creatinine assessment used by all three in-house analysers may be due to better 
agreement with ‘true values’ determined by HPLC. 
Of the published studies assessing veterinary in-house analysers, only three have assessed the 
analysers assessed in this study with feline samples.
3-4,8
  Mischke et al assessed eight of the 
analytes assessed in this study, with results of plasma samples from 22 cats tested using an 
IDEXX VetTest compared to results from a Hitachi 704 commercial laboratory analyser.
3
    
Sutton et al (1999) assessed ten of the analytes assessed in this study on an Abaxis Vetscan 
analyser compared to a commercial laboratory Hitachi 911 analyser with 26 feline serum 
samples.
4
  Flatland et al (2014) assessed all 13 analytes in this study on a Heska SpotChem 
analyser compared to an Hitachi 911 analyser with plasma results from 53 cats.
8
 Across these 
studies, similar results to the current study were seen for half to three-quarters of the analytes 
but different methodologies preclude direct comparisons. Potential reasons for differences in 
findings may be due to one or more of the following:  smaller sample sizes, different ranges 
of concentrations, assessing serum instead of plasma and different reference laboratory 
equipment.   
This is the first study to assess the correlation and bias of multiple in-house veterinary 
biochemistry analysers.  These results show that, for many analytes, results from in-house 
analysers are not directly comparable to those from the commercial laboratory or other in-
house analysers and universal reference intervals (such as those published in text books) may 
not be appropriate.  Additionally, practitioners should not compare results from different 
analysers only on the basis of if results are within, above or below the provided reference 
interval.  The potential affect on clinical decision making may be overcome by the use of 
appropriately generated reference intervals, or reference change values which have recently 
been described as more appropriate for most feline biochemistry analytes.
18
 Further, universal 
guidelines such as grading of renal disease or diagnosis of diabetes mellitus cannot be made 
on the basis of absolute values; however guidelines could be made on the basis of percentage 
increases from a cat’s prior results or above the upper limit of a reference interval.  
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Assessments of feline plasma 
biochemistry reference intervals for 
three in-house analysers and a 
commercial laboratory analyser 
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Krockenberger2 and Merran Govendir2 
 
Abstract 
The manufacturers of in-house analysers (and commercial laboratories) provide standard reference 
intervals for each species that do not account for any differences such as geographical population 
differences and do not overtly state the potential for variation between results obtained from serum 
or plasma. Additionally, biases have been demonstrated for in-house analysers which result in 
different reference intervals for each different type of analyser. The objective of this study was to 
calculate reference intervals (with 90% confidence intervals) for 13 biochemistry analytes when 
tested on three commonly used in-house veterinary analysers as well as a commercial laboratory 
analyser.  The calculated reference intervals were then compared to those provided by the in-house 
analyser manufacturers and the commercial laboratory. Plasma samples were collected from 53 
clinically normal cats, after centrifugation, plasma was divided into four aliquots.  One aliquot was 
sent to the commercial laboratory and the remaining three were tested using the in-house 
biochemistry analysers. The distribution of results was used to choose the appropriate statistical 
technique for each analyte from each analyser to calculate reference intervals. Provided reference 
limits were deemed appropriate if they fell within the 90% confidence intervals of the calculated 
reference limits. Transference validation was performed on provided and calculated reference 
intervals.  Twenty nine of a possible 102 provided reference limits (28%) were within the calculated 
90% confidence intervals.   To ensure proper interpretation of laboratory results, practitioners 
should determine reference intervals for their practice populations and/or use reference change 
values when assessing their patients’ clinical chemistry results. 
 
Introduction 
Population-based reference intervals for clinical pathology analytes usually describe the 
central 95% of normally distributed results found in healthy individuals.
1-3
  The difficulties in 
establishing such intervals are well described and relate to the definition and selection of 
healthy individuals, and selection of appropriate statistical techniques based on whether a 
normal distribution of results is found, or can be established.
1-3
  
Several studies have indicated that in-house analytes show bias for several analytes compared 
to results determined by commercial laboratory analysers when analysing feline samples.
4-10
  
Such biases influence the reference interval of each  analyte determined by each analyser, and 
potentially for every individual analyser of each model, let alone accounting for differences 
between populations of individuals between veterinary practices, cities and continents.  The 
manufacturers of in-house analysers (and commercial laboratories) provide standard 
reference intervals for each species that, in many cases, do not account for any differences 
such as geographical population differences; further, the potential for variation between 
results obtained from serum or plasma is not 
readily apparent.   
The objective of this study was to calculate 
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reference intervals for 13 biochemistry analytes using feline plasma when tested on three 
commonly used in-house veterinary analysers as well as a commercial laboratory analyser.  
Each reference interval accounted for the central 95% of a normal distribution and each upper 
and lower limit was determined with 90% confidence intervals. The calculated reference 
intervals were then compared to those provided by either the in-house analyser manufacturers 
or the commercial laboratory. 
The provided reference interval limits were assessed whether they fell within 90% confidence 
intervals of the calculated reference intervals (or not).  Additionally, both the provided and 
calculated reference intervals were assessed by transference validation.
3, 11
   
 
Materials and methods 
Reference intervals were determined by: 
 Choosing clinically normal individuals. 
 Determining if the distribution of analyte values was normal and, if not, transforming the 
data to establish normality (where possible). 
 Choosing the appropriate statistical technique for each analyte from each analyser, 
depending on the distribution of results, to calculate reference intervals (with 90% 
confidence intervals for upper and lower limits) based on American Society of Veterinary 
Clinical Pathologists (ASCVP) recommendations.
3
  
Subjects  
Plasma samples were collected from 53 cats identified as being clinically normal in a primary 
accession, feline-only practice (Paddington Cat Hospital, Sydney, Australia), over a two 
month period.  These comprised 28 spayed females and 25 castrated males, ranging in age 
from 1 to 16 years (mean: 8.4 years, median: 8.8 years); 26 were domestic shorthairs, 10 were 
Burmese, 11 breeds (Abyssinian, Bengal, British Shorthair, Cornish Rex, Devon Rex, 
Domestic Longhair, Persian, Ragdoll, Russian Shorthair, Siamese, Tonkinese, Turkish Van) 
were represented in the remaining 17 cats with no more than 2 cats of any specific breed. 
This is representative of the breeds of cats seen in the primary author’s (RB) practice.  Only 
one sample was assessed from each cat. 
The health status at the time of testing of cats was determined by: (1) reason for presentation; 
and (2) physical examination assessing body condition score, hydration, abdominal palpation, 
thoracic auscultation and body temperature.  
Sampling 
Blood samples were collected from each cat by single jugular venipuncture into a 2 mL 
lithium heparin tube (Becton Dickinson, New Jersey, USA). Each tube was centrifuged at 
4000 rpm (1790 x G) for 5 minutes within 30 minutes of collection and the plasma was then 
immediately divided into four separate aliquots.  One aliquot was sent by courier to the 
commercial laboratory and processed by a Cobas-Integra 400 biochemical analyte analyser 
and the remaining three were immediately tested on three in-house biochemistry analysers: 
Abaxis Vetscan® VS-2 Point of Care Analyser (Abaxis, California, USA), Heska Dri-
Chem® Veterinary Chemistry Analyser (Heska, Colorado, USA) and IDEXX VetTest and 
Vetlyte® (IDEXX, Maine, USA) for the following 13 biochemistry analytes: albumin, 
alkaline phosphatase (ALP), alanine aminotransferase (ALT), total bilirubin, calcium, 
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chloride (not available for Abaxis), creatinine, glucose, phosphate, potassium, sodium, total 
protein and urea. 
Laboratory methods 
The assay methods used by each instrument for each analyte are shown in Table 1.   
The Cobas-Integra 400 analyser at a National Association of Testing Authorities (NATA) 
accredited commercial laboratory (Gribbles Veterinary laboratory, Rhodes, Sydney, 
Australia) underwent assay calibration (with concurrent verification) weekly to monthly 
(depending on the individual analyte) according to manufacturer's recommendations. Both 
Heska and Abaxis analysers were less than one year old and installed to the manufacturers’ 
specifications by the distributing agents.  Although 10 years old, the IDEXX analysers had 
been serviced by the manufacturer three months prior to the assessment period.  Formal 
assessments commenced after training by the distributing agent and after a familiarization 
period of at least 10 runs on each analyser. Precision of each analyser was assessed by 
within-day and between-day assessments over the study period.
12
  
Table 1 Assay method for analyte concentrations by the Abaxis VetScan, IDEXX VetTest/VetLyte and Heska Dri-
Chem analysers, and by a Cobas-Integra biochemistry analyser at a commercial laboratory Cobas-Integra 
(commercial) 
Analyser: 
Cobas-Integra 
(commercial) 
Abaxis IDEXX Heska 
Analyte     
Albumin Bromcresol green 
binding 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alkaline 
Phosphatase 
p-NPP 
hydrolyzation 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alanine 
Aminotransferase 
Catalyzation 
(form pyruvate and 
N-glutamate)  
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Total Bilirubin 
Diazo method 
Enzymatic 
(bilirubin oxidase)  
Diazo-based dry film Diazo-based dry film 
Calcium 
Spectrophotometric 
(CPC)  
Spectrophotometric 
(arsenazo III) 
Spectrophotometric 
(arsenazo III)  
Spectrophotometric 
(Chlorophosphonazo 
III)  
Chloride Ion selective 
electrode (ISE)  
Not analyzed by this 
instrument 
as for Cobas-Integra Potentiometric 
Creatinine 
Jaffe reaction 
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine deiminase)  
Glucose Hexokinase as for Cobas-Integra Glucose oxidase Glucose oxidase 
Phosphate 
Phosphomolybdate 
Enzymatic  
(phosphoglucomutase) 
as for Cobas-Integra 
Spectrophotometric 
(PNP)  
Potassium 
Ion selective 
electrode (ISE)  
Enzymatic 
(pyruvate kinase)  
as for Cobas-Integra Potentiometric 
Sodium 
Ion selective 
electrode (ISE)  
Enzymatic 
(beta-galactosidase)  
as for Cobas-Integra Potentiometric 
Total Protein Biuret as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Urea Coupled-enzyme 
reaction 
as for Cobas-Integra Ammonia indicator 
Bromcresol 
green/ammonia 
‘as for Cobas-Integra’ indicates the same method as the commercial laboratory 
p-NPP = p-nitrophenylphosphate; CPC = o-cresolphthalein complexone; PNP = purine-nucleoside phosphorylase  
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Assessments and statistical analyses 
Outlying values were detected by the Tukey outlier identification method which determines 
outliers based on the median and interquartile range. In brief: Q1, Q2 and Q3 respectively 
represent the first, second and third quartiles of the distribution and IQ = Q3 - Q1 is the inter-
quartile range. Outliers are data smaller than Q1-3*IQ or greater than Q3+3*IQ and suspect 
data are contained in the interval between Q1-3 IQ and Q1-1.5 IQ or between Q3+1.5*IQ and 
Q3+3*IQ.
13
  
Histograms of the results were prepared for each analyte on each analyser and assessed for 
normal distribution.  Normality was also assessed by (1) skewness,
14
 (2) the kurtosis test 
statistic,
15
 (3) the Shapiro-Wilks test,
16
 and (4) the Anderson-Darling test.
17
  
Skewness is a measure of the asymmetry of the distribution; a zero value indicates that the 
values are relatively evenly distributed on both sides of the mean, typically (but not 
necessarily) implying a symmetric distribution.  A value between -0.5 and 0.5 was considered 
indicative of symmetry.
14
 
Kurtosis measures the height and sharpness of the peak of the distribution relative to the rest 
of the data. Higher values indicate a higher, sharper peak; lower values indicate a lower, less 
distinct peak.  The reference standard is a normal distribution, which has a kurtosis of 3. 
Excess kurtosis is presented in this study, which for a normal distribution is zero.  The excess 
kurtosis test statistic describes how many standard errors the sample excess kurtosis is from 
zero and was calculated by dividing the sample excess kurtosis by the standard error of 
kurtosis. A value between -2 and 2 was considered indicative of appropriate peakedness, i.e. 
if the kurtosis greater than twice its standard error (positively or negatively), then the 
distribution is considered significantly different from a normal distribution.
15
 
The Shapiro-Wilk
16
 and Anderson-Darling
17
 tests are both goodness of fit tests (also called 
omnibus tests) that assess normality of a distribution. The null hypothesis for each of these 
tests is that the population is normally distributed, so if a p-value <0.05, then the null 
hypothesis is rejected, and this indicates significant departures from normality. Two goodness 
of fit tests were used since there is controversy in the literature as to which omnibus test is 
preferable. 
A summary of the normality tests is provided in Table 2. 
A normal distribution was assumed if at least three of these four tests indicated normality 
(and was consistent with visual inspection of the histogram). 
In those cases where less than three of these tests indicated normality, Box-  
Cox transformations were made to assess the resultant data which was subjected to the same 
four tests of normality
14-17
 that were applied to the raw data using Genstat Version 14.0 (VSN 
International Ltd, UK).  Reference Value Advisor
18
 was used to calculate reference intervals 
with 90% confidence intervals (CI) for each analyte from each analyser by parametric 
Table 2 Summary of the normality tests. A normal distribution was assumed if at least three of these four tests indicated 
normality (and was consistent with visual inspection of the histogram). 
Parameter Description Indication of 
Normality 
Skewness measures symmetry of distribution (positive values indicate 
skewed to the left, negative to the right) 
-0.5 to 0.5 
Kurtosis measures the height and sharpness of the peak  3 
Excess Kurtosis Kurtosis minus 3 0 
Kurtosis Test Statistic Excess kurtosis divided by standard error of kurtosis -2 to 2 
Anderson-Darling Test Goodness of fit test (also called omnibus test) p> 0.05 
Shapiro-Wilks Test Goodness of fit test (also called omnibus test) p> 0.05 
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(standard and robust) methods for both raw and transformed data as well as non-parametric 
methods. Only the technique determined by the ASVCP guidelines (for each individual 
analyte on each analyser) is presented in this paper. 
The robust method was used when the data distribution (of raw or transformed data) was 
symmetric whether this was Gaussian or not. It is built using robust statistics (median and 
median absolute deviation) that are less sensitive to outliers. This reference interval is 
obtained by a process that iteratively gives a smaller weight to data far from the central 
location and uses ± 2 SD as the limits of the RI. The non-parametric method was used when 
the data distribution was not symmetrical, even after transformation, observations are ranked 
according to size, and the 2.5 and 97.5 percentiles are obtained as the 0.025(n+1) and 0.975 
(n+1) ordered observations. If the estimated rank values are not integers, then linear 
interpolation is carried out.
19
 
Confidence intervals were calculated using a non-parametric bootstrap technique within 
Reference Value Advisor. 
Results were compared with the reference limits provided by the manufacturer by assessing if 
the provided reference interval limits fell within the calculated 90% confidence intervals.  
Transference validation assessments 
Twenty values from each analyte from each analyser were randomly selected using the 
random number generator from column function of Excel (Microsoft, Redmond, Wa, USA) 
on two separate occasions resulting in two sets of twenty random values. The number of 
values from each set falling within the provided and calculated reference intervals was   
identified. A reference interval was considered valid if one or two results were outside the 
interval.  Transference is rejected if three or more results fall outside the reference interval; 
zero values falling outside the reference interval suggests that the reference interval is too 
wide and that its sensitivity in detection of abnormal individuals should be re-assessed.
3, 11
 
Therefore, transference validation results were assessed both including and excluding zero 
values falling inside the range. 
 
Results 
The total number of samples assessed for each analyte (across all four analysers) varied 
between 39 and 52 due to logistical reasons such as insufficient supply of test ‘slides’ on 
individual days, insufficient sample quantity, exceeding the provided number of tests or, on 
one occasion, instrument failure to report a result. 
Glucose concentrations determined by the commercial laboratory for the first twelve samples 
collected were substantially lower than those from all three in-house analysers. These results 
were excluded because it was suspected that red blood cells were accidentally aspirated into 
the plasma (which would have minimal, if any, effect on the in-house analyser results since 
they were tested immediately). 
For the remaining analytes, zero to two outlying values were detected by the Tukey outlier 
identification method
13
 on each analyser but none were excluded since no clinical, pre-
analytical or analytical factors justifying their exclusion could be identified.   
Basic descriptive statistics such as minima, maxima, means, medians and standard deviations 
of results from each analyser for each analyte are shown in Table 3.   
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Table 3 Descriptive statistics for feline reference intervals for each biochemical analyte for each analyser showing number of 
samples tested (n), minimum (Min), median (Med) and maximum (Max) results, as well as lower quartile (25th percentile), 
upper quartile (75th percentile), mean and SD 
 
Analyte Analyser 
n Min 
Lower 
Quartile 
Median 
Upper 
Quartile 
Max Range Mean SD 
Albumin (g/L) Abaxis 43 33 38 39 41 45 12 39.47 2.80 
IDEXX 52 24 30 33 34 39 15 32.40 3.02 
Heska 49 25 32 33 34 39 14 32.86 2.71 
Cobas-Integra 47 28 33 35 37 44 16 34.77 3.18 
ALP (U/L) Abaxis 44 11 19 24 29.5 70 59 25.66 10.79 
IDEXX 53 20 31 37 45.2 91 71 40.34 15.41 
Heska 52 23 32 35 42.5 87 64 38.87 12.34 
Cobas-Integra 48 9 18 22 27.0 77 68 25.38 13.70 
ALT (U/L) Abaxis 42 32 52.0 60 74.8 137 105 64.4 21.02 
IDEXX 51 10 23.5 34 52.5 93 83 37.5 19.69 
Heska 50 27 51.3 61 77.5 150 123 65.7 23.95 
Cobas-Integra 46 20 42.3 53 70.8 129 109 57.2 22.55 
Calcium 
(mmol/L) 
Abaxis 43 2.30 2.49 2.59 2.71 3.27 0.97 2.61 0.18 
IDEXX 51 2.39 2.53 2.61 2.70 3.10 0.71 2.63 0.13 
Heska 50 2.45 2.59 2.70 2.83 3.49 1.04 2.73 0.19 
Cobas-Integra 47 2.30 2.50 2.63 2.72 3.42 1.12 2.64 0.22 
Chloride 
(mmol/L) 
Abaxis NA NA NA NA NA NA NA NA NA 
IDEXX 51 120 123 125 126 130 10 124.7 1.97 
Heska 46 102 114 116 119 124 22 115.7 4.94 
Cobas-Integra 46 112 116 118 120 124 12 118.3 2.69 
Creatinine 
(umol/L) 
Abaxis 43 57 115.5 131 148.2 179 122 131.9 25.59 
IDEXX 52 118 152.0 165 182.5 233 115 167.2 25.80 
Heska 51 80 106.5 127 140.4 172 92 125.2 21.84 
Cobas-Integra 47 81 103.5 117 131.5 167 86 117.9 19.11 
Glucose 
(mmol/L) 
Abaxis 43 5.1 5.83 6.5 7.35 11.0 5.9 6.84 1.40 
IDEXX 52 4.4 5.96 6.6 7.21 10.9 6.6 6.84 1.46 
Heska 51 4.5 5.73 6.4 7.23 11.5 7 6.79 1.56 
Cobas-Integra 39 4.7 5.53 6.0 6.85 10.6 5.9 6.43 1.43 
Phosphate 
(mmol/L) 
Abaxis 43 0.75 1.18 1.47 1.66 2.74 1.99 1.47 0.38 
IDEXX 49 0.65 1.03 1.22 1.42 3.0 2.35 1.29 0.38 
Heska 50 0.67 1.06 1.24 1.48 2.9 2.23 1.30 0.37 
Cobas-Integra 45 0.59 1.01 1.20 1.38 2.6 2.01 1.26 0.37 
Potassium 
(mmol/L) 
Abaxis 43 2.9 3.7 4 4.4 5.0 2.1 4.05 0.47 
IDEXX 51 2.7 3.5 3.8 4.2 4.8 2.1 3.84 0.48 
Heska 46 2.3 3.3 3.6 3.9 4.6 2.3 3.57 0.49 
Cobas-Integra 47 2.8 3.4 3.6 4.0 4.5 1.7 3.66 0.41 
Sodium  
(mmol/L) 
Abaxis 43 146 149 151 153 156 10 150.8 2.68 
IDEXX 51 158 161 162 163 167 9 161.8 1.95 
Heska 46 130 149 152 154 157 27 150.3 5.28 
Cobas-Integra 47 145 148 149 151 155 10 149.5 2.16 
Total 
bilirubin 
(umol/L) 
Abaxis 43 3 4 4 4 14 11 4.37 2.02 
IDEXX 50 2 2 2 2 11 9 2.46 1.39 
Heska 50 1 1 1 1 10 9 1.36 1.41 
Cobas-Integra 47 3 5 6 7 13 10 5.94 1.80 
Total Protein 
(g/L) 
Abaxis 43 54 68 74 77 86 32 72.6 6.53 
IDEXX 52 53 66 70 74 81 28 69.8 6.19 
Heska 51 52 66 70 72 82 30 69.1 5.97 
Cobas-Integra 47 55 66 73 77 98 43 72.6 7.81 
Urea 
(mmol/L) 
Abaxis 43 6.4 7.9 8.9 10.05 13.0 6.6 9.14 1.55 
IDEXX 52 5.5 7.2 7.9 8.95 11.7 6.2 8.11 1.36 
Heska 51 6.2 8.4 9.6 10.63 14.4 8.2 9.76 1.72 
Cobas-Integra 47 6.2 7.8 9.3 10.25 13.1 6.9 9.30 1.73 
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Table 4  Normality assessments, bold indicates normality.  Positive values for skewness indicate skewed to the right, negative to the 
left.  Results for Box-Cox transformed data only for those analytes that raw data did not have a normal distribution.  When Box-Cox 
transformation was performed, reference interval (RI) technique was determined from the transformed data.  The terms used are 
described in Table 2. 
Analyte Analyser Skewness SE 
Skewness 
Excess 
Kurtosis 
SE 
Kurtosis 
Kurtosis 
Test 
Statistic 
Shapiro 
Wilks  
p value 
Anderson 
Darling  
p value 
RI 
technique 
Albumin Abaxis 0.12 0.36 -0.45 0.71 -0.64 0.14 0.04 Robust 
  IDEXX -0.27 0.33 0.07 0.65 0.11 0.63 0.34 Robust 
  Heska -0.32 0.34 0.55 0.67 0.83 0.38 0.17 Robust 
  Cob.-Int. 0.14 0.35 0.18 0.68 0.26 0.23 0.10 Robust 
ALP Abaxis 1.89 0.36 4.98 0.70 7.09 <0.001 <0.001 N/A 
  IDEXX 1.44 0.33 2.02 0.64 3.14 <0.001 <0.001 N/A 
  Heska 1.82 0.33 3.72 0.65 5.72 <0.001 <0.001 N/A 
  Cob.-Int. 1.95 0.34 3.95 0.67 5.87 <0.001 <0.001 N/A 
  B-C Abaxis 0.01 0.36 0.51 0.70 0.73 0.58 0.38 Robust 
  B-C IDEXX -0.47 0.33 -0.05 0.64 -0.08 0.21 0.22 Robust 
  B-C Heska -0.96 0.33 1.31 0.65 2.02 0.01 0.03 N-P 
  B-C Cob.-Int. -0.78 0.34 0.90 0.67 1.33 0.02 0.02 N-P 
ALT Abaxis 3.60 0.36 15.88 0.71 22.40 <0.001 <0.001 N/A 
  IDEXX 4.00 0.33 20.65 0.65 31.77 <0.001 <0.001 N/A 
  Heska 3.79 0.333 18.41 0.66 28.06 <0.001 <0.001 N/A 
  Cob.-Int. 3.76 0.35 17.95 0.68 26.36 <0.001 <0.001 N/A 
  B-C Abaxis -0.02 0.37 0.19 0.72 0.26 0.98 0.93 Robust 
  B-C IDEXX 0.48 0.33 -0.30 0.66 -0.45 0.16 0.25 Robust 
  B-C Heska 0.89 0.34 0.98 0.66 1.49 0.03 0.85 N-P 
  B-C Cob.-Int. 0.82 0.35 0.70 0.69 0.96 0.08 0.12 Robust 
Calcium Abaxis 1.13 0.36 2.79 0.71 3.94 0.02 0.24 N/A 
  IDEXX 1.08 0.33 1.84 0.66 2.80 0.01 0.06 N/A 
  Heska 1.44 0.34 3.87 0.66 5.84 0.002 0.03 N/A 
  Cob.-Int. 1.49 0.35 3.18 0.68 4.67 <0.001 0.001 N/A 
  B-C Abaxis -0.62 0.36 0.24 0.71 0.34 0.98 0.96 Robust 
  B-C IDEXX 0.10 0.33 -0.04 0.66 -0.07 0.06 0.98 Robust 
  B-C Heska 0.09 0.34 0.05 0.66 0.08 0.73 0.82 Robust 
  B-C Cob.-Int. -0.22 0.35 0.25 0.68 0.37 0.36 0.17 Robust 
Chloride IDEXX 0.13 0.33 -0.04 0.66 -0.06 0.22 0.08 Robust 
  Heska -0.80 0.35 0.38 0.69 0.55 0.03 0.02 N/A 
  Cob.-Int. 0.18 0.35 -0.22 0.69 -0.32 0.29 0.11 Robust 
  B-C Heska -0.36 0.35 -0.17 0.69 -0.25 0.43 0.25 Robust 
Creatinine Abaxis -0.39 0.36 0.4- 0.71 0.56 0.72 0.95 Robust 
  IDEXX 0.22 0.33 -0.26 0.65 -0.40 0.81 0.90 Robust 
  Heska 0.05 0.33 -0.79 0.66 -1.21 0.37 0.22 Robust 
  Cob.-Int. 0.19 0.35 -0.32 0.35 -0.92 0.93 0.94 Robust 
Glucose Abaxis 1.29 0.36 1.36 0.36 3.76 <0.001 <0.001 N/A 
  IDEXX 1.19 0.33 1.27 0.65 1.95 <0.001 <0.001 N/A 
  Heska 1.36 0.33 1.65 0.66 2.51 <0.001 <0.001 N/A 
  Cob.-Int.. 1.54 0.38 1.86 0.74 2.51 <0.001 <0.001 N/A 
  B-C Abaxis 0.02 0.36 -0.61 0.71 -0.86 0.71 0.89 Robust 
  B-C IDEXX -0.34 0.33 0.56 0.65 0.86 0.28 0.26 Robust 
  B-C Heska -0.05 0.33 -0.18 0.66 -0.28 0.61 0.38 Robust 
  B-C Cob.-Int. -0.70 0.38 0.30 0.74 0.41 0.10 0.25 Robust 
Phosphate Abaxis 0.93 0.36 1.59 0.71 2.24 0.06 0.16 N/A 
  IDEXX 1.90 0.34 6.49 0.67 9.71 <0.001 0.01 N/A 
  Heska 1.71 0.34 5.16 0.66 7.79 <0.001 0.01 N/A 
  Cob.-Int. 1.23 0.35 2.52 0.70 3.63 0.89 0.03 N/A 
  B-C Abaxis 0.01 0.36 0.34 0.71 0.48 0.96 0.79 Robust 
  B-C IDEXX -1.91 0.34 5.50 0.67 8.24 <0.001 <0.001 N-P 
  B-C Heska -2.00 0.34 5.88 0.66 8.88 <0.001 <0.001 N-P 
  B-C Cob.-Int. -1.64 0.35 4.55 0.70 6.54 <0.001 0.01 N-P 
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Normality Assessments 
The results of the normality assessments are shown in Table 4. Raw data for five analytes 
(albumin, creatinine, potassium, total protein and urea) were normally distributed from all 
four analysers (based on visual inspection of histograms and three parameters suggesting 
normality). A normal distribution was found for sodium on the Abaxis, IDEXX and Gribbles 
analysers but not the Heska analyser.  Additionally, raw data for chloride from the IDEXX 
and Gribbles analysers were normally distributed.  
Two parameter Box-Cox transformations of data resulted in normal distributions for calcium 
and glucose from all analysers, ALT on the Abaxis, IDEXX, and Gribbles analysers, ALP on 
the IDEXX analyser, chloride on the Heska analyser and phosphate from the Abaxis analyser. 
One parameter Box-Cox transformations resulted in normal distributions for ALP on the 
Abaxis analyser and chloride on the IDEXX analyser.  Histograms from raw data and Box-
Cox transformed data for ALP on the Abaxis analyser are shown in Figures 1a and 1b 
respectively.   
Normal distributions could not be obtained by transforming data for the remaining analytes: 
ALP on the Gribbles and Heska analysers, ALT on the Heska analyser, phosphate on 
IDEXX, Heska and Gribbles analysers, sodium in the Heska analyser and bilirubin on all four 
analysers. 
Table 4  (continued) 
 
Analyte Analyser Skewness SE 
Skewness 
Excess 
Kurtosis 
SE 
Kurtosis 
Kurtosis 
Test 
Statistic 
Shapiro 
Wilks  
p value 
Anderson 
Darling  
p value 
RI 
technique 
Potassium Abaxis 0.19 0.36 -0.24 0.71 -0.33 0.32 0.14 Robust 
  IDEXX 0.03 0.33 -0.22 0.66 -0.34 0.43 0.29 Robust 
  Heska 0.04 0.35 0.11 0.69 0.16 0.63 0.41 Robust 
  Cob.-Int. 0.11 0.35 -0.47 0.68 -0.70 0.48 0.43 Robust 
Sodium Abaxis -0.10 0.36 -0.86 0.71 -1.21 0.15 0.16 Robust 
  IDEXX 0.24 0.33 0.23 0.66 0.36 0.09 0.03 Robust 
  Heska -1.86 0.35 4.03 0.69 5.85 <0.001 <0.001 N-P 
  Cob.-Int. 0.31 0.35 0.03 0.68 0.05 0.21 0.05 Robust 
Total 
Bilirubin 
  
  
  
  
  
  
Abaxis 3.82 0.36 14.40 0.71 20.37 <0.001 <0.001 N/A 
Bilirubin IDEXX 4.92 0.34 27.00 0.66 40.79 <0.001 <0.001 N/A 
 
Heska 5.03 0.34 26.85 0.66 40.56 <0.001 <0.001 N/A 
 
Cob.-Int. 1.09 0.35 3.32 0.68 4.88 0.01 0.003 N/A 
 
B-C Abaxis 3.82 0.36 14.44 0.71 20.37 <0.001 <0.001 N-P 
 
B-C IDEXX 1.52 0.34 0.32 0.66 0.48 <0.001 <0.001 N-P 
 
B-C Heska 2.67 0.34 5.12 0.66 7.73 <0.001 <0.001 N-P 
 
B-C Cob.-Int. 1.73 0.35 6.11 0.68 8.97 <0.001 0.001 N-P 
Total Protein 
  
  
Abaxis -0.53 0.36 0.02 0.71 0.03 0.13 0.07 Robust 
 
IDEXX -0.38 0.33 -0.21 0.65 -0.32 0.46 0.42 Robust 
 
Heska -0.40 0.33 0.46 0.66 0.70 0.23 0.07 Robust 
 
Cob.-Int. 0.45 0.35 1.07 0.68 1.57 0.23 0.34 Robust 
Urea Abaxis 0.57 0.36 -0.21 0.71 -0.30 0.15 0.13 Robust 
  IDEXX 0.49 0.33 0.09 0.65 0.14 0.32 0.30 Robust 
  Heska 0.38 0.33 -0.04 0.66 -0.06 0.59 0.49 Robust 
  Cob.-Int. 0.40 0.35 -0.42 0.68 -0.62 0.24 0.29 Robust 
 
ALP = alkaline phosphatase; ALT = alanine aminotransferase; B-C = Box-Cox; Cob.-Int. = Cobas-Integra; NA = not applicable as 
technique determined from transformed data; N-P = non-parametric; SE = Standard Error 
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Figure 1 (a) Histogram of raw data for alkaline 
phosphatase (ALP) on the Abaxis analyser. Note the rightt 
skew (calculated as 1.9, notably greater than the 
allowable range of –0.5 to 0.5) and the high peakedness 
(kurtosis); excess kurtosis is any value >0, and this was 
calculated as 4.9. (b) Histogram of Box–Cox transformed 
data for ALP on the Abaxis analyser. 
Note that (compared with [a]), there is no longer any 
appreciable skew (calculated as –0.02), and excess 
kurtosis is greatly reduced to 0.5. This histogram was 
determined to be a normal distribution by both 
Anderson–Dowling and Shapiro–Wilk techniques 
  
 
 
Reference intervals 
Table 5 shows the reference intervals (with 90% 
confidence intervals) calculated for each analyte 
assessed on each analyser using the appropriate 
technique chosen from the normality test results 
on either raw data or Box-Cox transformed 
data, also depending on normality test results 
according to the ASVCP guidelines.
3
 Also 
included are the reference intervals provided by 
each manufacturer and the commercial 
laboratory. A tick or cross underneath the 
provided reference interval indicates that the 
provided reference values were within (tick) or 
outside (cross) the calculated 90% confidence intervals from the appropriate calculated 
reference limit. 
This table shows that, across all four analysers, only 29 of a possible 102 provided reference 
limits are within the calculated 90% confidence intervals. The Abaxis analyser had 6/24 
(25%), the IDEXX and Heska analysers each had 8/26 (31%), and the Gribbles commercial 
laboratory analyser had 7/26 (27%) of reference limits within the calculated 90% confidence 
intervals. 
Transference Validation Assessments 
Transference validation assessment results are shown in Table 6. 
When results from both tests of random values are included and rejecting zero values falling 
inside the range, 37% (38/102) of the provided reference intervals were validated by 
transference: 46% (11/24) for the Abaxis analyser, 50% (13/26) for the IDEXX analyser, 
42% (11/26) for the Heska analyser and 12% (3/26) for the Gribbles commercial laboratory 
analyser.  For the IDEXX analyser there was notable variation between each set of random 
samples with 31% (4/13) reference intervals validated from the first random set and 69% 
(9/13) validated from the second random set.  No reference intervals were validated from the 
first random set of results when assessed for the Gribbles commercial laboratory analyser 
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reference intervals and 23% (3/13) were validated by the second random set of results.  There 
were 25% (25/102) assessments with greater than four results falling outside the reference 
interval and the maximum was 80% (16/20) for calcium assessed on the Gribbles analyser 
from the second random set. 
For the calculated reference intervals, the total percentage of validated reference intervals by 
transference from both random sets (when rejecting zero values falling inside the range) was 
70% (71/102); by analyser: 71% (17/24) for the Abaxis, 73% (19/26) for the IDEXX , 77% 
(20/26) for the  Heska and 58% (15/26) for the Gribbles commercial laboratory analyser.   
Results were similar for each random set and all but two failures of this assessment were due 
to zero results falling outside the reference interval.  The other two results were associated 
with three results falling outside the range. 
When zero values falling inside the range are accepted, 72% (73/102) of the provided 
reference intervals are inside the range: 88% (21/24) for the Abaxis analyser  92% (24/26) for 
the  IDEXX analysers, 62% (16/26) for the Heska analyser reference intervals and 46% 
(12/26) for the  Gribbles commercial laboratory analyser. 
For the calculated reference intervals, the total percentage of validated reference intervals by 
transference from both random sets (when accepting zero values falling inside the range) was 
98% (100/102):  96% (23/24) for the Abaxis analyser, 100% (26/26) for the IDEXX analyser 
s, 100% (26/26) for the Heska analyser and 96% (25/26) for the Gribbles commercial 
laboratory analyser.   
 
Discussion 
This study is the first to assess calculated against provided reference intervals for these in-
house analysers. The major finding was that 72% of calculated reference interval limits 
varied significantly from the provided reference intervals, and in only four (out of 51) cases 
were both upper and lower provided reference limits consistent with those calculated. This 
means that only 8% (4/51) of the provided reference intervals were validated for this 
population of cats, from this hospital population, when assessing plasma.  Additionally, only 
between 12% and 50% of provided reference intervals were validated by transference when 
rejecting zero values falling inside the range and between 46% and 92% when accepting zero 
values falling inside the range.  It is important to note that only 70% of calculated reference 
intervals were validated by transference varying between 58% and 77% depending on 
analyser, when rejecting zero values falling within the range. All but one of the calculated 
reference intervals rejected by transference had no values within the range (meaning that it is 
a measure of 100% of healthy cats not 95% of healthy cats so the range is too wide) 
compared to 27 of the provided reference intervals rejected by transference having too many 
results outside the range.  Too wide a reference interval (zero values within the range) may 
result in false negative results as abnormal results may be considered normal. Transference 
assumes that patient populations are comparable. This means that complete demographic 
information on the original reference sample group should be available so that it can be 
assessed if it corresponds to the demographics of the new population.
2-3
 Enquiries to the 
manufacturers of the in-house analysers and the commercial laboratory for specific details of 
how the provided reference intervals were calculated were unrewarding.  Transference  
63 
 
 
Table 5  Calculated reference intervals (with 90% confidence intervals) for each analyte assessed on each analyser 
using the appropriate technique chosen from normality test results on either raw data or Box-Cox transformed 
data , also depending on normality test results.  Also included are the reference intervals provided by each 
manufacturer and the commercial laboratory.  A tick underneath the provided reference interval indicates that the 
provided reference points are within the calculated 90% confidence intervals from the calculated reference limit, 
while a cross indicates that it is not within the calculated 90% CI from the calculated reference limit. 
 Analyte Analyser Method (Data 
used) 
 
Calculated RI Provided RI 
RI Lower 
Limit 
RI Upper 
Limit 
RI 
Lower 
Limit 
RI 
Upper 
Limit Albumin (g/L) Abaxis Robust (raw) 33.0 44.6 22 44 
  
90% CI 32.4-34.6 43.6-46.4   
 
IDEXX Robust (raw) 26.4 38.7 23 39 
  
90% CI 24.9-27.7 37.2-40.0   
 
Heska Robust (raw) 27.5 38.5 23 35 
  
90% CI 26.1-28.8 37.2-39.7   
 
Cobas-Integra Robust (raw) 28.3 41.3 22 35 
  
90% CI 26.7-29.7 39.9-42.7   
ALP (U/L) Abaxis Robust (BC) 11.9 53.9 10 90 
  
90% CI 10.6-13.9 42.9-68.4   
 
IDEXX Robust (BC) 20.8 84.4 14 111 
  
90% CI 19.2-23.3 69.2-106.3   
 
Heska Non-parametric 23.7 81.1 22 124 
  
90% CI 23.0-26.0 65.0-87.0   
 
Cobas-Integra Non-parametric 9.2 73.4 5 80 
  
90% CI 9.0-11.0 57.9-77.0   
ALT (U/L) Abaxis Robust (BC) 34.1 117.6 20 100 
  
90% CI 30.1-39.2 99.3-144.7   
 
IDEXX Robust (BC) 8.8 87.4 12 130 
  
90% CI 6.6-12.0 74.5-99.7   
 
Heska Non-parametric 28.4 142.0 0 85 
  
90% CI 27.0-39.0 105.0-150.0   
 
Cobas-Integra Robust (BC) 24.5 117.0 5 80 
  
90% CI 21.0-28.8 99.8-138.2   
Calcium 
(mmol/L) 
Abaxis Robust (BC) 2.33 3.06 2.00 2.95 
  
90% CI 2.28-2.39 2.94-3.21   
 
IDEXX Robust (BC) 2.42 2.96 1.95 2.83 
  
90% CI 2.39-2.45 2.86-3.09   
 
Heska Robust (BC) 2.46 3.22 2.20 3.00 
  
90% CI 2.42-2.50 3.07-3.43   
 
Cobas-Integra Robust (BC) 2.33 3.26 1.75 2.50 
  
90% CI 2.28-2.38 3.04-3.49   
Chloride 
(mmol/L) 
IDEXX Robust (raw) 120.6 128.7 112 129 
  
90% CI 119.8-121.5 127.8-129.6   
 
Heska Robust (BC) 106.4 126.6 107 125 
  
90% CI 103.9-109.1 124.7-129.0   
 
Cobas-Integra Robust (raw) 112.7 123.7 115 123 
  
90% CI 111.5-113.7 122.3-124.9   
Creatinine 
(µmol/L) 
Abaxis Robust (raw) 80.9 185.5 27 186 
  
90% CI 69.2-94.5 173.3-196.4   
 
IDEXX Robust (raw) 113.7 218.8 71 212 
  
90% CI 104.6-124.8 207.0-229.2   
 
Heska Robust (raw) 80.5 169.6 71 159 
  
90% CI 71.3-89.4 161.3-179.0   
 
Cobas-Integra Robust (raw) 78.5 156.5 70 160 
  
90% CI 70.2-86.4 148.0-164.5   
Glucose 
(mmol/L) 
Abaxis Robust (BC) 5.07 10.74 3.9 8.3 
  
90% CI 4.94-5.25 9.41-12.17   
 
IDEXX Robust (BC) 4.74 10.60 3.94 8.83 
  
90% CI 4.51-5.00 9.25-12.56   
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Table 5 (Continued) 
 Analyte Analyser Method (Data 
used) 
 
Calculated RI Provided RI 
RI Lower 
Limit 
RI Upper 
Limit 
RI Lower 
Limit 
RI Upper 
Limit 
Glucose cont Heska Robust (BC) 4.73 10.94 3.9 7.2 
  
90% CI 4.53-4.96 9.42-12.83   
 
Cobas-Integra Robust (BC) 4.73 10.54 3.9 7.5 
  
90% CI 4.58-4.93 8.70-13.07   
Phosphate 
(mmol/L) 
Abaxis Robust (BC) 0.85 2.40 1.10 2.74 
  
90% CI 0.77-0.97 2.12-2.70   
 
IDEXX Non-parametric 0.69 2.75 1.00 2.42 
  
90% CI 0.65-0.90 1.78-3.00   
 
Heska Non-parametric 0.71 2.70 0.84 1.94 
  
90% CI 0.67-0.88 1.77-2.90   
 
Gribbles Non-parametric 0.61 2.52 1.29 2.26 
  
90% CI 0.59-0.86 1.80-2.60   
Potassium 
(mmol/L) 
Abaxis Robust (raw) 3.06 4.99 3.1 5.0 
  
90% CI 2.82-3.24 4.77-5.20   
 
IDEXX Robust (raw) 2.86 4.8 3.5 5.8 
  
90% CI 2.67-3.04 4.56-5.01   
 
Heska Robust (raw) 2.57 4.55 3.4 5.3 
  
90% CI 2.37-2.78 4.35-4.78   
 
Gribbles Robust (raw) 2.80 4.50 3.8 4.6 
  
90% CI 2.62-2.98 4.30-4.66   
Sodium 
(mmol/L) 
Abaxis Robust (raw) 145.3 156.3 142 164 
  
90% CI 144.2-
146.4 
155.1-157.3   
 
IDEXX Robust (raw) 157.7 165.7 150 165 
  
90% CI 156.9-
158.6 
164.8-166.5   
 
Heska Non-parametric 131.2 156.8 147 156 
  
90% CI 130.0-
139.1 
155.8-157.0   
 
Gribbles Robust (raw) 144.8 153.8 147 156 
  
90% CI 144.0-
145.8 
152.8-154.8   
Total Bilirubin 
(µmol/L) 
Abaxis Non-parametric 3.0 13.8 2 10 
  
90% CI 3.0-3.0 5.0-14.0   
 
IDEXX Non-parametric 2.0 9.1 0 15 
  
90% CI 2.0-2.0 4.0-11.0   
 
Heska Non-parametric 1.0 8.4 0 9 
  
90% CI 1.0-1.0 3.5-10.0   
 
Gribbles Non-parametric 3.0 12.2 2 10 
  
90% CI 3.0-4.0 8.0-13.0   
Total Protein  
(g/L) 
Abaxis Robust (raw) 59.6 85.9 54 82 
  
90% CI 56.2-63.3 82.0-90.9   
 
IDEXX Robust (raw) 57.6 82.8 57 89 
  
90% CI 54.6-60.3 80.2-85.2   
 
Heska Robust (raw) 57.4 81.9 60 80 
  
90% CI 54.7-60.3 79.6-84.4   
 
Gribbles Robust (raw) 56.3 88.2 56 80 
  
90% CI 52.8-60.9 84.5-91.9   
Urea (mmol/L) Abaxis Standard (raw) 5.76 12.18 3.6 10.7 
  
90% CI 5.16-6.34 11.27-12.90   
 
IDEXX Robust (raw) 5.2 10.80 5.7 12.9 
  
90% CI 4.73-5.73 10.08-11.34   
 
Heska Robust (raw) 6.11 13.13 5.35 11.43 
  
90% CI 5.50-6.89 12.38-13.89   
 
Gribbles Robust (raw) 5.62 12.69 5.4 10.7 
  
90% CI 5.05-6.28 11.91-13.52   
BC: Box-Cox transformed data 
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validation should not be considered as a substitute for correct calculation of reference 
intervals and its use should be limited to circumstances where the complexity, cost, effort and 
obtaining sufficient number of adequate specimens precludes de-novo production of reference 
intervals.
20
  
Poorly defined reference intervals can result in false positive results (if a range is too narrow) 
or false negative results (if a range is too wide).  For example, the 30% disparity between the 
provided and calculated reference limit when using the commercial laboratory analyser for 
calcium could mean numerous cats were interpreted as hypercalcaemic which may have 
meant unnecessary additional blood samples to confirm hypercalcaemia, assess ionized 
calcium and parathyroid hormone levels to determine the cause, as well as potentially 
unnecessary treatment. Conversely, the 20% disparity between calculated and provided 
reference limits for urea on the IDEXX analyser could mean pre-renal azotaemia is not 
recognised and a patient may fail to receive appropriate treatment. 
Table 6 Transference Results: a reference interval was considered valid (bolded) if one or two results were outside the interval. 
Total number (and percentage) of reference intervals validated for each analyser including and excluding zero values within the 
interval are shown. 
 
  
Abaxis IDEXX Heska Gribbles 
  
Provided Calculated Provided Calculated Provided Calculated Provided Calculated 
Albumin Random 
1 
1/20 1/20 0/20 1/20 4/20 1/20 11/20 0/20 
Random 
2 
0/20 1/20 0/20 1/20 4/20 1/20 12/20 1/20 
ALP Random 
1 
0/20 1/20 0/20 0/20 0/20 1/20 0/20 1/20 
Random 
2 
0/20 1/20 0/20 1/20 0/20 1/20 0/20 1/20 
ALT Random 
1 
1/20 1/20 1/20 1/20 5/20 1/20 5/20 1/20 
Random 
2 
1/20 1/20 2/20 1/20 1/20 1/20 1/20 1/20 
Calcium Random 
1 
1/20 1/20 1/20 2/20 1/20 2/20 13/20 1/20 
Random 
2 
1/20 1/20 2/20 0/20 2/20 1/20 16/20 2/20 
Chloride Random 
1 
NA NA 0/20 1/20 1/20 1/20 0/20 0/20 
Random 
2 
NA NA 1/20 1/20 0/20 0/20 2/20 3/20 
Creatinine Random 
1 
0/20 1/20 0/20 0/20 0/20 0/20 0/20 0/20 
Random 
2 
0/20 0/20 1/20 1/20 2/20 1/20 0/20 0/20 
Glucose Random 
1 
4/20 1/20 2/20 1/20 7/20 1/20 3/20 1/20 
Random 
2 
1/20 1/20 1/20 1/20 5/20 1/20 2/20 2/20 
Potassium Random 
1 
1/20 1/20 7/20 1/20 9/20 2/20 12/20 2/10 
Random 
2 
0/20 0/20 1/20 0/20 5/20 0/20 13/20 0/20 
Sodium Random 
1 
0/20 0/20 1/20 1/20 4/20 1/20 5/20 0/20 
Random 
2 
0/20 0/20 1/20 1/20 2/20 0/20 0/20 0/20 
Phosphate Random 
1 
4/20 1/20 10/20 1/20 3/20 1/20 13/20 1/20 
Random 
2 
1/20 1/20 2/20 1/20 2/20 1/20 9/20 1/20 
Total 
Bilirubin 
Random 
1 
0/20 3/20 0/20 1/20 1/20 1/20 0/20 0/20 
Random 
2 
2/20 1/20 0/20 0/20 0/20 0/20 0/20 0/20 
Total 
Protein 
Random 
1 
1/20 0/20 0/20 0/20 2/10 1/20 4/20 0/20 
Random 
2 
0/20 1/20 1/20 1/20 1/20 1/20 3/20 2/20 
Urea Random 
1 
2/20 0/20 0/20 0/20 2/20 0/20 3/20 1/20 
Random 
2 
4/20 1/20 0/20 1/20 4/20 1/20 3/20 1/20 
Total 
(excl 
0/20) 
 
11/24 17/24 13/26 19/26 11/26 20/26 3/26 15/26 
 
46% 71% 50% 73% 42% 77% 12% 58% 
Total   
(incl 0/20) 
(incl 0/20) 
 
21/24 23/24 24/26 26/26 16/26 26/26 12/26 25/26 
 
88% 96% 92% 100% 62% 100% 46% 96% 
NA = not available for this analyser 
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For all analysers, the provided upper reference for ALP was higher than those determined by 
this study; these differences are of a sufficient degree that cats with slight increases in ALP 
could be missed based on the provided reference interval. This is particularly important in the 
cat where even small increases in ALP may be significant due to the short half life (6 hours) 
of this enzyme compared to other species.
21
  
The calculated lower reference limits for albumin were significantly higher than the provided 
reference limits for all analysers.  This could result in failure to identify animals with slight 
decreases in albumin, which may be important for diagnosis, prognosis, greater 
concentrations of unbound therapeutic drugs and/or need for further monitoring.  
The variation between the provided and calculated reference limits did not always show the 
same trend for all analysers.  The generated upper reference limits for ALT were higher than 
the provided reference limit for two analysers (Abaxis and Heska) and lower for two (IDEXX 
and the Gribbles commercial laboratory analyser). Moderate elevations would be missed 
when the provided reference limit is lower and considered abnormal in those cases it is 
higher.  
Reference Value Advisor uses the Anderson-Darling technique to test for normality.  
Omnibus techniques like this are used to test for normality so that both kurtosis and skewness 
can be assessed together.  However, no omnibus test is perfect.
22-23
  The authors chose to 
additionally test with another omnibus test (Shapiro-Wilk) and if there was any disparity 
between the two tests (as there was for albumin on the Abaxis analyser and sodium on 
IDEXX analyser whose distribution of results were not considered normal for the Anderson-
Darling test but were for the Shapiro-Wilk test), then the ‘raw’ descriptors of skewness and 
kurtosis both needed to indicate a normal distribution for the distribution to be considered 
normal.  There is controversy in the literature as to which omnibus test is preferable.  One 
study found the Anderson-Darling test to be conservative.
24
  A recent study found the 
Shapiro-Wilk technique to be the most powerful test followed by Anderson-Darling 
technique.
22
  It has been previously recommended to use omnibus tests such as Shapiro-Wilk 
with kurtosis and skewness as done in this study.
23
 
Subject-based reference intervals (reference change values) have recently been advocated to 
assess veterinary clinical pathology results.
3, 25
 A recent study demonstrated that reference 
change values are more appropriate to use than reference intervals for most feline 
biochemistry analytes.
26
   
 
Conclusions 
This study demonstrates that many reference intervals for cats provided by in-house 
biochemistry analyser manufacturers or commercial pathology laboratories are not applicable 
to the population of cats sampled for this study  and, therefore, not necessarily applicable to 
the patient population of other veterinary practices.  To avoid under- or over-diagnosis of 
pathology, practitioners should look to determine reference intervals for the population of 
their practice and/or use reference change values when assessing their patients’ clinical 
chemistry results.  
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Biological variation and reference 
change values of feline plasma 
biochemistry analytes  
Randolph M Baral1,2, Navneet K Dhand2, Kathleen P 
Freeman3, Mark B Krockenberger2 and Merran 
Govendir2 
 
Abstract 
This is the first report concerning biological variation and reference change values of feline plasma 
biochemistry components in peer reviewed literature.  Biological variation refers to inherent 
physiological variation of analytes.  The ratio of individual biological variation to group biological 
variation is referred to as an analyte’s index of individuality; this index determines the suitability of 
an analyte to be assessed in relation to population-based or subject-based reference intervals. 
A subject-based reference interval is referred to as a reference change value or critical difference 
and is calculated from individual biological variation.  Fourteen cats were sampled for plasma 
biochemistry analysis once weekly for six weeks. Samples were stored and then tested at the same 
time.  Results were assessed in duplicate and coefficients of variation for each analyte were isolated 
to distinguish variation within each subject, between all subjects and by the analyzer. From these 
results, an index of individuality and reference change values were determined for each analyte.  
Five plasma biochemistry analytes (ALP, ALT, cholesterol, creatinine, and globulin) had high 
individuality and therefore subject-based reference intervals are more appropriate; only one analyte 
(sodium) had low individuality indicating population-based reference intervals are appropriate.  
Most analytes had intermediate individuality so population-based reference intervals should be 
assessed in relation to subject-based reference intervals.  The results of this study demonstrate high 
individuality for most analytes and therefore, that population-based reference intervals are of 
limited utility for most biochemical analytes in cats. 
 
Introduction 
Currently, veterinary clinical pathology results are assessed in relation to population-based 
reference intervals.
1
 However, it is considered more appropriate to use ‘subject-based’ 
reference values to assess analytes that have a high degree of inter-individual variation 
because many unhealthy individuals may have values that significantly differ from their 
regular analyte determination, but fall within population-based reference intervals.
2-4
 
Determination of ‘subject-based’ reference values requires knowledge of inherent  
physiological variation of analytes which is referred to as biological variation.
5
 
Suitability of an analyte to be assessed in relation to population-based or subject-based 
reference intervals is determined by that analyte’s index of individuality, a ratio of individual 
biological variation to group biological variation. A subject-based reference interval is 
referred to as a reference change value (RCV) or critical difference and is calculated from 
individual biological variation; it is used to 
determine if two consecutive results from an 
individual reach significance.
5-6
 
Biological variation data are also vital to 
objectively assess imprecision,
7-8 
accuracy and 
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total error
9 
of laboratory equipment
10
  since it is not possible to recognize the acceptable 
degree of variation occurring within equipment without knowing how much normal variation 
occurs within an individual for that analyte. 
Although biological variation data have been generated for several blood components in 
dogs,
11-13
 cows
14
 and budgerigars,
15
 there are no biological variation data for any feline blood 
component published in peer-reviewed literature.   
The objectives of this study were to determine biological variation data of feline plasma 
biochemistry analytes and calculate indices of individuality and RCVs as well as demonstrate 
the relevance of RCVs to feline medicine. 
 
Materials and methods 
Subjects  
This prospective study was performed on client-owned cats maintained in their normal 
environment and being fed their regular diets.  All cats were determined to be clinically 
healthy on the basis on physical examination and their owners’ weekly reports. Physical 
examination included determination of body weight, hydration status, heart rate and nature, 
and abdominal palpation.  The study was approved by The University of Sydney Animal 
Ethics Committee. 
Sampling 
Blood was collected from 14 cats weekly, for 6 weeks. Sampling occurred after an overnight 
fast of at least 10 hours, and all samples were collected between 8:30 to 10:30 am, with cats 
sampled in a consistent order so that sampling occurred at approximately the same time of 
day for each cat. 
Samples were collected by a single operator (RMB) from each cat by jugular venipuncture.  
Samples were collected using 23-ga needles and 3mL syringes and immediately transferred to 
lithium heparin plasma collection tubes (BD Vacutainer, Becton, Dickinson and Company, 
NJ, USA).  Each tube was centrifuged at 4000rpm (1790 x G) for 5 minutes within 10 
minutes of collection before immediately decanting the plasma into plain (no additive) 
collection tubes (BD Microtainer, Becton, Dickinson and Company, NJ, USA).  Plasma 
samples were stored at -20˚C for up to 6 weeks before thawing and analysis at a commercial 
veterinary laboratory (Gribbles, Bella Vista, NSW, Australia). 
Laboratory methods 
The following 20 biochemistry analytes were analyzed in duplicate: albumin, alkaline 
phosphatase (ALP), alanine aminotransferase (ALT), aspartate transaminase (AST), 
bicarbonate, calcium, chloride, cholesterol, creatinine, creatine kinase, gamma-glutamyl 
transferase (GGT), globulin, glucose, magnesium, phosphorus, potassium, sodium, total 
bilirubin, total protein and urea. All analytes were assessed using an Advia 1800 Clinical 
Chemistry System (Siemens Healthcare, Frankfurt am Main, Germany) on a single day by a 
single operator using single lots of reagents and calibrators for each analyte.  The chemistry 
methods used by the Advia 1800 analyzer for these analytes are provided in Table 1. 
Assessments and statistical analyses 
Outliers were assessed for each analyte using Tukey’s outlier identification method using 
Reference Value Advisor (Ecole Nationale Vétérinaire, Toulouse, France).
16
 Outliers were 
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assessed for each analyte on three levels: across the entire group of subjects, for each subject 
individually and for individual subjects with outlying variability compared to the other 
subjects in the group.  
Most outliers detected appeared to result from analytical or pre-analytical variation since 
these samples demonstrated considerable variation between duplicate samples from the same 
patient from the same day.  In these cases, both duplicates were excluded.  Any outliers that 
had a similar result for both duplicates from that subject for that day were retained, as the 
variation was assumed to be normal physiological variation as all cats maintained good health 
through the study duration. 
Restricted maximum likelihood (REML) was used to estimate variance components 
(including means and standard deviations) by specifying analytes as outcome variables, 
subject identification and day (nested within subject identification) as random effects using 
Genstat version 14 (VSN International, Hemel Hempstead, UK). Inter-individual or group 
coefficient of variation (CVG), intra-individual coefficient of variation (CVI) and the 
coefficient of variation occurring between duplicates, or analytical variation (CVA) were then 
calculated from the variance components. Assumption of normality of residuals for REML 
was evaluated by visual inspection of histograms and normal plots of residuals.    
For variables where the assumption of normality was valid, indices of individuality were 
calculated from coefficients of variation (CVs) by the ‘reciprocal formula’ with CVG as the 
numerator (inverse index of individuality), i.e. CVG /√( CVA 
2
+  CVI
2
 ) which results in higher 
values for increased intra-individual variation.
5-6, 13
 With the traditional use of CVG as the 
denominator, indices of individuality less than or equal to 0.6 indicate that subject-based 
reference values are more appropriate (and population-based reference intervals are of limited 
utility) and indices greater than or equal to 1.4 indicate population-based reference intervals 
Table 1 Chemistry methods used by the Advia 1800 analyser for biochemical analytes 
 
Analyte     Method 
 
Albumin      Bromcresol green dye  
Alkaline Phosphatase    Modified IFCC,no P5P, 25˚C  
Alanine aminotransferase   Modified IFCC,no P5P, 25˚C  
Aspartate aminotransferase   Modified IFCC,no P5P, 25˚C  
Bicarbonate    Enzymatic  
Calcium      Arsenazo III dye  
Chloride     ISE- diluted  
Cholesterol     Enzymatic  
Creatinine     Enzymatic  
Creatine Kinase     NAC- activated  
Gamma- glutamyl transferase   Modified IFCC,no P5P, 25˚C  
Globulin     Calculation (Total protein – albumin) 
Glucose      Hexokinase- color  
Magnesium     Xylidyl blue  
Phosphorus     Phosphomolybdate- UV  
Potassium     ISE-diluted  
Sodium      ISE-diluted  
Total bilirubin     Vanadate oxidation  
Total protein      Biuret  
Urea      Urease with GLDH, UV  
 
IFFC: International Federation of Clinical Chemistry and Laboratory Medicine reference method, P5P: Pyridoxal-5'-
phosphate , ISE: ion selective electrode, NAC: N-acetyl cystine, GLDH: Glutamate dehydrogenase, UV: ultra violet 
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are more appropriate. With the more intuitive inverse formula (CVG as the numerator) indices 
of individuality greater than or equal to 1.67 indicate that subject-based reference values are 
more appropriate and indices less than or equal to 0.7 indicate population-based reference 
intervals are more appropriate.   
RCVs were calculated to a 95% probability of significance in percentage terms according to: 
RCV = Z. √2 . √( CVA 
2
+  CVI
2
 ).  This means that any changes greater than this amount for 
two consecutive samples from an individual have a 95% probability of being significant.  
One-sided (Z = 1.65) or two-sided (Z = 1.96) results were calculated depending on whether 
Table 2: Biological variation for each analyte expressed as coefficients of variation (CV) for between cats, or group variation (CVG), 
and for within cats, or individual variation (CVI), within run variation of the duplicate samples or analytical variation (CVA) as well 
as the Index of Individuality (calculated as the more intuitive ‘reciprocal formula’).  Bolded analytes and indices of individuality 
indicate high individuality so subject based reference intervals are more appropriate. 
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the analyte is likely to require interpretation when concentrations are either high, or low (one-
sided) or for both high or low concentrations (two-sided).  
For those analytes where results were not normally distributed, data were log transformed (to 
base e) and then assessed in the same way as for the raw data, using residual diagnostics. CVs  
were then back transformed by CV = √(exp σ2 -1) as previously described.17-18 The RCV was 
calculated using the lognormal approach described by Fokkema et al.
17
 Briefly, the 
‘lognormal’ standard deviation was calculated from the untransformed CV such that σ = √log 
(CV
2
 +1) for each of CVI and CVA; then RCV was calculated as exp(+Z. √ [2. (σI
2+ σA
2
)] for 
increasing values and as  exp(-Z. √ [2. (σI
2+ σA
2
)] for decreasing values; where Z=1.65 when 
1-sided analysis is appropriate (interpretation of results only concerned with increased or 
decreased results) and Z=1.96 for 2-sided analysis (both increased and decreased results of 
significance) and accordingly these RCVs are not symmetrical. 
The number of results with CVA < ½ CVI were assessed as an indicator of adequate 
precision.
19
 The number of results with CVA < ½. √( CVI 
2
+  CVG
2
 ) were assessed as an 
indicator of whether analytical variation was sufficient to affect judgment of biological 
variation, individuality, and therefore, RCVs.
19-20
  
 
Figure 1   Residual plot for log transformed results (to base e) for total bilirubin.  The y-axis represents the percentage of results, 
the x-axis represents the standardized residuals of the log transformed results.  The normal trace represents the standard 
normal distribution curve for comparisons. The kernel trace represents a smoothed plot that approximates the probability 
density of the residuals. Although the curve appears to be normally bell shaped, note that over 60% of results are at the mean 
and this creates central peakedness (kurtosis) of the bell curve which indicates that this set of results approaches normality but 
is not entirely normal. 
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Results 
Cats were aged 5 to 17 years (median: 10 years; mean: 10 years 5 months); three were 
neutered males, 11 were neutered females. All cats were domestic short-hairs. 
Of the 84 sets of duplicate results, the following analytes had exclusions due to outliers: 
potassium (1 exclusion), urea (1), creatinine (2), albumin (3), globulin (3), total protein (3), 
phosphorus (7), calcium (9), chloride (9) and sodium (9). Three cats had exclusions from one 
week’s testing, one cat had exclusions on two weeks, and one cat had exclusions on three 
weeks.  Exclusions were from weeks 2 (affecting three cats), 3 and 4 (affecting two cats on 
each of these weeks) and weeks 1 and 5 (affecting one cat). A further 35 sets of results across 
10 analytes were determined to be outliers (across all three levels assessed) but as the 
duplicate results were similar, these results were considered to be physiological variation and 
maintained. 
Values for CVG, CVI and CVA were determined for all analytes, and from these, indices of 
individuality were calculated (Table 2). All results for GGT (from all cats, all weeks and both 
replicates) were reported as <1 U/L and were tabulated as 0 U/L meaning that the index of 
individuality could not be calculated.    
Analytical variation was less than half individual variation (CVA < ½ CVI) for twelve 
analytes (ALP, ALT, AST, cholesterol, creatinine, creatine kinase, globulin, glucose, 
phosphorus, potassium, total bilirubin and urea), indicating adequate precision for these 
analytes.  Analytical variation (CVA) was less than ½√( CVI 
2
+  CVG
2
 )  for all analytes except 
chloride, magnesium, sodium.  For these three analytes, analytical variation may have been 
great enough to affect judgment of biological variation, individuality, and therefore, RCV.  
For GGT all variation, including analytical variation, was zero. 
Using the inverse index of individuality formula the highest individuality was recognized for 
ALP (2.54) and the lowest for sodium (0.45). Five analytes (ALP, ALT, cholesterol, 
creatinine and globulin) had an index of individuality > 1.67, indicating that use of subject-
based reference values (RCV) is appropriate, and only sodium had an index of individuality < 
0.7, indicating that the use of population-based reference intervals is appropriate.   
Normal distributions of residuals were found for 15/19 analytes (GGT not applicable), the 
exceptions were ALT, creatinine kinase, glucose, total bilirubin.  Three of these had normal 
distributions from log transformed values, the exception was total bilirubin. For total 
bilirubin, all raw results were either 0 or 1 U/L. In order to enable log transformation 0.1 U/L 
was added to all total bilirubin results and the distribution of the log transformed results 
approached normality but showed excess kurtosis (see Figure 1).  For all of these analytes 
CVs were back transformed from the log transformed values and RCV calculated by the 
lognormal approach and therefore had differing values for increasing or decreasing values.
17
 
RCVs for all analytes are presented in Table 3. RCVs varied from 0% (i.e. any change is 
significant) for GGT, to greater than 360% for increases of creatine kinase and total bilirubin 
(that is, serial samples must show a 3.6 fold increase to be significant). Important RCVs 
relevant for feline medicine include ALP with 31%, creatinine with 14.6%, and potassium 
with 11.2%. 
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Discussion 
This is the first report concerning biological variation of feline plasma biochemistry analytes 
in peer reviewed literature. The results demonstrate high individuality for most analytes and 
therefore, that population-based reference intervals are of limited utility for these analytes. 
Using the criteria described by Fraser and Harris
6
 and recently reviewed in the veterinary 
literature,
5
 an index of individuality <0.6 indicates that subject-based reference values are 
more appropriate to use; when the index of individuality >1.4, population-based  reference 
intervals are more appropriate and when between 0.6 and 1.4, population-based ranges should 
be used with caution.  The semantic difficulty that low values indicate high analyte 
individuality can be overcome by using the inverse formula such that an inverse index of 
individuality >1.67 indicates that subject-based reference values are more appropriate to use; 
when inverse index of individuality <0.7, population-based reference intervals are more 
appropriate and when between 0.7 and 1.67, population-based ranges should be used with 
caution.
6, 13
 
This study found five analytes with inverse index of individuality >1.67: ALP, ALT, 
cholesterol, creatinine and globulin; one analyte with inverse index of individuality <0.7 
(sodium); and thirteen analytes with inverse index of individuality between 0.7 and 1.67.  
Both the indices of individuality for GGT could not be calculated as the CVs were zero (since 
Table 3 Reference change values for feline biochemistry analytes.   
 
Analyte 
 
Reference Change Value (%) 
          Decrease Both Increase 
Albumin (g/L) 
 
9.95  
Alkaline phosphatase(U/L)* 
 
30.99  
Alanine aminotransferase(U/L)* 34.50  52.68 
Aspartate aminotransferase (U/L)*  35.27  
Bicarbonate (mmol/L) 
 
20.76  
Calcium (mmol/L) 
 
7.59  
Chloride (mmol/L) 
 
4.21  
Cholesterol (mmol/L) 
 
31.21  
Creatinine (umol/L) 
 
17.39  
Creatine Kinase (U/L)* 34.06  361.45 
Gamma-glutamyl transferase (U/L)* 
 
0.00  
Globulin (g/L) 
 
12.74  
Glucose (mmol/L) 16.94  20.40 
Magnesium (mmol/L) 
 
15.17  
Phosphorus (mmol/L) 
 
23.97  
Potassium (mmol/L) 
 
11.20  
Sodium (mmol/L) 
 
3.50  
Total bilirubin (mmol/L)* 78.43  363.63 
Total protein (g/L) 
 
27.41  
Urea (mmol/L) 
 
29.39  
 
 
Those analytes with different values noted for increasing and decreasing concentrations had RCV calculated by the 
lognormal technique since the results did not have a normal distribution.  
* One-sided values calculated (Z=1.65) since change at one of the end of the reference interval (high or low) is important 
clinically.  All others are calculated as 2-sided (Z=1.96) since both ends of the reference interval are of clinical interest. 
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all results were the same) (see Table 2).  This means that population-based reference intervals 
alone are only appropriate to use for sodium. 
Interpreting clinical biochemistry results with RCVs requires a comparison to prior clinical 
biochemistry results from the same subject.  For example, a cat may have previously had a 
creatinine concentration of a 120µmol/L; an increase to 145µmol/L (an increase of 21%) in a 
subsequent sample represents an increase greater than the reference change value of 17.4% 
(Table 3), above which, there is a 95% probability that the change is significant, there and 
thus is an indicator of azotaemia even if 145µmol/L is within a correctly determined 
population-based reference interval of 70-160µmol/L. 
For those analytes with intermediate indices of individuality between 0.7 and 1.67, 
interpretations are made similarly, but with reference to the population-based reference 
interval as well.  For example, a cat may have a urea concentration of 11.3mmol/L that is 
higher than the reference interval of 5.5-10.5mmol/L.  If prior testing had noted a 
concentration of 9.4mmol/L, then 11.3mmol/L is only an increase of approximately 20%, 
within the reference change value of 29.4% and so may not indicate azotaemia (although it 
would be prudent to monitor further to see if the increase is part of a upwards trend). 
Previous biological variation studies have used analysis of variance (ANOVA) techniques
11-
14, 21-23
 whereas REML was used to estimate variance components in this study.   REML takes 
a similar approach as ANOVA, but yields variance components directly, whereas they have 
to be calculated from the output in ANOVA. The estimated variance components are 
identical for simple models with balanced designs but REML can also be used for non-
balanced designs.
24
 REML has become the standard method for estimating variance 
components.
25
 
Biological variation data, including CVs and RCVs, as described by Cotlove
19
 and Fraser and 
Harris
6
 depend on normally distributed data and equality of variance since normal 
distributions provide predictability of percentage of results above and below set points.  
When a dataset is not normally distributed, routine calculations result in significant errors 
such as implausible decreases of 100% or more (which can occur when standard calculations 
are applied when CVI  exceeds 33.3%).
26
 Due to non-normally distributed data for ALT, CK, 
glucose and total bilirubin lognormal approaches were used for these analytes in this study.
17-
18, 27
  Reasons for results not being normally distributed can vary but box and whiskers plots 
of the results from all cats for ALT (Figure 2)  illustrate that cat 10 had results notably 
different from the other thirteen cats which resulted in the data not being normally 
distributed.  Although this cat had ALT concentrations above the reference interval limits on 
two consecutive occasions, on neither occasion was the concentration greater than the 
reference change value of 52.68% (or 43.00% when calculated with this cat omitted) thus 
demonstrating that this increase above the reference interval likely did not indicate pathology.  
The log transformed dataset for total bilirubin was not entirely normal, displaying excess 
kurtosis or central peakedness (Figure 1).  This means that CVs and RCVs for this analyte 
must be assessed with caution, however, the results in Table 3 make intuitive clinical sense in 
that increases must be large (in the order of four-fold) to be clinically relevant.  Future work 
will be required to refine these values.  Along similar lines, conclusions can be made about 
GGT even though calculations for index of individuality could not be performed since all 
results were the same.  Since no variation from 0 U/L (reported as <1 U/L) was found across 
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fourteen cats, tested weekly on six occasions and tested in duplicate (resulting in 168 
analyses), any increase can be considered significant. 
As first described by Cotlove for people,
19
 the largest biological variability, both intra-
individual (9 to 12%) and inter-individual (15 to 25%), were associated for serum 
constituents that are end-products of catabolism such as urea (CVI=10.43% and CVG=15.54% 
in this study) or are released from tissues such as the liver enzymes (CVI’s 12-15% and 
CVG’s =15-34% in this study).  Physiological reasons may also explain the large variation for 
creatine kinase (CVI=30.96% and CVG=34.02%) as a cat may have sustained some tissue 
damage from minor trauma that resulted in no outward clinical signs. Outliers were 
recognized for creatine kinase (on two of the three levels assessed) but included in analyses 
as both duplicates were similar in each case. 
Cotlove also reported 
19
 that the lowest variation occurred for analytes with strict homeostatic 
regulation of the stability of the composition and volume of extracellular and intravascular 
fluids as well as total calcium which has complex regulatory mechanisms. Accordingly these 
Figure 2   Box and whiskers plots of ALT concentrations (U/L) from all cats.  The box is made by the first quartile (Q1), the 
median and the third quartile (Q3). The whiskers go up to the smallest and the largest observations within 1.5*IQR below 
and above the Q1 and Q3, respectively. Any observation outside these limits is displayed as an outlier. The + symbol 
indicates mean. Note that cat 10 has results notably higher than the other thirteen cats.  This resulted in a deviation from 
normality when assessing results of all the cats.  On two consecutive occasions this cat’s ALT concentrations were above 
the laboratory reference interval of < 80 U/L but were less than the RCV of 52.68%, demonstrating the importance of 
subject based reference intervals for analytes with an appropriate index of individuality.   
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analytes had the smallest CVI’s: sodium (0.86%), chloride (1.17%), calcium (2.34%) and 
albumin (3.00%) and had little difference between CVI and CVG (see Table 2).  
Analytes with low variation are faced with the problem that the ‘noise’ of analytical deviation 
may often mask their true biological variability, both within an individual and among 
individuals
19-20
 as when CVA approaches CVI, there is no certainty whether any variation is 
intra-subject or due to the limitations of the analytical equipment.   
Cotlove defined tolerable imprecision as CVA < 0.5. CVI
19
 and this standard was not achieved 
for seven analytes in the current study (albumin, bicarbonate, calcium, chloride, magnesium, 
sodium and total protein). It is recognized that desirable performance standards are not 
attainable for all analytes with current technology and methodology, and in these 
circumstances, minimum quality imprecision is assessed as CVA < 0.75. CVI .
20, 28
  Albumin, 
calcium and total protein reached this minimum standard but the tightly controlled 
electrolytes (bicarbonate, chloride, magnesium and sodium) did not. Artifactual increases of 
biological variation (CVI) due to analytic variation are minimal when CVA < ½. √( CVI 
2
+  
CVG
2
 )
19
  and this standard was achieved for all analytes except chloride, magnesium and 
sodium.  A further difficulty in assessing true CVA is made by the reporting of results as 
whole integers. For example, duplicate results for chloride reported as 115mmol/L and 
116mmol/L represent analytical variation of 0.87% whereas if the true concentrations were 
115.4mmol/L and 115.6mmol/L, the analytical variation would be 0.17%. 
Fraser and Harris noted that: “A single extraordinary observation, resulting from an 
analytical blunder in the assay, or a misidentification of the specimen, can exert a profound 
effect on summary statistics, especially variances. A distinction should be made between an 
aberrant observation, due to a mistake or accident in the analytical procedure, and an 
outlier. In some cases, the outlier is known to be aberrant, but more often no explanation can 
be found for an unusual value.”6 The decision to exclude outliers from the final statistical 
analyses was not taken lightly and exclusions were made when recognized outliers were from 
duplicate samples (both results were excluded). For example, a duplicate for sodium with 
results of 145mmol/L and 170mmol/L was excluded.  No reason was found for such dramatic 
variations that occurred in multiple cats, across multiple weeks.  Possibilities such as 
inadequate centrifugation, aspiration of red blood cells when decanting plasma, effect of 
freezing and thawing samples or imprecision of analyzer all seem unlikely because the varied 
results were across multiple cats and multiple weeks and no other indicators of possible 
operating error, such as low glucose concentrations if red blood cells were aspirated, were 
detected. 
Ideally, RCV should be calculated using the CVA for the instrument upon which the 
specimens are analyzed. CVA may differ amongst individual instruments of the same or 
different manufacturers and ages.
29
  However, the calculations provided in the ‘Materials and 
Methods’ are easily applied and could be instituted for any analyzer, either at a commercial 
laboratory or in-house, using the information regarding biological variation from this study 
and the imprecision of the analyzer (CVA) used for specimen analyses.  
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Conclusions 
This study represents the first assessment of biological variation for feline blood components 
within the peer-reviewed literature. Results of this study should be interpreted cautiously for 
analytes with low CVI and CVG (particularly chloride, magnesium and sodium) since CVA 
provides analytical ‘noise’ to the clinical ‘signal’.19-20 The high individuality of most analytes 
indicates that subject-based reference values should be used to assess feline plasma 
biochemistry samples.  Biological variation studies such as this one and another recently 
published for dogs
13
 provide strong evidence for serial sampling and reporting of RCVs 
values in small animal practice. 
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Repeatability of results from three in-
house biochemistry analysers and a 
commercial laboratory analyser used 
in small animal practice 
Randolph M Baral1,2, Navneet K Dhand2, John M Morton3, 
Mark B Krockenberger2 and Merran Govendir2 
 
Abstract 
The repeatability (precision) of clinical pathology results is vital for confidence in the measured 
values.  Comparison to biological variation is an accepted standard for instrument/method 
performance in human clinical pathology. This study aims to assess precision of biochemistry results 
from three in-house analysers and one commercial laboratory analyser in relation to biological 
variation; to compare precision between the in-house analysers and the commercial laboratory 
analyser. Two commercially available quality control materials (QCMs) were repeatedly tested on 
the same and different days.  Coefficients of variation were calculated and assessed in relation to 
published biological variation data for cats and dogs.  In-house analyser results were compared to 
results from the commercial laboratory. Seven of thirteen analytes assessed met desirable quality 
precision standards for one QCM and minimum quality standards for the other QCM on all analysers 
for both cats and dogs.  For more than half of all determinations across all in-house analysers, 
precision was as good as, or better than the commercial laboratory analyser.  The precision of results 
from the analysers assessed for most of the analytes tested is generally high, so large differences 
between repeated results from the same patient are probably due to biological changes rather than 
analyser variation. 
 
Introduction 
In-house plasma (or serum) biochemical analysis is commonplace in veterinary practice. An 
important aspect of clinical biochemistry analyser performance is the repeatability of the 
results.  
The results generated by analysers are affected by inherent analytical variation (also known 
as total analytical error).  Total analytical error consists of random error and systematic error.  
Systematic error (beyond the scope of this study) is also known as bias and reflects, for 
example, when one method for determining the concentration of a specific analyte results in a 
consistently higher or lower concentration than another.  Random error determines the 
repeatability or precision of results. Technically ‘precision studies’ assess ‘imprecision’ since 
any variation in results reflects a lack of precision.  Precision studies assess variability in 
repeated assessments of the same samples.
1
  Knowledge of within-day precision is important 
clinically when assays of the same sample from a patient are repeated (for example, when a 
result is unexpected).  In addition, between-day imprecision is important in evaluating serial 
results from repeated samplings from the 
same patient on different days in order to 
correctly identify variations in results that are 
clinically significant, and to avoid 
misinterpretation of changes due to analytical 
This chapter was accepted for publication in: 
 
Comparative Clinical Pathology, 
link.springer.com/journal/580 
 
On: 28 July 2014 
 
DOI: 10.1007/s00580-014-1977-8 
 
 
 
1 Paddington Cat Hospital, Paddington, NSW, Australia 
2  Faculty of Veterinary Science, The University of Sydney, 
Sydney,NSW, Australia 
3 Jemora Pty Ltd, Geelong, Victoria, Australia 
83 
 
imprecision as reflecting true changes in the patient. The overall acceptability of biochemical 
results obtained for clinical use is assessed on the basis of quality requirements that consider 
both precision and bias over a range of values.  
Analyser  method validation traditionally uses quality control materials (QCMs) to assess 
precision (at fixed values) and clinical samples to assess bias (across a range of values).
1
 
Precision (even when testing QCMs) should be assessed in relation to the biological variation 
(the inherent physiological variation of analytes) of each analyte
2-4
 using the coefficient of 
variation which describes the ratio of the standard deviation to the mean. Desirable precision 
has been determined as the analytical coefficient of variation (CVA) being less than half the 
average biological variation (the within patient coefficient of variation [CVI]).
4
 Biological 
variation  has only recently been determined for feline biochemistry analytes,
5
 and precision 
has not previously been assessed in relation to canine biological variation. The purpose of 
this study was to assess analytical coefficients of variation (CVAs) for multiple analytes in 
relation to biological variation values for both dogs and cats from results generated using 
QCMs by three in-house analysers and one commercial analyser, and to compare the CVAs 
for each analyte between the three in-house analysers and the commercial analyser.  
 
Materials and methods 
Study overview  
CVAs were compared using two commercially available QCMs: Chemtrak® H-1 and 
Chemtrak® H-3 (Microgenics, California, USA). Both are unassayed and prepared from 
human serum with added porcine, bovine and avian tissues. Chemtrak® H-1 analyte 
concentrations are mostly within reference intervals, Chemtrak H-3 analyte concentrations 
are either above or below reference interval values (depending on the analyte). Both of these 
QCMs were used to assess within-day and between-day precision of an Abaxis Vetscan® 
VS-2 Point of Care Analyser (Abaxis, California, USA), a Heska Dri-Chem®Veterinary 
Chemistry Analyser (Heska, Colorado, USA) and an IDEXX VetTest® VT8008 and an 
IDEXX VetLyte® (IDEXX, Maine, USA) [IDEXX has a separate instrument to measure 
electrolytes].  The results were compared with those, using the same QCMs, generated by a 
commercial laboratory analyser; the Cobas-Integra 400 (Roche Diagnostics GmbH, 
Mannheim, Germany), operated at Gribbles Veterinary Pathology, (Rhodes, NSW, 
Australia).  This study was performed with the co-operation of, but independent of, all 
companies represented. 
Samples and testing frequencies 
Chemtrak® H-1 was tested on the three in-house biochemistry analysers, for 13 plasma 
biochemical analytes (albumin, alkaline phosphatase [ALP], alanine aminotransferase [ALT], 
total bilirubin, calcium, chloride [not available for Abaxis], creatinine, glucose, phosphate, 
potassium, sodium, total protein, and urea) on 7 or 10 occasions ('runs') on one single day to 
assess within-day precision. The number of runs varied since electrolytes were not tested on 
the IDEXX machine on three occasions due to human error.  
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Additionally, results were obtained from Chemtrak® H-1 for all 13 analytes, each tested once 
daily, on 11 to 15 days over a one month period, to assess between-day precision.  The 
number of runs varied due to insufficient supply of test ‘slides’ on individual days, exceeding 
the total number of tests provided. 
Chemtrak® H-3 was used to assess a different range of concentrations for the same analytes 
on these same three analysers once daily, on 8 to 11 days over the same one month period.  
Again, the number of runs varied due to insufficient supply of test ‘slides’ on individual days, 
exceeding the total provided number of tests or, rarely, instrument failure. 
Analyses were not repeated within-day using Chemtrak-3, since materials for only a limited 
number of tests were provided by each manufacturer.  Between-day imprecision was 
considered to provide the most useful information when considering variation in serial 
collections from patients in which specific analytes were being frequently monitored as, in 
these situations, samples are usually collected from  patients on different days. Between-day 
imprecision is generally greater than within-day imprecision.
6
 
Table 1 Assay method for analyte concentrations by the Abaxis VetScan, IDEXX VetTest/VetLyte and Heska Dri-Chem 
analysers, and by a Cobas-Integra biochemistry analyser at a commercial laboratory Cobas-Integra (commercial) 
Analyser: 
Cobas-Integra 
(commercial) 
Abaxis IDEXX Heska 
Analyte     
Albumin Bromcresol green 
binding 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alkaline 
Phosphatase 
p-NPP hydrolyzation as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alanine 
Aminotransferase 
Catalyzation 
(form pyruvate and 
N-glutamate)  
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Total Bilirubin 
Diazo method 
Enzymatic 
(bilirubin oxidase)  
Diazo-based dry film Diazo-based dry film 
Calcium 
Spectrophotometric 
(CPC)  
Spectrophotometric 
(arsenazo III) 
Spectrophotometric 
(arsenazo III)  
Spectrophotometric 
(Chlorophosphonazo 
III)  
Chloride Ion selective 
electrode (ISE)  
Not analyzed by this 
instrument 
as for Cobas-Integra Potentiometric 
Creatinine 
Jaffe reaction 
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine deiminase)  
Glucose Hexokinase as for Cobas-Integra Glucose oxidase Glucose oxidase 
Phosphate 
Phosphomolybdate 
Enzymatic  
(phosphoglucomutase) 
as for Cobas-Integra 
Spectrophotometric 
(PNP)  
Potassium 
Ion selective 
electrode (ISE)  
Enzymatic 
(pyruvate kinase)  
as for Cobas-Integra Potentiometric 
Sodium 
Ion selective 
electrode (ISE)  
Enzymatic 
(beta-galactosidase)  
as for Cobas-Integra Potentiometric 
Total Protein Biuret as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Urea Coupled-enzyme 
reaction 
as for Cobas-Integra Ammonia indicator 
Bromcresol 
green/ammonia 
‘as for Cobas-Integra’ indicates the same method as the commercial laboratory 
p-NPP = p-nitrophenylphosphate; CPC = o-cresolphthalein complexone; PNP = purine-nucleoside phosphorylase  
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Quality control analyses using the same batch of Chemtrak® H-1 and Chemtrak® H-3 were 
also run at the commercial laboratory on the same 15 days (between-day) over the same one 
month period. 
Laboratory methods 
The assay methods used by each instrument for each analyte are shown in Table 1.   
The Cobas-Integra 400 analyser at a NATA accredited commercial laboratory (Gribbles 
Veterinary Pathology, Rhodes, Sydney, Australia) underwent assay calibration (with 
concurrent verification) weekly to monthly (depending on the individual analyte) with 
calibrators provided by the manufacturers and traceable to the International Federation of 
Clinical Chemistry (IFCC) standards.  QCMs were stored at 4 to 8˚ C according to 
manufacturer’s instructions at both test sites.  Heska and Abaxis analysers were less than one 
year old and installed to the manufacturers’ specifications by the distributing agents.  
Although 10 years old, the IDEXX analysers had been serviced by the manufacturer three 
months prior to the assessment period.  Formal assessments commenced after training by the 
distributing agent and after a familiarization period of at least 10 runs on each analyser.  
Statistical analyses 
Assessments in relation to biological variation 
Feline and canine biological variation (i.e. CVI) data for cats and dogs from prior studies 
5, 7-9
 
of the analytes assessed in this study are presented in Table 2, and results for each analyte 
were categorized as minimum quality precision (CVA ≤ 0.75 x CVI,) desirable quality 
precision (CVA ≤ 0.5 x CVI,) or optimum quality precision  (CVA ≤ 0.25 x CVI). 
10-11
 
Means (with associated 95% CI), standard deviations and CVAs for each analyte for each in-
house analyser were calculated from within-day and between-day results. CVAs within each 
quality standard were determined for each analyte on each analyser for Chemtrak-1 (within-
day and between-day) and Chemtrak-3 (between-day only) for both species. 
Comparisons to commercial laboratory analyser 
CVAs for each analyte on each analyser (for both QCMs) were compared to the CVA for that 
analyte on the commercial analyser with a bootstrap technique implemented using R 
(http://www.r-project.org/) adapted from previously published code 
12
 to allow two-sided 
interpretation.  The following criteria were used to interpret the statistical results: 
   p-value of < 0.025 = significant difference whereby CVA in-house > CVA commercial 
    p-value of > 0.975 = significant difference whereby CVA commercial > CVA in-house 
   p-value between 0.025 and 0.975 = no significant difference in CVAs 
 
Results 
For within-day Chemtrak-1 results (Table 3), the IDEXX analyser, 11/13 analytes attained 
the minimum precision standard for cats (exceptions were albumin and chloride); and 12/13 
analytes for dogs (except calcium). On the Heska analyser, 10/13 analytes reached the 
minimum standard for cats (except calcium, chloride and creatinine); and 12/13 analytes for 
dogs (except calcium). On the Abaxis analyser, 7/12 attained the minimum performance 
standard for cats (except ALP, calcium, creatinine, phosphate and sodium); and 9/12 for dogs 
(except calcium, creatinine and potassium).   
For between-day Chemtrak-1 results (Table 4), on the commercial laboratory analyser, 10/13 
analytes attained the minimum performance standard for both cats and dogs (the exceptions 
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for cats were chloride, creatinine and sodium; and for dogs were calcium, chloride and 
creatinine). On the Abaxis analyser, 9/12 analytes attained this standard for both cats and 
dogs (exceptions for cats were creatinine, potassium and sodium; and for dogs were calcium, 
creatinine and potassium). On the IDEXX analyser 9/13 analytes attained the minimum 
performance standard for cats (except albumin, chloride, potassium, sodium) and 10/13 
analytes for dogs (except calcium, chloride and potassium). On the Heska analyser, 8/13 
analytes reached this standard for cats (except albumin, calcium, chloride, potassium and 
sodium) and 9/13 for dogs (except calcium, chloride, potassium, sodium). 
For between-day Chemtrak-3 results (Table 4), 12/13 analytes determined by the IDEXX 
analyser attained the minimum performance standard for cats (except albumin) and all 
analytes attained this standard for dogs; 10/12 of analytes determined by the Abaxis analyser 
attained this standard for cats (except calcium and sodium) and 11/12 reached this standard 
for dogs (except calcium); 10/13 analytes determined by the Heska analyser, reached this 
standard for cats (except chloride, potassium and sodium) and 9/13 reached this standard for 
dogs (except calcium, chloride, potassium, sodium); 9/13 of analytes determined by the 
commercial laboratory analyser, attained this standard for cats (except calcium, chloride, 
creatinine and potassium) and 10/13 for dogs (except calcium, chloride, creatinine and 
sodium).  
For Chemtrak-1, the commercial analyser had the lowest observed CVAs for 6/13 analytes 
(ALP, bilirubin, glucose, phosphate, potassium and sodium) (Table 5).  However the in-house 
analysers had lower observed CVAs for ALT (Heska), calcium (Abaxis and IDEXX), chloride 
(IDEXX and Heska), creatinine (IDEXX and Heska), total protein (Abaxis and IDEXX) and 
urea (IDEXX and Heska).  
Table 2 Cutpoints for minimum, desirable and optimal quality requirements for precision for biochemistry analytes based on 
biologic variation in cats and dogs 
Analyte 
Within 
cat CV 
(CVI) 
Minimum 
quality  
(0.75 * CVI) 
Desirable 
quality   
(0.5 * CVI) 
Optimum 
quality 
(0.25 * CVI) 
 
Analyte 
Within 
dog CV 
(CVI) 
Minimum 
quality 
(0.75 * CVI) 
Desirable 
quality   
(0.5 * CVI) 
Optimum 
quality 
(0.25 * CVI) 
Albumin 3.00% 2.25% 1.50% 0.75%  Albumin 5.80% 4.35% 2.90% 1.45% 
ALP 12.45% 9.33% 6.22% 3.11%  ALP 13.40% 10.05% 6.70% 3.35% 
ALT 17.94% 13.45% 8.97% 4.48%  ALT 19.50% 14.63% 9.75% 4.88% 
Calcium 2.34% 1.75% 1.17% 0.58%  Calcium 1.20% 0.90% 0.60% 0.30% 
Chloride 1.17% 0.88% 0.59% 0.29%  Chloride** 2.96% 2.22% 1.48% 0.74% 
Creatinine 5.97% 4.48% 2.99% 1.49%  Creatinine 6.60% 4.95% 3.30% 1.65% 
Glucose 7.49% 5.62% 3.75% 1.87%  Glucose 10.70% 8.03% 5.35% 2.68% 
Phosphorus 8.49% 6.37% 4.25% 2.12%  Phosphorus 12.70% 9.53% 6.35% 3.18% 
Potassium 3.63% 2.72% 1.81% 0.91%  Potassium* 3.30% 2.48% 1.65% 0.83% 
Sodium 0.86% 0.65% 0.43% 0.22%  Sodium** 2.77% 2.08% 1.39% 0.69% 
Total Bilirubin 87.46% 65.59% 43.73% 21.86%  Total Bilirubin 27.50% 20.63% 13.75% 6.88% 
Total Protein 8.31% 6.23% 4.15% 2.08%  Total Protein 5.30% 3.98% 2.65% 1.33% 
Urea 10.43% 7.82% 5.22% 2.61%  Urea 13.10% 9.83% 6.55% 3.28% 
 
CVI:  intra-individual coefficient of variation 
Feline biologic variation results from Baral et al., 2013 
Canine biologic variation results from Ruaux et al., 2012 unless otherwise stated 
* Jensen et al., 1993 
** Schweindenwein et al., 2012 
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For Chemtrak-1, the Heska analyser had a significantly lower CVA (p=0.99) than the 
commercial laboratory analyser for ALT and the CVA was not significantly different (p-
values between 0.025 and 0.975) for a further six analytes (ALP, ALT, chloride, creatinine, 
glucose, total protein, and urea).  The IDEXX analyser had a lower CVA approaching 
significance (p=0.96) for calcium and the CVA was not significantly different for a further 5 
analytes (ALP, calcium, chloride, creatinine, total protein and urea).  The CVAs did not differ 
significantly between the Abaxis analyser and the commercial laboratory analyser for 4/12 
analytes (albumin, calcium, total protein and urea). For Chemtrak-3, the commercial analyser 
had the lowest observed CVA for only 3/13 analytes (ALP, bilirubin, and phosphate). For 
Chemtrak-3, for 22/38 in-house-analyte combinations, CVAs did not differ significantly from 
the CVAs from the commercial laboratory analyser.  CVAs from the Heska analyser did not  
Table 3  Within-day performance with QCM (Chemtrak 1) on Heska VetScan, IDEXX VetTest and Heska analysers.  
 
Analyte (units)  Analyzer Mean 95% CI 
(lower limit, upper limit) 
SD CVA (%) Cat Dog 
Albumin (g/L) 
Abaxis 68.70 68.11, 69.29 0.82 1.19
 
D O 
IDEXX 38.40 37.71, 39.09 0.97 2.53
 
- D 
Heska 51.10 50.69, 51.51 0.57 1.12 D O 
Alkaline Phosphatase  (ALP)(U/L) 
Abaxis 46.40 43.14, 49.66 4.55 9.81
 
- M 
IDEXX 65.10 64.12, 66.08 1.37 2.10
 
O O 
Heska 49.50 48.89, 50.11 0.85 1.72
 
O O 
Alanine Aminotransferase (ALT) 
(U/L) 
Abaxis 30.90 29.30, 32.50 2.23 7.22
 
D D 
IDEXX 37.20 35.49, 38.91 2.39 6.42
 
D D 
Heska 32.70 31.94, 33.46 1.06 3.24
 
O O 
Total Bilirubin (umol/L) 
Abaxis 14.90 14.49, 15.31 0.57 3.83
 
O O 
IDEXX 13.60 13.23, 13.97 0.52 3.82 O O 
Heska 16.20 15.75, 16.65 0.63 3.89 O O 
Calcium (mmol/L) 
Abaxis 1.66 1.63, 1.68 0.04 2.41
 
- - 
IDEXX 1.71 1.70, 1.72 0.02 1.17
 
D - 
Heska 1.65 1.64, 1.67 0.02 1.21
 
M - 
Chloride  (mmol/L) 
IDEXX* 111.29 110.41, 112.17 0.95 0.85
 
M D 
Heska 116.10 114.54, 117.66 2.18 1.88
 
- M 
Creatinine  (Umol/L) 
Abaxis 69.90 65.96, 73.84 5.51 7.88 - - 
IDEXX 69.70 68.94, 70.46 1.06 1.52
 
D O 
Heska 60.00 58.69, 61.31 1.83 3.05
 
M D 
Glucose  (mmol/L) 
Abaxis 3.52 3.47, 3.57 0.06 1.70
 
O O 
IDEXX 3.50 3.42, 3.57 0.11 3.14
 
D D 
Heska 3.21 3.17, 3.25 0.06 1.87 O O 
Phosphate  (mmol/L) 
Abaxis 0.93 0.89, 0.97 0.06 6.45
 
- M 
IDEXX 0.82 0.81, 0.83 0.02 2.44
 
D O 
Heska 0.88 0.87, 0.89 0.01 1.14 O O 
Potassium  (mmol/L) 
Abaxis 2.71 2.66, 2.76 0.07 2.58
 
M _ 
IDEXX* 2.66 2.61, 2.71 0.05 1.88
 
M D 
Heska 2.44 2.40, 2.48 0.05 2.05 M M 
Sodium (mmol/L) 
Abaxis 146.80 144.87, 148.73 2.70 1.84
 
- M 
IDEXX* 156.57 156.08, 157.07 0.53 0.34 D O 
Heska 146.00 144.89, 147.51 2.11 1.45
 
- M 
Total Protein (g/L) 
Abaxis 71.20 70.39, 72.01 1.14 1.60 O D 
IDEXX 66.60 65.76, 67.44 1.17 1.76 O D 
Heska 69.80 68.86, 70.74 1.32 1.89 O D 
Urea  (mmol/L) 
Abaxis 5.32 5.23, 5.41 0.12 2.26 O O 
IDEXX 5.16 5.12, 5.20 0.05 0.97 O O 
Heska 5.49 5.45, 5.53 0.06 1.09 O O 
 
Ten tests were performed per analyte-analyzer combination except those marked with ‘*’ where 7 tests were performed. The 
columns ‘Cat’ and ‘Dog’ indicate whether the analyte reached the minimum (M), desirable (D), or optimum (O) quality precision 
standard for that species; '-' indicates that the minimum standard was not reached.  CVAs reaching desirable or optimum quality 
standards for both dogs and cats are in bold.   
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Table 4 Between-day performance on QCM (Chemtrak-1 and Chemtrak-3) by the Abaxis VetScan, IDEXX Vet Test and Heska analysers with 
comparisons of analytical coefficients of variation (CVAs) to those from a commercial laboratory Cobas-Integra analyser (Gribbles) by a 
bootstrap technique.  The columns Cat’ and ‘Dog’ indicate whether the analyte reached the minimum (M), desirable (D), or optimum (O) 
quality precision standard for that species; '-' indicates that the minimum standard was not reached. CVAs reaching desirable quality 
standards for both cats and dogs are in bold.  ** indicates a p-value<0.025, meaning that the CVA of the commercial laboratory analyser 
was significantly lower than that of the in-house analyser.  A single * asterisk indicates a p-value between 0.025 and 0.05 which provides 
some evidence that the CVA is lower.  †† indicates a p-value>0.975 meaning that the CVA of the in-house analyser was significantly lower 
than that of the commercial analyser.  A single † indicates a p-value between 0.95 and 0.975, which provides some evidence that the CVA is 
lower.  
Analyte 
(units) 
 
(units) 
  
Analyser Chemtrak 1 Chemtrak 3 
  n Mean SD CVA% Cat Dog P value
#
 n Mean SD CVA% Cat Dog P value
#
 
Albumin 
(g/L) 
Abaxis 14 68.36 1.01 1.50
 
D D 0.92 11 45.55 0.93 2.1
0
 
 
M D 0.06 
IDEXX 15 38.60 1.68 4.40
 
- D <0.01** 11 24.45 1.37 5.6
0 
- M <0.01** 
Heska 13 51.46 1.51 2.90 - D 0.01** 9 33.33 0.5 1.5
0
 
 
D D 0.72 
Cob-Int  30 45.10 0.8 1.80 - D  28 30.04 0.51 1.7
0
 
 
M D   
ALP (U/L) 
Abaxis 14 45.07 3.27 7.30 M M <0.01** 11 486.8
2  
8.34 1.7
0
 
 
O O 0.92 
IDEXX 15 65.80 2.62 4.00 D D 0.20 11 332.0
9 
18.8 5.7
0
 
 
D D <0.01** 
Heska 13 50.00 2.61 5.20 D D 0.07 10 357.4 19.0
3 
5.3
0
 
 
D D 0.03* 
Cob-Int 31 45.55 1.67 3.70 D D  29 339.8
6 
8.31 2.4
0
 
 
O O   
ALT (U/L) 
Abaxis 14 32.43 2.82 8.70 D D <0.01** 11 213.0
9 
4.74 2.2
0 
D O <0.01** 
IDEXX 15 35.73 2.6 7.30 D D <0.01** 11 219.2
7 
4.36 2.0
0
 
 
D O <0.01** 
Heska 13 32.77 0.6 1.80 D O 0.99†† 11 215.0
9 
12.0
6 
5.6
0
 
 
D D <0.01** 
Cob-Int 29 29.28 0.88 3.00 D O  27 232.4
8 
1.55 .7
0
 
 
O O   
Total 
Bilirubin 
(umol/L) 
Abaxis 14 13.57 1.91 14.10 O M <0.01** 11 102.8
2 
6.4 6.2
0
 
 
O O 0.02** 
IDEXX 14 10.79 1.85 17.10 O M <0.01** 9 92.22 8.29 9.0
0
 
 
O D <0.01** 
Heska 13 13.54 1.56 11.50 O D 0.03* 11 98.82 5.78 5.8
0
 
 
O O 0.02** 
Cob-Int 30 15.43 0.86 5.60 O D  28 123.6
1 
4.64 3.8
0
 
 
O O   
Calcium 
(mmol/L) 
Abaxis 14 1.61 0.02 1.50 M - 0.66 11 2.96 0.05 1.8
0
 
 
- - 0.50 
IDEXX 15 1.70 0.02 1.20 M - 0.96† 10 2.88 0.02 .7
0
 
 
D M 0.99†† 
Heska 13 1.63 0.04 2.60 - - 0.02** 9 3.21 0.05 1.4
0 
M - 0.76 
Cob-Int 35 1.61 0.03 1.70 M -  33 3.11 0.06 1.8
0 
- -   
Chloride 
(mmol/L) 
IDEXX 14 111.7
9 
3.95 3.50 - - 0.89 9 95.22 0.67 .7
0 
M D >0.99†† 
Heska 11 113.0
9 
5.63 5.00 - - 0.689 9 96.11 2.98 3.1
0 
- - 0.94 
Cob-Int 90 111.2 6.48 5.80 - -  86 96.63 6.44 6.7
0 
- -   
Creatinine 
(Umol/L) 
Abaxis 14 68.79 10.5
5 
15.30 - - 0.01** 11 565.3
6 
21.8
4 
3.9
0 
M M 0.80 
IDEXX 15 68.47 2.95 4.30 M M 0.85 11 68.3
6 
23.9
1 
3.6
0 
M M 0.92 
Heska 13 65.31 2.9 4.40 M M 0.70 10 518.7 9.42 1.8
0
 
 
D D 0.94 
Cob-Int 37 66.51 5.08 7.60 - -  33 517.8
5 
27.7
6 
5.4
0 
- -   
Glucose 
(mmol/L) 
Abaxis 14 3.60 0.1 2.90 D D <0.01** 11 18.88 0.18 1.0
0
 
 
O O 0.572 
IDEXX 15 3.47 0.14 4.00 D M <0.01** 11 16.49 4.87 2.2
5§
 
 
D O <0.01** 
Heska 13 3.19 0.05 1.50 O O 0.31 11 17.45 0.16 0.9
0
 
 
O O 0.69 
Cob-Int 22 3.22 0.04 1.30 O O  28 18.6 0.19 1.0
0
 
 
O O   
Phosphate 
(mmol/L) 
Abaxis 14 1.10 0.06 5.80 M D <0.01** 11 2.87 0.07 2.3
0 
D O <0.01** 
IDEXX 13 0.88 0.03 3.30 D D 0.02** 8 2.24 0.05 2.4
0
 
 
D O 0.02** 
Heska 13 0.94 0.04 3.80 D D <0.01** 9 2.70 0.08 3.0
0
 
 
D O <0.01** 
Cob-Int 29 0.84 0.02 2.00 O O  27 2.39 0.03 1.2
0
 
 
O O   
Potassium 
(mmol/L) 
Abaxis 14 2.71 0.15 5.40 - - <0.01** 11 6.08 0.13 2.2
0
 
 
M M <0.01** 
IDEXX 14 2.71 0.23 8.50 - - <0.01** 9 6.46 0.05 .8
0
 
 
O O 0.56 
Heska 11 2.39 0.12 5.10 - - <0.01** 9 5.66 0.19 3.3
0 
- - <0.01** 
Cob-Int 87 2.60 0.02 0.60 O O  81 6.09 0.05 .9
0
 
 
O D   
Sodium 
(mmol/L) 
Abaxis 14 147.6
4 
2.84 1.90 - M <0.01** 11 125.7
3 
1.95 1.6
0
 
 
- M 0.01** 
IDEXX 14 157.2
9 
2.23 1.40 - M <0.01** 9 127.1
1 
0.78 .6
0 
M O 0.62 
Heska 11 145.1
8 
6.32 4.40 - - <0.01** 9 22.0 3.57 2.9
0 
- - <0.01** 
Cob-Int 88 142.9
1 
1.01 0.70 - D  82 117.3
3 
0.89 .8
0
 
 
- D   
Total 
Protein 
(g/L) 
Abaxis 14 71.64 1.15 1.60 O D 0.77 11 9.45 0.82 2.1
0
 
 
D D 0.70 
IDEXX 15 65.87 0.99 1.50 O D 0.91 11 39.36 0.92 2.3
0
 
 
D D 0.55 
Heska 13 67.77 1.54 2.30 D D 0.17 10 40.6 1.26 3.1
0
 
 
D D 0.16 
Cob-Int 29 72.79 1.37 1.90 O D  27 39.93 0.96 2.4
0
 
 
D D   
Urea 
(mmol/L) 
Abaxis 14 5.44 0.19 3.40 D D 0.33 11 23.62 0.41 1.8
0
 
 
O O 0.90 
IDEXX 15 5.27 0.14 2.60 O O 0.81 11 18.93 0.29 1.5
0
 
 
O O 0.93 
Heska 13 5.53 0.14 2.60 O O 0.67 10 23.7 0.47 2.0
0
 
 
O O 0.78 
Cob-Int 21 5.43 0.17 3.00 D D  27 24.42 0.58 2.4
0
 
 
O O   
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differ significantly compared to the commercial laboratory analyser for 8/13 analytes 
(albumin, ALP, calcium, chloride, creatinine, glucose, total protein, and urea). CVAs from the 
Abaxis analyser did not differ significantly compared to the commercial laboratory analyser 
for 7/12 analytes (albumin, ALP, calcium, creatinine, glucose, total protein and urea) and the 
IDEXX analyser had either significantly lower, or not significantly different CVAs, compared 
to the commercial analyser for 7/13 analytes (calcium, chloride, creatinine, potassium, 
sodium, total protein and urea), with calcium (p=0.99) and chloride (p>0.99) having 
significantly lower CVAs. 
CVAs for the in-house analysers were either less than (p>0.975) or not significantly different 
(p between 0.025 and 0.975) from CVAs for the commercial laboratory analyser for 18/38 of 
Chemtrak-1 assessments and 22/38 of Chemtrak-3 assessments and therefore 40/76 of all 
assessments. When combining Chemtrak-1 and Chemtrak-3 assessments, the Heska analyser 
had significantly lower or not significantly different CVAs to the commercial laboratory 
analyser for 16/26 of analyses; the IDEXX equipment had 13/26 and the Abaxis instrument, 
11/24.  A single extreme result was obtained for glucose from the IDEXX analyser, where the 
result was approximately ten times less than the other analysers’ results with Chemtrak-3; the 
CVA was 2.25% and 29.5% when this result was excluded and included, respectively.   
 
Discussion 
The most important finding of this study is that seven analytes (ALP, ALT, glucose, 
phosphorus, total bilirubin, total protein and urea) met desirable quality precision standards 
for Chemtrak-3 and minimum quality standards for Chemtrak-1 on all analysers, meaning 
that clinicians can be confident that results determined for these analytes are repeatable and 
that variation in results due to imprecision is small relative to variation in biological status. 
However, 15-31% of analyte determinations did not reach minimum quality precision 
standards pooled across both QCMs for cats and dogs.   
Since commercial laboratory biochemical results are usually considered the ‘gold standard’ 
by veterinarians, it was surprising that fewer analytes reached the minimum quality precision 
standard (as determined by biological variation) for the commercial analyser compared to two 
of the in-house analysers (see Table 5).  Given the results in relation to biological variation, it 
was  not surprising that the precision of more than half of all analyte determinations across all 
in-house analysers for both Chemtrak-1 and Chemtrak-3 was  not significantly different to or 
better than, that determined by the commercial laboratory analyser. The IDEXX analyser had 
a lowest CVA (of all four analysers) for more assessments with similar results from the 
commercial laboratory analyser. 
In the seminal work concerning biological variation,
13
 Cotlove reported that the lowest 
biologic variation occurred for analytes where there is strict homeostatic regulation of the 
stability of the composition and volume of extracellular and intravascular fluids (such as 
sodium, potassium, chloride and albumin) as well as total calcium which has complex 
regulatory mechanisms. In general, those analytes that did not reach the described quality 
standards in this study were those that Cotlove identified as having lowest biologic variation, 
and included the electrolytes (sodium, potassium, and chloride), calcium and albumin. In 
addition, the desirable quality standard (for both species) for creatinine, an analyte not 
considered to be under strict homeostatic control,
13
 was only reached by the Heska analyser 
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when assessing Chemtrak-3.    For analytes with low biological variation, the ‘noise’ due to 
analytical imprecision is likely to be large relative to biological variability, both within an 
individual and between individuals.
11, 13
 When CVA approaches CVI, proportionally more of 
the observed variation is due to the limitations of the analytical equipment rather than intra-
subject (biological) variation.   
The current American Society for Veterinary Clinical Pathology (ASVCP) guidelines for 
biochemistry allowable total error 
14
 note that some instrument/method performance may not 
be achievable using biological variation speciﬁcations, as is also recognised for human 
clinical pathology.
11
 However, these guidelines also note “Improvements in 
instrument/method performance in the future may allow improved quality requirements based 
on biologic variation” 14. Improvement can only be assessed by measurement and this study 
represents the initial assessment of precision of small animal analysers by this rigorous 
standard. 
Another difficulty in assessing CVA arises when results are reported as whole integers (as for 
numerous analytes in this study). For example, duplicate results for chloride reported as 
115mmol/L and 116mmol/L represent analytical variation of 0.87% whereas if the true 
concentrations were 115.4mmol/L and 115.6mmol/L, the analytical variation would be 
0.17%.  
Table 5 Summary of number of results reaching at least minimum
1
, at least desirable
2
 and optimum
3
 quality precision 
standards based on biologic variation in cats and dogs for each analyser. 
 
Analyser     
Abaxis IDEXX Heska Cobas-
Integra 
Within day (Chemtrak-1) Minimum Cat   7/12 11/13 10/13  
  Dog   9/12 12/13 11/13  
 Desirable Cat   6/12 10/13 8/13  
  Dog   6/12 12/13 9/13  
 Optimum Cat   4/12 4/13 7/13  
  Dog   4/12 6/13 7/13  
Between day (Chemtrak-1) Minimum Cat   9/12 9/13 8/13 9/13 
  Dog   9/12 10/13 9/13 10/13 
 Desirable Cat   6/12 6/13 7/13 8/13 
  Dog   6/12 7/13 8/13 10/13 
 Optimum Cat   2/12 3/13 3/13 5/13 
  Dog   0/12 1/13 3/13 5/13 
Between day (Chemtrak-3) Minimum Cat   10/12 12/13 10/13 9/13 
  Dog   11/12 13/13 9/13 10/13 
 Desirable Cat   7/12 9/13 9/13 8/13 
  Dog   9/12 10/13 9/13 10/13 
 Optimum Cat   4/12 3/13 3/13 6/13 
  Dog   6/12 7/13 4/13 6/13 
         
Between day Minimum Cat   19/24 21/26 18/26 19/26 
Pooled Chemtrak-1 and 3  Dog   20/24 23/26 18/26 20/26 
Between day        
Pooled Chemtrak-1 and 3  
for cats and dogs 
Minimum Cat and dog  39/48 44/52 36/52 38/52 
 
1 at least minimum means CVA ≤ 0.75 x CVI ie any of minimum, desirable or optimum quality precision standards;  
2 at least desirable means CVA ≤ 0.5 x CVI ie either of desirable or optimum quality precision standards 
3 CVA ≤ 0.25 x CVI 
CVA = analytical CV; CVI = biological CV 
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Several studies have assessed precision of the same models of the veterinary in-house 
analysers used in this study.
15-21
  However, these precision estimates were neither assessed in 
relation to biological variation nor statistically compared to a commercial laboratory analyser. 
In these studies, most analytes had CVAs <5%.  Where CVAs were high, most studies noted 
that the quality control solution had very low concentrations of that analyte
16-18
 as was 
observed in this study.  This is consistent with other studies that have shown that precision 
varies with the concentration being assessed;
22-24
 as is the case for bilirubin for which the 
CVA can be greater than 20% for concentrations less than 17 umol/L (a concentration similar 
to Chemtrak-1), and 5 to 6% at concentrations around 100 umol/L (similar to Chemtrak-3) 
regardless of method used.
22
 For many analytes, precision at low concentrations is clinically 
less relevant since despite analytical variation, results will still be well within reference 
intervals.  Therefore, results from Chemtrak-3 (where concentrations were either above or 
below the reference interval depending on the analyte) could be considered more clinically 
relevant.  When assessing results for Chemtrak-3 only, more analytes reached the minimum 
(and desirable) standards and notably, the IDEXX analyser met the minimal standards for 
dogs for all analytes and, for cats, the only exception was albumin.  However, for some 
analytes, most analysers still failed to reach the minimum standards (particularly those with 
low biological variation such as calcium, chloride and sodium for cats). 
Ideally, QCMs should be ‘commutable’ with patient plasma or serum; that is, the results from 
QCMs should be consistent with those from plasma or serum samples from healthy and 
diseased individuals.
25
 Species-specific plasma or serum samples, pooled from multiple 
individuals, are considered the ideal standard for QCMs instead of  commercially available 
QCMs.
26
  However, with pooled plasma samples,  analyte concentrations can decline over 
time,  requiring new batches of material to be prepared at regular intervals and the 
concentrations of analytes within each batch to be re-established to confirm that each batch is 
comparable.
27
 Also analyte concentrations in pooled plasma samples can differ from 
population normal ranges, pooled plasma may be not be commutable for all analytes being 
assessed, there can be difficulty recruiting donors with pathologic analyte concentrations, and 
only limited quantities of pooled plasma may be available. For these reasons, authentic 
clinical specimen pools are not practical for large multi-constituent surveillance quality 
assurance studies.
28
 Additionally, commercial QCMs are acceptable for precision studies 
under the American Society for Veterinary Clinical Pathology (ASVCP) guidelines.
29
 
Therefore, QCMs were chosen as the most practical specimen for determination of precision 
for the period of this study.  
Statistical comparisons of CVs have been problematic since the distributions of results can 
vary between populations 
12
 as observed in the current study.  Parametric approaches have 
been used, but these methods make assumptions that may not be valid about the underlying 
distribution of the statistical parameter.
30-32
 The bootstrapping (also known as resampling) 
technique
12
 used in this study overcomes these problems. However, this approach only 
provides information about whether results differ in comparison to those from the 
commercial analyser but provides no information about the likely magnitude of differences; 
the results for one analyser may vary more greatly than the commercial analyser yet still be 
within the biological variations guidelines (as for ALT on the IDEXX and Heska analysers).  
Further, in-house analyser results may not be statistically different to the commercial 
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laboratory analyser on occasions where neither the in-house analyser nor the commercial 
laboratory analyser meets the biological variation standards (as is the case for creatinine 
when assessed with Chemtrak-1 on the Abaxis analyser). 
Some individual analyte inconsistencies were noted; the reason for the very high albumin 
results for all samples tested on the Abaxis analyser alone is unclear.  All in-house analysers, 
as well as the commercial analyser, determine albumin by the ‘bromcresol green’ method.33  
The high values from the Abaxis analyser may relate to some other substance in the QCM 
bound by the bromcresol green dye however this does not occur with plasma samples.
34
 
There was also a single aberrant, low reading of glucose with Chemtrak-3 on the IDEXX 
machine. This glucose result was approximately ten times lower than the other results found 
for this analyte using Chemtrak-3 and most likely represents random error.  In clinical use, 
unusual results such as this should trigger repeat analysis of the same or a different sample 
from the patient, and thus, the CVA without this result was also assessed; this was 2.25% 
(down from 29.5% when this result was included).  Thus this IDEXX equipment mostly gives 
glucose results with a 2.25% CVA at a concentration approximately double the high end of 
the reference interval but occasionally gives spurious incorrect results. 
Finally, in summarizing the relative performance of the in-house analysers: the IDEXX 
analysers (followed by the Abaxis analyser) met the minimum quality standards on more 
occasions than the other analysers for both QCM’s for both dogs and cats (see Table 5).  The 
commercial laboratory analyser performed better for Chemtrak-1 analyses and had more 
analytes reaching the optimum standards for Chemtrak-1 and Chemtrak-3 for both dogs and 
cats. Confining analyses to Chemtrak-3, which is likely to be more clinically relevant, the 
IDEXX analyser had 25/26 of assessments (dog and cat) meeting the minimum standard, the 
Abaxis analyser had 21/24 of assessments meeting the minimum standard and the Heska and 
commercial laboratory analysers each had 19/26 of assessments meeting this standard.  
However, comparisons between analyser models are limited by variation in precision 
between instruments of the same model. In a recent study of multiple in-house analysers, 
precision varied between analysers of the same model. 
21
 
It can be concluded the precision (repeatability) of results from these in-house and 
commercial laboratory analysers for ALP, ALT, glucose, phosphorus, total bilirubin, total 
proteins and urea, is generally high, so large differences between repeated results from the 
same patient are more likely to be due to biological changes rather than analyser variation. 
The few analytes (such as calcium, creatinine and electrolytes) that do not achieve desirable 
or minimally acceptable specifications for precision based on biologic variation require 
special attention including repeated testing, monitoring of trends within the patient over time, 
and interpretation in conjunction with results of other tests and clinical evaluation in order to 
correctly interpret these results.  
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Comparisons of results between three 
in-house biochemistry analysers and a 
commercial laboratory analyser for 
feline plasma using multiple quality 
specifications 
Randolph M Baral1,2, Navneet K Dhand2,  
Mark B Krockenberger2 and Merran Govendir2 
 
Abstract 
In-house plasma biochemistry analysis is commonplace in veterinary practice but there are few 
studies assessing the results from such instruments.  Method comparison in human clinical 
pathology uses results from both precision and bias studies to determine whether results fall within 
a margin of ‘acceptable’ or ‘allowable’ total error. This study aimed to assess the clinical 
acceptability of plasma biochemistry results determined by in-house analysers compared to a 
commercial laboratory analyser.  Clinical acceptability of analytes from in-house biochemistry 
analysers was assessed by determining the percentage of results from feline plasma samples within 
coverage ranges determined from (a) biological variation, (b) those published by the American 
Society for Veterinary Clinical Pathology (ASVCP), as well as, (c) calculated total error and (d) 
expanded measurement uncertainty. Calculated total error and expanded measurement uncertainty 
ranges were calculated from prior quality control material analyses. Between 80% to 87% of results 
fell within minimal quality standards determined from biological variation.  Approximately 90% of 
results fell within ‘acceptable total error’ ranges published by ASVCP. Overall, in-house analysers 
provide acceptable results, with few clinical decisions affected by results determined from any the 
three in-house analysers compared to the commercial laboratory results.   
Introduction  
In-house plasma (or serum) biochemical analysis is commonplace in veterinary practice.  
Several in-house analysers are available and each manufacturer provides descriptions of 
acceptability of results relative to commercial laboratory results.  Method comparison in 
human clinical pathology uses results from both precision and bias studies to determine 
whether results fall within a margin of ‘acceptable’ or ‘allowable’ total error (TEa).3-4 Several 
independent studies have assessed the performance of in-house biochemistry analysers 
commonly used for obtaining results from small animal patients.
6-18
  However, only two of 
these studies
17-18
 have assessed their findings in relation to TEa in a small animal veterinary 
setting; one assessed only the precision and accuracy of multiple analysers using quality 
control materials only;
17
 the other assessed one analyser for multiple species.
18
 
Standard method comparison studies are based on the assumption that all analysers are able 
to be calibrated for each analyte by the end-user so that results reflect in vivo concentrations, 
however veterinary in-house biochemistry analysers are factory calibrated, based on the 
suggestion that calibration by an unskilled user may compromise the quality of results.
19
  
Factory calibrations result in bias from in vivo values that the manufacturers aim to overcome 
by providing different reference intervals.  
These biases for each analyte introduce 
further complexity to method comparison for 
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such analysers.  
Our group has previously assessed performance using quality control materials (QCMs), to 
assess the precision of in-house biochemistry analysers.  The precision was generally good 
with most coefficients of variations (CVs) for the in-house analysers similar to, and in some 
cases better than, those found with the commercial laboratory instrument.
2
  Additionally, our 
group assessed feline plasma samples from clinical cases to assess the bias of results obtained 
from the three in-house analysers with results determined by  a commercial laboratory 
analyser, and found variable but widespread bias; in many cases  proportional bias for many 
analytes, that is, the amount of bias varied depending on the concentration of the analyte.
20
 
The aim of this study was to assess the clinical acceptability of the results obtained using 
three commonly used in-house biochemistry analysers compared to those determined by  a 
commercial laboratory using the results of quality control material studies
2
 and feline plasma 
studies.
20
 Commercial analyser analysis was chosen as the ‘gold standard’ for this study since 
this is generally considered the ‘highest standard’ routinely available to practitioners.  
Comparisons of clinical results were made by assessing the proportion of results falling 
within (a) TEa limits determined from biological variation,
1
 (b) determined by an expert 
panel,
5
 (c) calculated total error (TEc) limits (95% confidence that the results agree with the 
commercial laboratory results),
4
 and (d) expanded measurement uncertainty (EMU) limits
21
 
(95% confidence range of the true concentration of that analyte),with an offset for each of 
these based on the average observed bias. These quality specifications follow a heirarchy 
defined for human clinical pathology.
22
 Typically, specifications calculated from 
observations made on the analyzer being assessed (such as TEc and EMU) are used to assess 
if results from an individual analyser compared to defined specifications (such as those 
determined from biological variation or by an expert panel).
23
 This study uses TEc and EMU 
both in this way as well as using these measures as quality specifications to compare 
analysers. 
 
Materials and methods 
Quality Control Material Studies  
Two commercially available QCMs, Chemtrak® H-1 and Chemtrak® H-3 (Microgenics, 
California, USA), were used to assess within and between day precision of Abaxis 
Vetscan®VS-2 Point of Care Analyser (Abaxis, California, USA), Heska Dri-
Chem®Veterinary Chemistry Analyser (Heska, Colorado, USA) and the Idexx VetTest® 
VT8008 and IDEXX Vetlyte® (Idexx, Maine, USA) [NB Idexx has a separate instrument to 
measure electrolytes].  CVs were determined for 13 plasma biochemical analytes (albumin, 
alkaline phosphatase [ALP], alanine aminotransferase [ALT], total bilirubin, calcium, 
chloride [not available for Abaxis], creatinine, glucose, phosphate, potassium, sodium, total 
protein, and urea) and full details of these data and analyses are described elsewhere.
2
 
Clinical Samples 
Full details of subjects and sample collection and handling are described elsewhere.
20
  In 
brief, 101 plasma samples were collected from 94 cats seen as clinical cases in a primary 
accession, feline-only practice (Paddington Cat Hospital, Sydney, Australia), over a two 
month period. Blood was collected from the jugular vein into lithium heparin tubes. After 
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appropriate centrifugation, the plasma was immediately divided into 4 separate aliquots.  One 
aliquot was sent by courier to the commercial laboratory and the remaining three aliquots 
were immediately tested on three in-house biochemistry analysers (Abaxis, Heska and 
IDEXX) for the 13 biochemistry analytes noted above. Cats ranged in age from 16 weeks to 
20 years; 49 cats were male (6 entire) and 45 were female (5 entire); 48 were domestic 
shorthairs, 14 were Burmese, 6 were Siamese, 5 were Russian Shorthairs and the remainder 
were other breeds (such as Devon Rex, Cornish Rex, Maine Coon, Persian or Himalayan).  
The health status at the time of testing of cats ranged from entirely healthy (63) to clinically 
unwell (38). 
Laboratory methods 
The analyte assay methods used by each instrument for each analyte are shown in Table 1.  
The Cobas-Integra 400 analyser at a NATA accredited commercial laboratory (Gribbles 
Veterinary laboratory, Rhodes, Sydney, Australia) underwent assay calibration (with 
concurrent verification) weekly to monthly (depending on the individual analyte) with 
calibrators provided by the manufacturers and traceable to International Federation of  
Table 1 Assay method for analyte concentrations by the Abaxis VetScan, IDEXX VetTest/VetLyte and Heska Dri-Chem 
analysers, and by a Cobas-Integra biochemistry analyser at a commercial laboratory Cobas-Integra (commercial) 
Analyser: 
Cobas-Integra 
(commercial) 
Abaxis IDEXX Heska 
Analyte     
Albumin Bromcresol green 
binding 
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alkaline 
Phosphatase 
p-NPP hydrolyzation as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Alanine 
Aminotransferase 
Catalyzation 
(form pyruvate and N-
glutamate)  
as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Total Bilirubin 
Diazo method 
Enzymatic 
(bilirubin oxidase)  
Diazo-based dry film Diazo-based dry film 
Calcium Spectrophotometric 
(CPC)  
Spectrophotometric 
(arsenazo III) 
Spectrophotometric 
(arsenazo III)  
Spectrophotometric 
(Chlorophosphonazo III)  
Chloride Ion selective 
electrode (ISE)  
Not analysed by this 
instrument 
as for Cobas-Integra Potentiometric 
Creatinine 
Jaffe reaction 
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine 
amidohydrolase)  
Enzymatic 
(creatinine deiminase)  
Glucose Hexokinase as for Cobas-Integra Glucose oxidase Glucose oxidase 
Phosphate 
Phosphomolybdate 
Enzymatic  
(phosphoglucomutase) 
as for Cobas-Integra 
Spectrophotometric 
(PNP)  
Potassium 
Ion selective 
electrode (ISE)  
Enzymatic 
(pyruvate kinase)  
as for Cobas-Integra Potentiometric 
Sodium 
Ion selective 
electrode (ISE)  
Enzymatic 
(beta-galactosidase)  
as for Cobas-Integra Potentiometric 
Total Protein Biuret as for Cobas-Integra as for Cobas-Integra as for Cobas-Integra 
Urea Coupled-enzyme 
reaction 
as for Cobas-Integra Ammonia indicator 
Bromcresol 
green/ammonia 
‘as for Cobas-Integra’ indicates the same method as the commercial laboratory 
p-NPP = p-nitrophenylphosphate; CPC = o-cresolphthalein complexone; PNP = purine-nucleoside phosphorylase  
98 
 
 
Table 2 Total error ranges.  Quality standards are determined from previously published biological variation (BV) values 
1
 and 
calculated as shown in footnotes to this table.  
 
  TE quality standards from BV             TEa (ASVCP) 
Analyte Minimal 
(TEmin)
1
 
Desirable 
(TEdes)
2
 
Optimal 
(TEopt)
3
 
Below RI Within/Above RI 
Albumin  5.56% 3.70% 1.85%   15% 
Alkaline Phosphatase  28.88% 19.25% 9.63%   25% 
Alanine Aminotransferase  26.30% 17.53% 8.77%   20% 
Total Bilirubin  156.46% 104.31% 52.15%   30% 
Calcium  4.18% 2.78% 1.39%   10% 
Chloride  2.07% 1.38% 0.69%   5% 
Creatinine  12.23% 8.15% 4.08% 
 
20% 
Glucose  12.31% 8.21% 4.10% 10% 20% 
Phosphate  15.96% 10.64% 5.32% 20% 15% 
Potassium  6.78% 4.52% 2.26% 
 
5% 
Sodium  1.46% 0.97% 0.49% 
 
5% 
Total Protein  16.37% 10.91% 5.46% 
 
10% 
Urea  19.93% 13.29% 6.64% 15% 12% 
 
Allowable total error (TEa) limits assessed by a panel of experts for American Society of Veterinary Clinical Pathologist (ASVCP). 
5
 
TE= total error, TEa= allowable total error, TEmin= minimal total error quality standard as determined from biological variation, 
TEdes= desirable total error quality standard as determined from biological variation, TEopt= optimal total error quality standard 
as determined from biological variation, RI= reference interval, ASVCP= American Society of Veterinary Clinical Pathologists 
 
1: TEmin= 1.65(0.75CVi) + 0.375.√(CVi
2
  + CVg
2
) 
2: TEdes= 1.65(0. 5CVi) + 0.25.√(CVi
2
  + CVg
2
) 
3: TEopt= 1.65(0.25CVi) + 0.125.√(CVi
2
  + CVg
2
) 
 
Table 3  Coverage ranges calculated from analyser precision as well as bias used for assessments of results.  
 
 
 Abaxis   IDEXX Heska   
Analyte 
Mean bias 
(%) 
TEc  
(%) 
EMU  
(%) 
Mean bias 
(%) 
Tec  
(%) 
EMU 
 (%) 
Mean bias 
(%) 
Tec  
(%) 
EMU 
 (%) 
Albumin  14.00 2.95 4.62 -7.22 8.71 9.42 -3.86 5.85 6.86 
Alkaline Phosphatase  10.32 14.51 16.26 71.64 7.98 10.84 66.54 10.46 12.78 
Alanine Aminotransferase  12.02 17.40 18.42 -32.35 14.57 15.78 17.33 3.66 7.04 
Total Bilirubin  -16.60 28.15 30.26 -53.04 34.25 36.02 -71.88 35.33 25.60 
Calcium  -1.71 3.02 4.50 -0.92 2.35 4.08 3.77 5.25 6.22 
Chloride  * * * 5.53 7.06 13.62 -1.84 9.96 15.32 
Creatinine  11.33 30.67 34.26 41.11 8.61 17.54 6.60 8.87 17.66 
Glucose  6.96 5.77 6.36 7.72 8.04 8.46 5.67 3.09 4.08 
Phosphate  15.50 11.66 12.32 2.23 6.67 7.78 4.60 7.62 8.60 
Potassium  10.58 10.76 10.82 4.28 17.06 17.10 -3.09 10.21 10.28 
Sodium  1.38 3.85 4.10 8.52 2.84 3.18 0.67 8.71 8.82 
Total Protein  2.48 3.21 4.96 -3.88 3.01 4.82 -4.42 4.53 5.90 
Urea  -2.72 6.87 9.18 -14.44 5.26 8.04 4.90 5.23 8.02 
 
TEc, and EMU were calculated from CV from prior QCM study.
2
  Mean bias was determined for each analyte on each analyser 
from the observations used in this study.   
TEc = total calculated error, EMU = expanded measurement uncertainty, CV = coefficient of variation, ASVCP= American Society 
of Veterinary Clinical Pathologists. 
* Chloride not available on Abaxis analyser 
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Clinical Chemistry (IFCC) standards.  The QCMs and instrument reagents/test kits were 
stored at 4 to 8˚ C according to manufacturer’s instructions at both test sites. The Heska and 
Abaxis analysers were less than one year old and installed to the manufacturers’ 
specifications by the distributing agents.  Although 10 years old, the Idexx analysers had been 
serviced by the manufacturer three months prior to the assessment period.  Formal 
assessments commenced after training by the distributing agent and after a familiarization 
period of at least 10 runs on each analyser. All analyses were run by one of three regular 
technicians. 
Assessments and Statistical analyses 
Results for each analyte were only assessed when available for all four analysers.   Individual 
results were not available for some analytes from some analysers due to the following 
reasons:  insufficient plasma volume, insufficient stock of test kits on specific days, and 
depletion of the number of tests provided by the distributor.  Additionally, a number of 
samples were excluded when the potential for pre-analytical error arose due to some samples 
not being centrifuged appropriately (so some red blood cells may have remained in the 
sample when tested) or when dilutions were required.  Consequently, the number of samples 
for each analyte varied between 69 and 83. 
Relative difference ‘Bland-Altman’ plots were constructed based on the percentage 
difference of each result on each in-house analyser from the equivalent result from the 
commercial laboratory analyser.  The mean percentage difference (average bias) from the 
commercial laboratory results was determined for each analyte on each in-house machine. 
Coverage ranges were determined by adding or subtracting each quality standard from the 
mean difference of results (for each in-house analyzer) from the Cobas-Integra analyzer for 
each of: (1) quality standards derived from biological variation (minimal, desirable, optimal), 
(2) TEa (as determined by an expert panel and published by ASVCP),
5
 (3) TEc, and (4) EMU 
were determined around this average observed bias.   
Scatter plots were constructed with the concentration of each result from the commercial 
laboratory analyser (x-axis) plotted against the concentration of the equivalent result from 
each in-house analyser (y-axis).  A concordance line and the ASVCP TEa limits were plotted 
(with the average bias of each in-house analyser taken into account in absolute terms and not 
by percentage). 
The quality standards determined from biological variation and the ASVCP TEa standards 
are shown in Table 2. The mean bias for each analyte is presented with the latter two 
coverage ranges in Table 3.   
Quality standards determined from biological variation are essentially acceptance limits 
determined from the physiological variation of each analyte being assessed.  These ranges 
were calculated from the biological variation values determined in a prior study
1
 as 
previously described.
4, 24
 In short, acceptance limits for bias and precision were calculated 
from within and between individual biological variation values and then summated with the 
multipliers for each of bias and precision varying with each quality standard level. These 
calculations can be summarized as: 
 
Allowable imprecision=X.CVi 
100 
 
 
Where CVi = intra-individual biological variation and X varies from 0.75 to 0.5 to 0.25 for 
minimal, desirable and optimal quality standards. 
 
Allowable bias = Y.√(CVi2  + CVg2) 
 
Where CVg = between individual biological variation and Y varies from 0.375 to 0.25 to 
0.125 for minimal, desirable and optimal quality standards. 
Total allowable error = 1.65.(Allowable imprecision) + Allowable bias, or 
 
TEa= 1.65.(X.CVi) + Y.√(CVi2  + CVg2) 
 
The factor 1.65 is valid for the 95% tolerance limits.
25
  The ranges calculated for biological 
variation quality specifications were then offset by the average bias determined for each 
analyser from the results of this study; that is, individual patient results on each of the in-
house analysers were assessed within a range of the quality specification added to or 
subtracted from the average bias for that analyser. Bias was calculated as the mean bias from 
all results for each analyte on each analyser.  The calculated quality standard ranges are 
shown in Table 2. 
TEa is based on the recommendations for analytical quality specifications published by the 
American Society of Veterinary Clinical Pathology (ASVCP).
5
 These ranges are also shown 
in Table 2.  This range was offset by the amount of bias shown for each analyte on each 
analyser (as for quality standards).   
TEc is a quality standard derived from results from the analyser being assessed, and is 
therefore a measure of that analyser’s margin of error. It is determined from the imprecision 
and bias of each in-house analyser and was calculated using the prior QCM studies
2
 (and bias 
determined from this study) for each analyte for each analyser as: 
 
Bias + 2 x CVin-house.
26-27
 
 
The ‘multiplier’ factor chosen can vary, typically from 2 to 6; 2 x CV is considered a strict 
standard and 2 x CV falling within the TEc range is commonly used to represent an 
approximately 95% probability level.
27
 Since CV is a percentage expression of standard 
deviation (SD), 2 x CV is the same 2 x SD from the mean which provides a 95% confidence 
limit for the mean. Bias was calculated as the mean bias from all results for each analyte on 
each analyser.  The calculated ranges for TEc for each analyte are shown in Table 3. 
EMU is derived from results from both the commercial laboratory analyser and the in-house 
analyser being assessed and therefore provides a range that results from each analyser would 
be expected to fall within based on imprecision of both the commercial analyser and each in-
house analyser.  Each EMU coverage range was calculated using the prior QCM studies
2
 (and 
bias determined from this study) for each analyte for each analyser as: 
 
Bias + 2 x √(CV2commercial + CV
2
in-house)
4, 21, 28
. 
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The ‘multiplier’ factor of 2 is commonly used to give a confidence level of 95%.21, 28 This 
means there is 95% confidence that the true value for each analyte would lie within this 
range.  The calculated ranges for EMU for each analyte are shown in Table 3.  Bias was 
calculated as the mean bias from all results for each analyte on each analyser. 
Results within the biological variation quality specification ranges indicate that the results for 
that analyte on that in-house analyser are identical to the commercial laboratory analyser 
within the inherent biological variation of that analyte in cats.  The different quality standards 
(minimal, desirable, and optimal) denote the degree of stringency applied.  Results within the 
ASVCP TEa range indicate that interpretation errors are unlikely to be made based on the 
numerical results; results within the TEc are generally a stricter interpretation range 
indicating 95% confidence that the results agree with the commercial laboratory results; the 
EMU range indicates a 95% confidence range of the true concentration of that analyte based 
on the previously determined CV of the commercial laboratory analyser and each in-house 
analyser. 
The percentage of values falling within each of these coverage ranges was determined for all 
values for all analytes on all analysers.   The percentages of values falling within each 
coverage range were compared between analysers for significance using the chi-squared test. 
 
Results 
Assessments of numbers (and percentages) of results falling within the quality specification 
(determined by biological variation) coverage ranges (Table 2) are presented in Table 4.  
From this table, it can be seen that 80% to 87% of results reach the minimal quality standard.  
When assessing by analyte, on the Abaxis and Heska analysers, 6 analytes (ALT, bilirubin, 
glucose, phosphate, total protein and urea) have 90% or more of results falling within the 
minimal quality standard; for the Idexx analysers, 5 analytes (bilirubin, glucose, phosphate, 
total protein and urea) have 90% or more of results reaching this standard.  Each analyser has 
6 analytes with 75% or more of results within the desirable quality standard coverage range: 
for the Abaxis analyser, these are ALT, bilirubin, glucose, phosphate, total protein and urea; 
for the Idexx analyser, bilirubin, glucose, phosphate, potassium, total protein and urea; and 
for the Heska analyser ALT, bilirubin, glucose, phosphate, total protein and urea.  Over all 
analytes, the Abaxis and Idexx analysers had a significantly greater percentage of values 
falling within the minimal quality standard range than the Heska analyser (p<0.001 for each 
comparison) as well as the desirable quality range (p<0.001 compared to Abaxis; and p<0.01 
compared to Idexx).  No significant difference was found between the analysers when 
assessing the percentage of analytes falling within the optimal quality standard. 
Assessments of numbers (and percentages) of results falling within the ASVCP, TEc and 
EMU coverage ranges (Table 3) are presented in Table 5.  From this table, it can be noted 
that the vast majority of analytes on each of the in-house analysers have greater than 90% of 
results falling within the ‘acceptable error’ (TEa) range, as shown in bold print.  The most 
notable exceptions are found with ALP for all in-house analysers and particularly the Idexx 
and Heska instruments for which only 56% and 55% of results fall within this range; 
therefore many values of clinical relevance for this analyte are outside the TEa range.  Figure  
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Table 4 Summary of number (and percentages) of results within quality standard ranges.  Note that 80-87% of results (depending 
on analyser) fall within the minimal total error standard (TEmin). Analytes with >90% of results within TEa range are shown in bold.  
TEmin= minimal total error quality standard as determined from biological variation, TEdes= desirable total error quality standard 
as determined from biological variation, TEopt= optimal total error quality standard as determined from biological variation, 
*Abaxis analyser does not assess chloride 
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Table 5 Summary of number (and percentages) of results within TEa coverage ranges calculated from analyser precision. Note 
that for all three in-house’ analysers, approximately 90% of results fall within the total allowable error (TEa) range. Analytes with 
>90% of results within TEa range are shown in bold.  TEa = Total allowable error, TEc = total calculated error, EMU = expanded 
measurement uncertainty, CV = coefficient of variation. RI = reference interval. 
*Abaxis analyser does not assess chloride. 
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Figure 1a Difference plot for ALP Abaxis.  Note the marked positive bias shown by the in-house analyser for concentrations 
<40U/L that reduces as concentrations increase.  These results affect the mean bias so that, even though bias is mostly constant 
at concentrations >40U/L, many of these results end up out of the coverage ranges.  
 
 
Figure 1b Difference plot for ALP (IDEXX).  The results show a remarkably similar pattern to those from the Abaxis instrument for 
this analyte.  The consequent affect on the mean bias and the effect on coverage ranges is, therefore, the same. 
 
 
 
Figure 1c Difference plot for ALP (Heska).  The same pattern can be seen as for Abaxis and IDEXX analysers. 
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1 (a to c) shows the difference plots by percentage for ALP on each analyser demonstrating 
that all three in-house analysers measured significantly lower values of ALP than the 
commercial laboratory analyser for values <40U/L at which point the differences level out.  
Removal of all values <40U/L resulted in 100% of Abaxis and IDEXX results (n=17) falling 
within the TEa coverage range (see Figures 2a and 2b) with only 3 of 17 results outside this 
range when assessed on the Heska instrument (see Figure 2c).    Comparing ALP results from 
each in-house analyser with the commercial laboratory analyser in terms of concentration and 
not percentage showed 74/82 (90%), 73/82 (89%) and 80/82 (98%)  of results from the 
Abaxis, Idexx and Heska analysers analyser respectively were within the TEa range (see 
Figures 3a, 3b and 3c).   Some differences from the commercial laboratory analyser were 
 
Figure 2a Difference plot for ALP (Abaxis, results >40U/L).  Note that when only concentrations >40U/L are accounted for, 
all results fall within the coverage ranges. 
 
Figure 2b Differences plot for ALP (IDEXX, results >40U/L).  All result are within the TEa coverage range. 
 
Figure 2c Difference plot for ALP (Heska, results >40U/L).  Most results congregate about the average difference mark 
(purple line). 
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consistent across all three in-house analysers for some individual cats (see Figures 4a, 4b and 
4c). Tabulating the results from all three in-house analysers (shown in Table 5) found that 
2244/2911 (78%) of all results across all analysers fell within the TEc coverage range (95% 
confidence limit about the mean based on imprecision of that analyser) and 2405/2911 (84%) 
of results fell within the EMU coverage range (95% confidence limit about the mean based 
on the joint imprecision of that analyser and the commercial laboratory analyser). A summary 
of these results by analyser is shown in Table 5 which shows that the Abaxis and IDEXX 
equipment have similar overall results with 91% of values falling within TEa (p=0.70), Heska 
has 89% of values falling within TEa which is not significantly different (p=0.08 when 
compared to Abaxis; and p=0.6 when compared to IDEXX); Abaxis has a greater percentage 
of values falling within the TEc range (p=0.03 compared to IDEXX; and p<0.001 compared 
to Heska). Results are similar for all three analysers when the EMU coverage range is 
assessed (with no statistical significant differences found).   
For Chemtrak-1, the commercial analyser had the lowest observed CVAs for 6/13 analytes 
(ALP, bilirubin, glucose, phosphate, potassium and sodium) (Table 5).  However the in-house 
analysers had lower observed CVAs for ALT (Heska), calcium (Abaxis and IDEXX), chloride 
(IDEXX and Heska), creatinine (IDEXX and Heska), total protein (Abaxis and IDEXX) and 
urea (IDEXX and Heska).  
For Chemtrak-1, the Heska analyser had a significantly lower CVA (p=0.02) than the 
commercial laboratory analyser for ALT and the CVA was not significantly different for a 
further six analytes (ALP, ALT, chloride, creatinine, glucose, total protein, and urea).  The 
IDEXX analyser had a lower CVA approaching significance (p=0.08) for calcium and the 
CVA was not significantly different for a further 5 analytes (ALP, calcium, chloride, 
creatinine, total protein and urea).  The CVAs did not differ significantly between the Abaxis 
analyser and the commercial laboratory analyser for 4/12 analytes (albumin, calcium, total 
protein and urea). For Chemtrak-3, the commercial analyser had the lowest observed CVA for 
only 3/13 analytes (ALP, bilirubin, and phosphate). 
For Chemtrak-3, for 22/38 in-house-analyte combinations, CVAs did not differ significantly 
from the CVAs from the commercial laboratory analyser.  CVAs from the Heska analyser did 
not differ significantly compared to the commercial laboratory analyser for 8/13 analytes 
(albumin, ALP, calcium, chloride, creatinine, glucose, total protein, and urea). CVAs from the 
Abaxis analyser did not differ significantly compared to the commercial laboratory analyser 
for 7/12 analytes (albumin, ALP, calcium, creatinine, glucose, total protein and urea) and the 
IDEXX analyser had either significantly lower, or not significantly different CVAs, compared 
to the commercial analyser for 7/13 analytes (calcium, chloride, creatinine, potassium, 
sodium, total protein and urea), with calcium (p=0.02) and chloride (p<0.02) having 
significantly lower CVAs. 
CVAs for the in-house analysers were either less than (p<0.05) or not significantly different 
from CVAs for the commercial laboratory analyser for 18/38 of Chemtrak-1 assessments and 
22/38 of Chemtrak-3 assessments and therefore 40/76 of all assessments. When combining 
Chemtrak-1 and Chemtrak-3 assessments, the Heska analyser had significantly lower or not 
significantly different CVAs to the commercial laboratory analyser for 16/26 of analyses; the 
IDEXX equipment had 13/26 and the Abaxis instrument, 11/24.  A single extreme result was 
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obtained for glucose from the IDEXX analyser, where the result was approximately ten times 
less than the other analysers’ results with Chemtrak-3; the CVA was 2.25% and 29.5% when 
this result was excluded and included, respectively.   
 
Discussion 
This is the first study to assess clinical samples from multiple veterinary in-house analysers 
using currently accepted method comparison approaches with performance standards 
determined by biological variation.    This study found that 80 to 87% of results (depending 
on analyser) were within the minimal total acceptable error range determined by biological 
variation and 69 to 77% of results were within the desirable acceptable total error range.  
Approximately 90% of results determined on all in-house analysers assessed were acceptable 
according to the ASVCP TEa guidelines.
5
 Those 10% of results outside TEa, were 
sufficiently far outside the reference intervals that, in these cases, no clinical doubt would 
have arisen from these variations from the commercial laboratory analyses. However, the 
findings suggest that there is the potential that up to 10% of clinical biochemistry results from 
in-house analysers could lead to incorrect clinical interpretations.  
Clinical pathology in human medicine recognizes the inevitability of laboratory error and 
determined acceptable limits to such error; these limits should represent the necessary 
performance to not affect clinical decisions and thus not affect medical care.
29-31
  Currently 
accepted standards for analytical quality specifications are based on the ‘Stockholm 
Consensus’22 which defines a hierarchy.  The highest level defined in this hierarchy is 
‘evaluation of the effect of clinical performance on clinical outcomes in specific clinical 
situations’, however it is generally regarded that the required conditions are difficult to define 
and need complicated and individualized models which may not be relevant in other clinical 
settings.
32
 Therefore, most international professional bodies such as  the International 
Federation of Clinical Chemistry (IFCC) and Clinical and Laboratory Standards Institute 
(CLSI) generally use the next lower hierarchical level based on biological variation to 
determine quality specifications.
32
 Data based on analysis of clinicians’ opinions comes next 
in the hierarchy, consistent with the ASVCP TEa limits.
5
 Despite widespread literature 
devoted to TEa within human clinical pathology,
24-25, 32-39
 performance standards remain an 
emerging concept within veterinary clinical pathology. 
4, 40-42
. 
Analytes with greater than 90% of values within the desirable range (total bilirubin, glucose 
and total protein for all analysers, additionally ALT for Abaxis and Heska analysers and urea 
for Abaxis and Idexx analysers and phosphate for the Heska analyser alone) can be 
considered to give equivalent results to the commercial laboratory analyser greater than 90% 
of the time within the limits created by inherent biological variation.  The tiered approach 
adapted
43
 in this study recognizes that analytes with large biological variation (such as 
bilirubin)  easily attain quality standards  and accordingly  optimal quality standards are 
appropriate (which were met by 94-100% of results from all analysers for bilirubin).  
Conversely, available methodology and technology limit the ability to reach desirable (or 
even minimal) quality standards for those analytes with minimal biological variation such as 
electrolytes.  For this reason, it is likely that the performance limits set by the ASVCP are 
more appropriate for closely regulated analytes such as albumin, calcium, sodium, potassium 
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Figure 3b ALP IDEXX scatter plot with TEa 
ranges.  As with the Abaxis analyser, most 
results fall within the TEa coverage range when 
the difference in concentration is assessed in 
absolute (not percentage) terms. 
 
 
Figure 3c ALP Heska scatter plot with TEa ranges.  
The results congregate about the concordance 
line (when the bias is taken into account). 
 
and chloride.  Those analytes with greater than 90% of values within the limits determined by 
the ASVCP guidelines can be considered to be unlikely to affect clinical decision (greater 
than 90% of the time).  Analytes reaching this standard include albumin, calcium, creatinine, 
glucose, phosphate, total protein and urea for all analysers and additionally ALT for the 
Abaxis and Heska analysers, and bilirubin for the IDEXX and Heska analysers and sodium 
for the Abaxis and IDEXX analysers as well as chloride for the IDEXX analyser alone (Table 
5).  
The fifth and final level of the ‘Stockholm Consensus’ hierarchy is ‘goals based on the 
current state of the art’.22 The measures of TEc and EMU used in this study are consistent 
with this goal. TEc is defined as bias + Z*SD or bias + Z*CV, where bias is the estimate of 
systematic error, SD is the estimate of random error, CV is the coefficient of variation, and Z 
is the multiplier that represents the desired probability interval. Different recommendations 
have been made for the Z value, ranging from 2 to 6. Most commonly, a Z value of 2 is used 
to represent an approximately 95% probability level. The intended use of TEc is to describe 
 
Figure 3a ALP Abaxis scatter plot with TEa ranges.  
Note that, when concentration differences 
(compared to percentage differences) in results 
are assessed, most results fall within the TEa 
coverage range since the mean result is not as 
greatly affected in absolute terms.   
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the maximum error that might occur in a test result obtained from a measurement procedure. 
It provides a measure of quality that can be compared with TEa.  Acceptable performance of 
a test or method is represented by TEc < TEa.
17, 26-27
 In this study, bias was calculated as the 
average bias from all results for each analyte on each analyser; in some cases, the average 
bias was not representative of the bias within clinically important ranges as demonstrated for 
ALP on all in-house analysers. TEc was less than TEa (ASCVP standards) for 29 of the 38 
(76%) in-house analytes assessed, the exceptions being creatinine on the Abaxis analyser; 
bilirubin on the IDEXX analyser; bilirubin and sodium on the Heska analyser and potassium 
and chloride on all analysers (NB the Abaxis analyser does not assess chloride).  These 
results are similar to another study assessing quality of results of in-house and reference 
laboratory biochemistry analysers in which TEc was less than TEa for 73% across all 
analytes tested on in-house analysers.
17
 The results of the current study appear, at first glance, 
to suggest that the performance is unacceptable for these analytes.  On further evaluation,  all  
results for chloride on the IDEXX equipment were within TEa and thus acceptable (despite 
TEc being greater than TEa); bilirubin is difficult to assess from this study since all results 
were within the reference interval on the commercial analyser; 95% of creatinine results on 
the Abaxis analyser were within TEa when assessing results out of the reference interval and 
90% of potassium results on the IDEXX analyser were within TEa when assessing those 
results outside of the reference interval.  Analysing the results in this way suggests that only 
potassium on the Abaxis analyser and all electrolytes on the Heska instrument did not reach 
acceptable standards when assessing TEc in relation to TEa as well as TEa of results outside 
reference intervals. 
EMU is based on the joint imprecision of the commercial analyser and each in-house 
analyser.
4, 21
  The coverage range was again created using the average bias of all results.  The 
multiplier factor of 2 gives a MU range that indicates a 95% confidence range of the true 
concentration of that analyte based on the previously determined CV of the commercial 
laboratory analyser and each in-house analyser.
21, 28
 As for TEc, average bias may not be 
appropriate for all analytes.  Around 80-85% of results were within the EMU coverage range 
for the three assessments (percentage difference of all results and those above or below the 
reference interval as well as absolute difference of results). EMU was greater than TEa for 
potassium and chloride on all in-house analysers, for sodium on the Heska equipment, and for 
bilirubin on each of the Abaxis and IDEXX (and no other analytes) suggesting that the 
combination of precision and bias of these analysers is not sufficient to reach the desired 
acceptability standards (although there is also an influence from the precision and bias of the 
commercial laboratory analyser). 
As plasma biochemistry method comparison is made difficult due to bias and lack of ability 
to calibrate the in-house analysers, these difficulties are compounded in many cases when 
bias is proportional, that is, the amount of bias varies at different concentrations.  The average 
bias found across all samples was considered most appropriate to use as an offset; the notable 
exceptions to this were the liver enzymes ALP and ALT where the results on in-house 
analysers varied considerably from the commercial laboratory results at lower concentrations.  
This meant that most results at clinically important concentrations were outside the TEa 
range (Figure 1 a-c) and thus considered unacceptable, meaning that an incorrect clinical 
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interpretation could result.  However, when the clinically unimportant low values for these 
enzymes were removed, most values were within the TEa (Figure 2 a-c).  Additionally, using 
absolute bias (compared to percentage bias), as shown by the scatter plots in Figure 3 a-c also 
resulted in more values within the TEa range.   The consistency of results across all in-house 
analysers may suggest that the commercial laboratory results were incorrect, either due to the 
equipment itself or ‘pre-analytical’ changes, perhaps associated with the time for samples to 
travel and be analysed by the laboratory. Alternatively, the in-house analysers may all be 
 
Figure 4a Differences plot for Calcium (Abaxis).  Note the results from 2 cats with high calcium concentrations were 
lower on this instrument compared to the commercial laboratory. Similar differences for all three in-house analyser  
were noted for albumin. 
 
 
Figure 4b Difference plot for Calcium (IDEXX).  The two results outside the TEa range and noted as lower than the 
commercial laboratory are from the same two cats as noted for the Abaxis and Heska analyser. 
 
 
Figure 4c Difference plot for Calcium (Heska).  The two results >3.25mmol/L and outside the TEa range are from the 
same two cats noted above.   
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incorrect and have difficulty accurately determining low concentrations of ALP. The two cats 
with consistent albumin and calcium results across the in-house analysers that were aberrant 
with the commercial laboratory results (Figures 4a-c) may also indicate that commercial 
laboratory results do not always represent a ‘gold standard’ (either for analytical or pre-
analytical reasons). An alternative explanation is that some other substance (‘matrix effect’) 
interfered with the analysis of all three in-house analysers on these two particular occasions 
and that this may be due to factors inherent to these two individual animals.  If albumin was 
artificially increased for any reason, protein bound calcium may account for the concurrent 
increase in calcium found at the commercial laboratory.  
Most plasma biochemistry method comparison analyses, particularly ‘Bland-Altman’ 
difference plot assessments are performed in terms of absolute differences.
44-46
 Comparisons 
of ‘absolute’ values are only appropriate when the data being assessed have a Gaussian 
distribution.
44, 46
 Ideally, the decision whether to compare absolute results or percentage 
differences should be made on the distribution of the results found.
46
 Percentage difference 
assessments as used in this study are appropriate in most cases since the margin of difference 
is not influenced by concentration of the analyte; additionally, different analytes can be 
compared to each other. 
Overall, this study suggests that in-house analysers provide acceptable results; few clinical 
decisions would be affected by the results found on the three in-house analysers compared to 
the commercial laboratory results.  The different analysers had varied acceptability of results, 
depending on the analytes assessed.  For example, the IDEXX analyser was clearly better for 
electrolytes and, conversely, the Heska instrument was most problematic for electrolytes and 
was the only analyser using a different technique to assess electrolytes.  The Heska analyser 
was, however, the best for liver enzymes.  The Abaxis machine was the most consistent with 
only potassium results being potentially problematic.  
These conclusions can be applied to the individual machines assessed in the study but do not 
necessarily apply to all instruments from these manufacturers.  One recent study documented 
variation in performance between analysers of the same brand and model.
17
  Individual 
instrument performance evaluation should be performed in order to know where each in-
house instrument falls with regard to acceptable performance.  Within the commercial 
laboratory setting, with more sophisticated instruments, it is acknowledged that individual 
instrument performance must be validated before introduction for routine testing and that 
evaluation of inherent ‘error’ within the testing system is needed to better understand and 
interpret the results obtained.  
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Chapter 7: 
Conclusions, limitations and future directions 
This project has used evidence-based approaches to analyse the validity, and therefore reliability, of 
feline clinical biochemistry analyte values in two ways: (1) by adapting current method comparison 
approaches so they can be used with in-house analysers that have inherent bias; and (2) determining 
biological variation values and using them to determine which analytes should ideally be assessed by 
subject-based reference change values. 
 
Recapitulation of key findings 
Chapter 1 (Literature Review) reported the difficulties of establishing objective criteria for 
evaluation of method performance for in-house analysers, as well as an absence of critical 
evaluation of manufacturer provided reference intervals for in-house analysers which are now 
common-place in veterinary practice.  Additionally, contrary to human and canine clinical 
pathology, biological variation for feline biochemistry analytes had not been determined.  
Consequently, Chapter 2 defined the inherent bias of three popular in-house biochemistry 
analysers compared to a commercial laboratory analyser and demonstrated that results from 
analysers cannot be directly compared
1
 because substantial bias was evident relative to the 
commercial analyser results for at least half of the analytes tested for each machine and for 
many analytes, the bias was proportional and reference intervals are not transferable between 
analysers.  Chapter 3 explored the premise that manufacturers of in-house analysers 
overcome the inherent bias of these analysers by providing instrument specific reference 
intervals.  However, this study not only demonstrated that the provided reference intervals 
rarely overcome the biases of these analysers but also that the reference intervals provided by 
the commercial laboratory were not applicable to the veterinary hospital population of cats 
assessed. 
Biological variation of common feline plasma biochemistry analytes as well as reference 
change values for these analytes was determined in Chapter 4.  These landmark findings 
assist veterinary practitioners to determine clinical pathology values based on biological 
variation, where appropriate to do so.  These findings also facilitate method comparison by 
quality standards determined from biological variation, a widely accepted standard used in 
human clinical pathology
2-4
 which is then explored in subsequent chapters. 
Repeatability of values determined by biochemistry analysers is of vital importance since, in 
many cases, bias can be overcome by adjustment of reference intervals or use of reference 
change values.  Biological variation provides an objective standard to assess repeatability on 
a species-specific basis,
5-8
 as demonstrated in Chapter 5 for both dogs and cats on three 
commonly used in-house biochemistry analysers as well as a commercial laboratory analyser.  
Precision for most analytes on all four analysers was found to be acceptable. 
The overall clinical acceptability of values (a.k.a. acceptable total error [Tea]) determined by 
the analysers was assessed in Chapter 6.  This required adapting existing approaches used in 
human clinical pathology
9-10
 which include using an offset based on average bias for each 
analyte on each analyser.  A further innovation was concurrently assessing all values 
determined through the duration of the study. This study then assessed the generated values 
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by several quality standards, including those determined by biological variation and overall 
found that most analysers provided clinically acceptable results on most occasions for the 
analytes assessed. Despite widespread literature devoted to TEa within human clinical 
pathology,
6, 11-19
 performance standards remain an emerging concept within veterinary 
clinical pathology.
10, 20-22
 A 2006 report, still relevant today, noted that veterinary diagnostic 
laboratories often lacked defined quality standards to assess TEa. 
23
 The ASVCP only 
published TEa limits in 2013
24
 and biological variation data to derive quality specifications 
for cats was first described in the course of this research project.
25
 The approach used in 
Chapter 6 in relation to multiple quality standards determined from the ‘Stockholm 
heirarchy’,26 reflects that the appropriate standard to assess values generated by biochemistry 
analysers may vary. Biological variation standards are too easy to attain when biological 
variation is large, such as for bilirubin. Conversely, for tightly controlled analytes, such as 
electrolytes, currently available technology limits the ability to reach the standards 
determined by biological variation. 
There is an apparent inconsistency between Chapters 2 and 6 in that the widespread 
proportional bias of many analytes determined by the in-house analysers compared to the 
commercial laboratory analyser (Chapter 2) is not apparent when the acceptable total error of 
these same analytes on these same analysers is assessed (Chapter 6).  The major reasons for 
this are that total acceptable error was (1) determined after values were offset by the average 
bias; and (2) determined on a percentage basis compared to bias that was compared by 
analyte concentration.  Bias was appropriate to be compared in relation to concentration since 
this is what the practitioner would observe in practice without any calculation and provides a 
direct recognition of the magnitude of the differences found.  In contrast, comparing in 
relation to concentration is more appropriate for the ‘acceptable total error’ study for several 
reasons: (1) different analytes can be directly compared to each other; and (2) the biases have 
already been demonstrated and are being taken into account.  Comparing values determined 
by different analysers on a percentage basis (instead of analyte concentration) changes the 
degree of any bias between analysers.  For example, the bias between analysers was 
exaggerated at low concentrations for ALP and ALT and it could be argued that it is more 
appropriate to assess these analytes by their concentration (as noted in the Chapter 6), 
although comparisons by concentration are only appropriate when the data being assessed 
have a Gaussian distribution. 
27-28
 In such studies, decisions on the basis of comparison 
should be made on an analyte-by-analyte basis but when multiple analytes are being assessed, 
it seems more logical to use the same basis of comparison (as was undertaken here). 
A potential weakness of Chapters 5 and 6 is that commercial quality control materials were 
used to assess precision (as opposed to pooled plasma or serum samples).  Commutability is 
defined as the equivalence of the mathematical relationships between the results of different 
measurement procedures for a QCM and for representative samples from healthy and 
diseased individuals.
29
 Commutability of commercial QCM’s has not been assessed in 
relation to veterinary patient samples so it is not possible to determine the impact pooled 
serum versus  plasma  would have on the findings.  Assessing commutability is an important 
future direction for veterinary clinical pathology.   
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Quality standards in relation to biological variation and expert opinions are the new paradigm 
for performance evaluations of veterinary clinical pathology analysers. 
 
What these findings mean to veterinary practitioners 
Interpretation of clinical biochemistry values depends on the acceptability of values 
generated by analysers; further, the reliability of population-based reference intervals or 
reference change values must be considered.  In other words, any interpretation of an 
increased or decreased concentration of an analyte is dependent on the reliability of the 
analyser as well as what approach is used to assess the result (i.e. population-based reference 
intervals or reference change values).   
On the positive side for practitioners, this research project determined that values generated 
from in-house analysers had comparable imprecision to those generated by a commercial 
laboratory analyser and that most values generated had acceptable total error. However, an 
earlier study had determined that analysers of the same model may give different results,
30
 so 
a blanket recommendation cannot be made and evaluation of individual analyser performance 
is required before any analyser is used for analysis of patient specimens.  
On the negative side, this research project demonstrated that results from different analysers 
cannot be compared and that the reference intervals provided by the in-house analysers or the 
commercial laboratory assessed may not be appropriate for their hospital population of cats. 
This requires additional time and expense to determine if the provided reference intervals can 
be validated for use with their hospital population. 
In summary, the analysers assessed generated acceptable results but the routinely accepted 
basis to assess these results is not sound. 
There are two main problems with the use of population based reference intervals: (1) 
widespread acceptance that reference intervals provided by analyser manufacturers or 
commercial laboratories are correct for each clinician’s practice; and (2) the appropriateness 
of use of population-based reference intervals based on the index of individuality of each 
analyte to be assessed. 
To overcome these problems, clinicians should be prepared to assess if provided reference 
intervals are appropriate for their practice (by transference validation)
31-32
 and, if necessary, 
recalculate reference intervals for their practice.  Additionally, practitioners should assess if 
their patients would be better served by assessing clinical pathology data in relation to subject 
based reference intervals (reference change values). However, reference change values 
require determination of individual instrument analytical CV which is used in calculations of 
reference change values.  
Both of these approaches require re-education of clinicians.  Transference is simple to 
perform, requiring only twenty healthy patients but there is a lack of awareness of the 
importance of this process among practitioners. Transference validation is not without 
problems and it is insensitive in detection of reference intervals that may be too wide and 
result in misclassification of patients due to insensitivity in detection of abnormal results.
33
 
There are readily available descriptions and tools to determine reference intervals within 
practices,
34-35
 however, these tools are not widely known about outside clinical pathology 
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circles.  The author is currently collating data and drawing upon an international 
collaboration of veterinary clinical pathologists and internists to provide a database of 
biological variation values for all species for which such data has been published.  This 
database is intended to be presented as a website with a reference change value calculator that 
will determine both the appropriateness of using RCV (based on index of individuality) as 
well as calculating RCV from the precision of the clinician’s own analyser (or the precision 
of the laboratory they are using).  The biological variation database will provide a clear 
indication of where there are current gaps in knowledge, such as for whole species (such as 
horses) as well as for analytes (such as most haematology analytes for most species). A 
description of the website, along with instructions are intended to be submitted to relevant 
veterinary clinical journals, as well as promoted through online seminars, such as through 
VIN (www.vin.com).   
This approach will require clinicians to know the precision of their analysers, which is 
already part of the ASVCP point-of-care-testing guidelines
36
 but not widely practiced outside 
veterinary clinical pathology circles. 
Widespread adoption of reference change values will encourage veterinary laboratories and 
analyser manufacturers to report results in these terms with analyser software or laboratory 
information systems having the ability to identify serial results within defined time intervals 
and calculate the percentage change in serial results, thus calculating reference change values. 
These changes will not be easy to institute and require a paradigm shift for practitioners from 
the entrenched approach of using population-based reference intervals.  It is easy to lose sight 
however that the use of population-based reference intervals within veterinary practice, as 
they are currently used, was in itself a paradigm shift in the early 1980’s after Lumsden’s first 
descriptions of such a system in 1978.
37
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